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The endogenous free radical signalling molecule, nitric oxide (NO), is the
mediator of many physiological processes including control of vasomotor tone, and
the inhibition of smooth muscle cell (SMC) proliferation and platelet activation.
Additionally, NO plays an important role in the regulation of the inflammatory
response through its ability to influence apoptosis in a variety of cells. This
fundamental process governing cell survival is cmcial to ensuring the successful
resolution of the inflammatory response as apoptotic inflammatory cells are removed
from a site of tissue injury by non-inflammatory phagocytosis. NO has both pro- and
anti-apoptotic properties depending on its concentration, the NO-related species
generated and the cell type in question. Pharmacological manipulation of apoptosis
by NO may aid the resolution of inflammation during chronic inflammatory
disorders such as atherosclerosis.
NO is often reported as having paradoxical effects in many biological settings.
This may be due to the formation of NO-related species in vivo: NO combines
rapidly with superoxide anion to generate peroxynitrite (ONOO ) and with
endogenous thiols to form S-nitrosothiols (RS-N=0). Both ONOO" and RS-N=0
have biological properties that are independent of the liberation of NO radical per se.
Characterisation of the NO-related species generated by the NO donor
compounds 1,2,3,4,-oxatriazolium, 5-amino-3-(3,4-dichlorophenyl)-chloride (GEA-
3162), diethylamine diazeniumdiolate (DEA/NO), (Z)-l-[2-(2-Aminoethyl)-N-(2-
ammonioethyl)amino]diazen-l-ium-l,2-diolate (DETA/NO), S-nitroso-N-valeryl-D-
penicillamine (SNVP) and S-nitrosoglutathione (GSNO), was carried out by a
combination of electrochemistry and electron paramagnetic resonance. Results
revealed the diazeniumdiolates, DEA/NO and DETA/NO, spontaneously liberate NO
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radical in solution. However, GEA-3162 was found to release NO and O2"
concomitantly, and therefore, should be regarded as a ONOO generator. SNVP and
GSNO release only small amounts of free NO in solution, however, the mechanism
of action of these compounds is likely to also involve the transfer of NO+.
The effect of each of these compounds on cell viability was investigated in
human monocyte-derived macrophages (Mcp) and an aortic SMC line. In both Mcp
and SMC, only the ONOO" generator, GEA-3162, induced cell death. Analysis by
flow cytometry revealed GEA-3162 caused cell surface phosphatidylserine exposure
characteristic of apoptosis. Only a prolonged delivery of NO radical was able to
genuinely inhibit SMC proliferation. These results demonstrate, that contrary to
previous reports, NO per se is incapable of inducing cell death.
Finally, apoptotic cell death induced by GEA-3162 in human monocyte-derived
M(p was inhibited by pre-treatment of the cells with a low dose of the NO-releasing
compound, DETA/NO. This effect was enhanced by augmenting cGMP levels using
a direct guanylate cyclase stimulator, BAY 41-2272. Pre-treatment with DETA/NO
failed to protect SMC against GEA-3162-induced cell death, irrespective of inclusion
of BAY 41-2272. These results demonstrate that pre-conditioning of Mcp with
cGMP protects them against subsequent cell death.
Taken together, these studies demonstrate that the outcome of any NO-
induced response depends on the concentration and precise NO-related species
generated in the microenvironment, as well as the nature of the target cell.
Exploiting these differences as a therapeutic strategy for the treatment of
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The endogenous free radical, nitric oxide (NO), is a signalling molecule
responsible for mediating various physiological and pathophysiological processes
including modulation of vascular tone, inhibition of platelet and inflammatory cell
activation and adhesion, and neurotransmission at non-adrenergic, non-cholinergic
(NANC) neurones (Moncada et al. 1991; Quinn et al. 1995; Ignarro et al. 1999). In
addition, NO plays an important role in the regulation of inflammatory processes
through its ability to manipulate apoptosis in a variety of cell types (Nicotera et al.
1997; Fiscus et al. 2002; Taylor et al. 2003). However, due to the free radical status
of NO, it rapidly combines with reactive oxygen species present in the milieu, and
with various cellular components such as cysteine residues on proteins, to form a
variety of NO-related species in vivo. The net outcome of any NO-regulated process
therefore critically depends not only on the cell type in question, but also on the NO
concentration liberated and the precise NO-related species formed in the
microenvironment.
Alterations in both the synthesis and bioavailability of NO are likely to
influence cellular processes occurring in a wide range of diseases, including those
with a chronic inflammatory component, such as atherosclerosis. Atherosclerosis is
a multi-factorial disease with a complicated aetiology. Atherosclerosis and the
associated acute clinical events, such as stroke and myocardial infarction, are a major
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Chapter One: Introduction
cause of morbidity and mortality in industrialised nations and, despite decades of
research, the clinical consequences of atherosclerosis still account for vast numbers
of adult deaths in Western society (The American Heart Association Statisical
Update 2005). Atherosclerosis has been the most common underlying cause of adult
death in the United States almost every year since 1900 and mortality rates from
atherosclerosis continue to exceed those for cancer, infectious diseases and trauma
(Callow 2002; The American Heart Association Statisical Update 2005).
Atherosclerosis is characterised by the formation of lipid-rich plaques in the
sub-endothelial space of major conduit vessel such as the coronary arteries and aorta
(Ross 1993; Davies 1997). It is widely recognised that there is an inflammatory
component to the pathogenesis and progression of this condition, and atherosclerosis
is now considered to be the consequence of a chronic, low-grade inflammatory
response (Ross 1999a; Ross 1999b; Libby 2002; Libby et al. 2002). Progression of
the inflammatory response depends on the balance between the recruitment and
activation of inflammatory cells and of their subsequent removal from the
inflammatory milieu by phagocytosis. Apoptosis, or programmed cell death, is a
fundamental process governing cell survival and is critically involved in ensuring the
successful resolution of the inflammatory response (Kerr et al. 1972; Haslett 1997;
Wyllie 1997). Apoptotic cells are instantly recognised for non-inflammatory
clearance by phagocytes (e.g. macrophages) and removed from the vicinity of
inflammation without the release of their histotoxic, pro-inflammatory contents
(Savill et al. 1993). Dysregulation of apoptosis or of phagocytic clearance
3
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mechanisms may have drastic consequences for the resolution of inflammation,
resulting in an exacerbation of the inflammatory response (Haslett 1997).
1.2 Nitric Oxide
It is now over quarter of a century since the importance of the vascular
endothelium was realised. During the response to various agonists, including
acetylcholine, bradykinin, and thrombin, the endothelium was observed to release an
endothelium-derived relaxing factor (EDRF) which induced both vascular relaxation
(Furchgott and Zawadzki 1980; Furchgott 1984; Furchgott et al. 1984; Furchgott et
al. 1987; Amezcua et al. 1988) and a potent inhibition of platelet aggregation and
adhesion (Alheid et al. 1987; Busse et al. 1987; Furlong et al. 1987; Radomski et al.
1987a; Bhardwaj et al. 1988; Hogan et al. 1988; Macdonald et al. 1988; Sneddon and
Vane 1988). Subsequently, EDRF was found to have chemical and pharmacological
properties indistinguishable from the inorganic free radical, nitric oxide (NO;
Furchgott and Zawadzki 1980; Ignarro et al. 1987a; Ignarro et al. 1987b; Palmer et
al. 1987; Ignarro et al. 1988a; Ignarro et al. 1988b). Since then, it has become
increasingly clear that NO is the signalling molecule responsible for a wide range of
diverse physiological and pathophysiological processes. NO is now known to
control vascular smooth muscle tone (Amezcua et al. 1989; Ekelund and Mellander
1990; Faraci 1990; Gardiner et al. 1990; Kelm and Schrader 1990; Tare et al. 1990),
to inhibit platelet and inflammatory cell activation (Radomski et al. 1990; May et al.
1991; Radomski et al. 1991; Kanwar and Kubes 1995; Quinn et al. 1995; Armstrong
2001), to be a bi-functional regulator of apoptosis in a variety of cell types (Albina et
4
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al. 1993; Nicotera et al. 1997; Taylor et al. 2003) and to be a transmitter at non-
adrengeric non-cholinergic (NANC) synapses (Graham and Sneddon 1993;
Hernandez et al. 1995; Postorino et al. 1995; Simonsen et al. 1995; Yunker and
Galligan 1996).
1.2.1 NO Synthesis
NO is synthesised endogenously by three isoforms of the enzyme NO
synthase (NOS; Charles et al. 1996). A series of studies in the early 1990s isolated
three NOS isoforms: endothelial NOS (eNOS or NOS III: (Pollock et al. 1991;
Lamas et al. 1992; Marsden et al.; Nishida et al. 1992), neuronal NOS (nNOS or
NOS I: (Bredt et al. 1991a), and inducible NOS (iNOS or NOS II: (Yui et al. 1991a;
Sherman et al. 1993; Wood et al. 1993). These isoenzymes are cytochrome P450-
reductase related enzymes (Bredt et al. 1991b; White and Marietta 1992) which
catalyse the formation of NO and L-citrulline (L-Cit) from L-arginine (L-Arg) and
oxygen (02; Mayer et al. 1989; Johns and Rengasamy 1991; Bush et al. 1992a; Bush
et al. 1992b). eNOS and nNOS are constitutively expressed, are calcium/calmodulin
(Ca2+/CAM) dependent (Bredt and Snyder 1990; Schmidt et al. 1992a; Schmidt et al.
1992b) and synthesise relatively low NO concentrations (in the pM range). iNOS is
Ca2+/CAM independent (Yui et al. 1991b) and expressed in response to various
cytokines and bacterial endotoxins to generate high NO concentrations (nM - pM;
Moncada et al. 1991; Berdeaux 1993).
NOS isoenzymes exist as homodimers, with each monomer containing an
oxygenase domain linked to a reductase domain (Griffith and Stuehr 1995; Alderton
5
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et al. 2001). The reductase domain contains binding sites for flavin mononucleotide
(FMN), flavin adenine dinucleotide (FAD), and nicotinamide adenine dinucleotide
(NADPH; Marietta 1994; Ghosh and Stuehr 1995), whilst the oxygenase domain
contains the binding sites for L-Arg, and the co-factor tetrahydrobiopterin (BH4),
plus a haem prosthetic group (Crane et al. 1998; Raman et al. 1998). NADPH
donates electrons which flow from the reductase domain via the flavin cofactors to
the haem group of the oxygenase domain, where they reduce ferric (Fe3+) haem to
the ferrous (Fe2+) form, allowing O2 to bind (Siddhanta et al. 1996; Adak et al. 1999;
Poulos et al. 1999). NO is then formed by the oxidation of L-Arg via the formation
of the intermediate, N^-hydroxy-L-arginine (Korth et al. 1994; Alderton et al. 2001).
BH4 is a required co-factor for NO synthesis by NOS (Tayeh and Marietta 1989;
Kilbourn 1991; Mayer et al. 1991; Gross and Levi 1992; Sakai et al. 1993; Schoedon
et al. 1993), and recent studies have demonstrated that a lack of BH4 leads to
uncoupling of NOS with a resulting generation of superoxide anion (02~) rather than
NO (Xia and Zweier 1997; Vasquez-Vivar et al. 1998; Xia et al. 1998; Vasquez-










Figure 1.1 Schematic Representation of The Structure of NOS
Electrons flow from NADPH through the flavins (FAD and FMN) of the reductase domain of
one subunit via calmodulin (CaM) to the haem group of the oxygenase domain in the other
subunit. Tetrahydrobiopterin (BH4) is a required co-factor for the synthesis of NO from L-
arginine (L-Arg). Adapted from Alderton et al. (2001).
1.2.2 Mechanism ofAction of NO
The classical pathway by which NO exerts its effects is via activation of the
enzyme soluble guanylate cyclase (sGC), resulting in the conversion of guanosine 5'-
triphosphate (GTP) to 3',5'-cyclic guanosine monophosphate (cGMP) (Schroder et
al. 1985; Feelisch and Noack 1987; Mulsch et al. 1987; Mayer and Bohme 1989;




1.2.2.1 NO-Mediated Activation of sGC
NO diffuses from the site of production, for example endothelial cells, and
passes through the plasma membrane of target cells such as smooth muscle cells,
platelets or inflammatory cells without the need for a membrane bound receptor or
transporter. Following diffusion into target cells, NO activates sGC present in the
cytosol. sGC exists as a heterodimer of a and (3 monomer subunits (Kamisaki et al.
1986; Harteneck et al. 1990). Each sGC monomer consists of a catalytic domain at
the C-terminal, a central dimerisation region and a haem binding domain at the N-
terminal (figure 1.2; Zhao and Marietta 1997; Andreopoulos and Papapetropoulos
2000). NO binds the haem moiety of sGC to form a nitrosyl-haem complex (Ignarro
et al. 1986), increasing the enzymatic activity by up to 400 fold (Stone and Marietta
1996). A histidine residue (His-105) on the P subunit has been identified as critical
for haem-dependent NO binding (Wedel et al. 1994; Zhao et al. 1998), however
several other residues including Cys-78 & 214 (Friebe et al. 1997), Tyr-125, Arg-
139, (Schmidt et al. 2004) and Ser-137 (Schmidt et al. 2005) have more recently
been identified as playing important roles during NO-activation of sGC, as has the
requirement for a complete heterodimer (Foerster et al. 1996). Formation of the
nitrosyl-haem complex leads to activation of the enzyme as the bond with the axial
histidine residues breaks, resulting in changes to the tertiary and quaternary structure
of the enzyme (Deinum et al. 1996; Hobbs 1997). This conformational change in
structure results in a marked increase in the Vmax of sGC and a reduction in the Km of
the substrate GTP from -100 pM — 50 pM, hence resulting in the formation of











Figure 1.2 Schematic Representaion of the Structure of sGC
sGC consisits of three domains as indicated. A hisitidine residue (His 105) on the (3 subunit
is amongst several residues thought to be critical for the binding of NO to the haem
prosthetic group. Adapted from Hobbs (1997).
1.2.2.2 cGMP-Mediated Responses
Elevation of cGMP mediates the cellular effects of NO principally via
activation of cGMP-dependent kinase (PKG) (Carvajal et al. 2000). PKG is a
serine/theronine protein kinase, which exists in two isoforms - PKG I and PKG II
(Vaandrager and de Jonge 1996). PKG acts principally to inhibit Ca2+ signalling, by
2+
triggering a reduction in intracellular calcium concentration, [Ca ]j in platelets
(Geiger et al. 1992; Menshikov et al. 1993; Heemskerk et al. 1994) and smooth
muscle cells (Rashatwar et al. 1987; Chen and Rembold 1992; McDaniel et al. 1992).
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PKG has been demonstrated to phosphorylate a serine residue on the inositol
triphosphate (IP3) receptor of the sarcoplasmic reticulum, preventing Ca2+ efflux into
the cytoplasm, thereby decreasing [Ca2+]; (Komalavilas and Lincoln 1994; Cavallini
et al. 1996; El-Daher et al. 2000; Murthy and Zhou 2003). cGMP can also inhibit the
activity of phospholipase C (PLC), the enzyme responsible for the generation of the
second messenger, IP3 (Lincoln and Cornwell 1993; Carvajal et al. 2000). In
addition to its effects on the IP3 system, PKG has been proposed to elicit decreases in
[Ca2+]i via various other direct and indirect mechanisms. In smooth muscle cells,
direct inhibition of membrane Ca2+ channel activity (Clapp and Gurney 1991;
Quignard et al. 1997), activation of Ca2+/ATPase pumps in the plasma membrane
(Furukawa et al. 1988) and the sarcoplasmic reticulum (Cornwell et al. 1991;
Trepakova et al. 1999), and indirect reduction of the sensitivity of the contractile
filaments to Ca2+ (Carvajal et al. 2000) have been proposed as additional actions of
PKG. PKG may also phosphorylate additional cellular proteins including heat shock
proteins (Hsp), in both smooth muscle cells (Carvajal et al. 2000) and platelets (Butt
et al. 2001). In platelets, vasodilator-stimulated phosphoprotein (VASP) is
phosphorylated by PKG (Halbrugge et al. 1990; Butt et al. 1994; Meinecke et al.
1994). VASP regulates actin polymerisation and organisation in platelets (Reinhard
et al. 1992; Reinhard et al. 2001). Phosphorylation of this protein decreases its
ability to interact with actin filaments (Harbeck et al. 2000) and this correlates with
platelet GPIIb/IIIa receptor inhibition (Horstrup et al. 1994). Overall, these
combined actions of PKG result in inhibition of platelet activation and reduced
10
Chapter One: Introduction
smooth muscle contraction (vasodilatation). Addionally, cGMP has cytostatic effects
in smooth muscle cells (see section 1.4.2.2.1).
Platelet




NO cGMP-independent ► ^ AGGREGATION
pathways
Figure 1.3 The Actions of Endothelial NO on Smooth Muscle Cells and Platelets
NO diffuses from endothelial cells to activate soluble guanylate cyclase (sGC) in target cells.
sGC converts GTP to cGMP. cGMP activates cGMP-dependent protein kinase G (PKG) to
cause a decrease in intracellular calcium concentration [Ca2+]j. Decreasing [Oa2*], results in
inhibition of aggregation in platelets, and in VSMC results in relaxation and hence,
vasodilatation. Extracellular NO can also activate cGMP-independent pathways available to





cGMP is rapidly inactivated by phosphodiesterase enzymes (PDEs), which
convert cyclic nucleotides (both cGMP and cyclic adenosine monophosphate;
cAMP) to their inactive 5'-nucleotides (Moncada et al. 1991; Maurice et al. 2003).
A large family of PDE isoforms exists in mammals, (Beavo 1995; Soderling and
Beavo 2000) most of which will hydrolyse both cGMP and cAMP (Matsumoto et al.
2003). Most cells contain representatives of several isoforms of the PDE family in
varying amounts, however, arguably the most relevant PDE in the cardiovascular
system is PDE V, which specifically hydrolyses cGMP (Thomas et al. 1990;
McAllister-Lucas et al. 1995), and is expressed abundantly in vascular smooth
muscle cells and platelets (Matsumoto et al. 2003). Recently it has been
demonstrated that PKG and protein kinase A (PKA: the enzyme activated by cAMP)
can phosphorylate PDE enzymes in both smooth muscle cells and platelets (Mehats
et al. 1999; Corbin et al. 2000; Liu et al. 2000; Murthy et al. 2002; Mullershausen et
al. 2003). This may provide a long term feedback mechanism to modulate the
responses elicited by cyclic nucleotides.
1.2.2.4 NO-Mediated cGMP-lndependent Responses
Recent studies have established that, in addition to the cGMP-dependent
mechanism of action, NO can also act via a number of cGMP-independent pathways.
The existence of such cGMP-independent pathways has been demonstrated in
several biological systems, most notably during inhibition of platelet aggregation
(Gordge et al. 1998; Tsikas et al. 1999; Sogo et al. 2000a; Crane et al. 2002; Crane et
12
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al. 2005), and regulation of inflammatory cell apoptosis (Ward et al. 2000). The site
of NO production (or delivery in the case of NO donor drugs) appears, to some
degree, to determine whether NO acts via cGMP-dependent or cGMP-independent
pathways. This appears to be the case in platelets, with cGMP-independent
pathways only becoming activated by NO generated extracellularly (Sogo et al.
2000a; Crane et al. 2005); NO-mediated smooth muscle relaxation shows a similar
cGMP-independent component, but its contribution is less significant than in
platelets (Miller et al. 2004).
The existence and understanding of NO-mediated cGMP-independent
pathways has been significantly advanced by the development of the potent and
specific inhibitor of sGC, l-//-[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ;
Garthwaite et al. 1995; Schrammel et al. 1996). ODQ oxidises the ferrous haem of
sGC to the ferric form, vastly reducing NO-stimulated sGC activity (Zhao et al.
2000). ODQ offers significant advantages over previously used sGC inhibitors such
as methylene blue and LY 83583 (6-anilino-5,8-quinolinequinone) which can
generate superoxide anion (O2) and interfere with prostanoid synthesis (Martin et al.
1989; Wolin et al. 1990; Hasegawa et al. 2004).
1.2.3 Chemistry of NO
The simplicity of the NO molecule belies the complex chemistry of this
versatile signalling mediator. Due to its free radical nature, NO can rapidly with
molecular oxygen and reactive oxygen species (ROS) to form a variety of NO-
related species, which may have indirect biological effects of their own. There are
13
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many reports in the literature of NO having opposing effects in various systems. For
example, is has both antioxidant and pro-oxidant properties (Goss et al. 1995; Rubbo
et al. 1995; Struck et al. 1995; Joshi et al. 1999; Wei et al. 2000), cytotoxic and
cytoprotective actions (Polte et al. 1997; Stefanelli et al. 1999; Mason et al. 2000;
Keira et al. 2002; Hattori et al. 2004) and can be pro- or anti-apoptotic (Ward et al.
2000; Kim et al. 2001; Fiscus et al. 2002). This dual modality, and apparent paradox
of NO activity may be explained, at least in part, by the production of intermediary
NO-related species, with the ultimate outcome of any NO-mediated response
depending on the precise NO-related species formed in the microenvironment, as
well as by the concentration of NO generated and the nature of the target cell type.
1.2.3.1 Reaction of NO with Molecular Oxygen
The biological half-life of NO in vivo is extremely short because it reacts
readily with a host of other molecules present in the milieu. NO is oxidised by
molecular oxygen (02) in the gaseous or aqueous phases, to form nitrogen dioxide
(N02: equation 1; Lewis and Deen 1994; Wink et al. 1994). N02 will react with
water (FI20) to form nitrite (NOT) and nitrate (N03~: equation 2; Butler et al. 1995),
but preferentially reacts with NO to form N203 (equation 3; Wink et al. 1993; Espey
et al. 2001). N203 is a powerful S-nitrosating species (see section 1.2.3.2. below)
and will also react with H20 to generate NOL (equation 4).
NO + 02 ). N02 (1)
2N02 + H20 ► NOT + NOT + 2H+ (2)
N02 + NO ► N203 (3)
N203 + H20 ► 2N02" + 2H+ (4)
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1.2.3.2 Reaction of NO with Thiol Groups
N203 is a particularly important NO-related mediator as it is the most relevant
nitrosonium ion (NO+) donor in biological systems (Wink and Mitchell 1998). NO+
is exceedingly reactive in vivo, and 'free' NO+ is never specifically liberated at
physiological pH; instead it is transferred to reduced cysteine residues in proteins, or
thiol groups of low molecular weight compounds, resulting in the formation of S-
nitrosothiols (RS-N=0: equation 5; Kharitonov et al. 1995; Liu et al. 1998;
Jourdlieuil et al. 2003). For example, the S-nitrosation of the plasma protein
albumin, leads to the formation of S-nitrosoalbumin (Stamler et al. 1992; Keaney et
al. 1993; Marley et al. 2001). The production of S-nitrosothiols, including S-
nitrosoalbumin, has recently been proposed as a mechanism for the formation of a
slow release in vivo NO reservoir which may prolong NO bioavailability (Simon et
al. 1993; Scharfstein et al. 1994; Minamiyama et al. 1996; Crane et al. 2005; Orie et
al. 2005).
N203 + RSH ► RS-N=0 + H+ + N02" (5)
S-Nitrosothiols have many of the actions of NO, including the induction of
vasodilatation (Keaney et al. 1993; Kukreja et al. 1993; Rayner et al. 2004) and
apoptosis (Xie et al. 2003; Yasinska et al. 2004), and the inhibition of platelet
aggregation (Simon et al. 1993; Langford et al. 1994; Gordge et al. 1998; Megson et
al. 2000; Miller et al. 2003). The precise mechanism for these actions is not yet fully
understood and may occur without the liberation of NO per se (Kowaluk and Fung
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1990; Ceron et al. 2001), but via rapid transnitrosation reactions resulting in the
transfer ofNO+ from one thiol moiety to another (equation 6; Scharfstein et al. 1994;
Sexton et al. 1994; Askew et al. 1995; Dicks and Williams 1996; Gorren et al. 1996;
Liu et al. 1998; Hogg 1999). However, S-nitrosothiols will liberate free NO under
certain circumstances, including the presence of copper (I) ions (Cu+) or exposure to
light (equation 7; Sexton et al. 1994; Gordge et al. 1995; Dicks and Williams 1996;
Gorren et al. 1996; Singh et al. 1996).
R,SNO + R2S-N=0 ► RjSH + R2S-N=0 (6)
2RS-N=0 , ► 2RSSR + 2NO (7)light v '
S-nitrosation of a range of cellular proteins is now considered to be one of a
number of post-translational modifications that can alter protein function and these
modifications are likely to be responsible for many of the cGMP-independent effects
ofNO (Li et al. 1997; Melino et al. 1997;Mohret al. 1997).
1.2.3.3 Reaction of NO with Superoxide
A further critical reaction of NO in biological systems is that with the ROS,
superoxide (Of), resulting in the formation of peroxynitrite (ONOO": equation 8;
Saran et al. 1990; Czapski and Goldstein 1995; Goldstein and Czapski 1995; Reiter
et al. 2000). ONOO" rapidly forms peroxynitrous acid (ONOOH; equation 9), which
then further decomposes to form N02 and hydroxyl radicals (OH': equation 10;
Wink et al. 1993; Butler et al. 1995) .
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NO + 02" ► ONOO" (8)
ONOO + H+ ► ONOOH (9)
ONOOH ► N02 + OH* (10)
02" is generated in vivo by enzymes including xanthine oxidase (Terada et al.
1991; White et al. 1996; Houston et al. 1999; Sawa et al. 2000; Spiekermann et al.
2003), the family of NADPH oxidases during host defence against invading
pathogens (Mohazzab et al. 1994; Pagano et al. 1995; Somers et al. 2000; Forman
and Torres 2001; Souza et al. 2002) and co-factor deficient NOS (Vasquez-Vivar et
al. 1998; Vasquez-Vivar et al. 1999a; Vasquez-Vivar et al. 1999b). Additionally, 02"
generated by the electron transport chain during respiration can 'leak' from the
mitochondria (Zhang et al. 1998; Liu 1999; Staniek et al. 2002; Nohl et al. 2003).
ONOO" is a powerful oxidising agent, which may be responsible for the cytotoxicity
of high concentrations of NO in many cell types (Szabo 2003; Virag et al. 2003)
including smooth muscle cells (Cao and Li 2004), endothelial cells (Chung et al.
2000; Hashida et al. 2000; Knepler et al. 2001) and macrophages (Tommasini et al.
2002). ONOO" is able to initiate lipid peroxidation (Radi et al. 1991; Graham et al.
1993; Rubbo et al. 1994; Leeuwenburgh et al. 1997a), DNA strand breaks (Szabo et
al. 1996; Zingarelli et al. 1996; Guidarelli et al. 2000) and to induce various protein
modifications including oxidation and nitration of, for example, tyrosine residues
forming nitrotyrosine. The presence of nitrotyrosine is often taken to be the
'footprint' of protein damage by reactive nitrogen species such as ONOO" (van der
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Vliet et al. 1996; Halliwell 1997; Reiter et al. 2000; Sawa et al. 2000; Virag et al.
2003; Radi 2004; Quijano et al. 2005).
Although generally accepted to be cytotoxic in most cells, there is some
evidence that low concentrations of ONOO can be beneficial. For example, ONOO"
has been shown to induce vasodilatation (Davidson et al. 1997; Trakranrungsie and
Will 2001; Li et al. 2004), inhibit platelet activation and aggregation (Brown et al.
1998; Low et al. 2002; Nowak and Wachowicz 2002) and, more recently, to induce
apoptosis in human inflammatory cells - a process which is thought to be critical to
the successful resolution of the inflammatory response (Blaylock et al. 1998; Taylor
et al. 2004). The exact mechanism of these responses remains a source of debate;
some studies suggest that ONOO" undergoes transnitrosation reactions with thiol
groups and that the resultant S-nitrosothiols elicit the response (Mayer et al. 1995;
van der Vliet et al. 1998). However, other studies suggest that S-nitrosothiols are not
involved (Graves et al. 1998), and that ONOO" acts via an alternative mechanism,
possibly by the nitrosation of tyrosine residues (Mondoro et al. 1997; Low et al.
2002; Nowak and Wachowicz 2002)
The reaction of NO with O2" is usually prevented in vivo by the battery of
antioxidants that inactive ROS. For instance, the enzyme superoxide dismutase
(SOD) removes 02" by catalysing its conversion to hydrogen peroxide (H202:
equation 11), which is subsequently further inactivated by catalase (equation 12;




02 + 2H ► O2 + H2O2 (11)
Catalase
02 + H202 ► 02 + 1120 (12)
However, if the production ofROS is such that the antioxidant capacity of the
cell is overcome, then any free NO present will combine rapidly with the ROS to
form ONOO". This situation occurs in oxidative stress, which can be defined as an
imbalance between oxidants and antioxidants in favour of the former.
Overproduction of ROS and the resultant increase in oxidative stress has been
implicated in the pathophysiology of endothelial dysfunction, which is thought to be
a critical early event during atherogenesis (see section 1.4; Harrison et al. 2003;










Figure 1.4 The Chemistry of NO
Nitric oxide (NO) can be oxidised to N203, which is able to transfer a nitrosonium ion (NO+)
to reduced cysteine residues, forming S-nitrosothiols (RS-N=0). NO will combine rapidly
with superoxide ion (02) to form the oxidant species peroxynitrite (ONOO"). ONOO can
react with H+ to form peroxynitrous acid (ONOOH), which can subsequently combine with
NO to generate N203.
1.2.4 iNOS-Derived NO
Although NO production is generally regarded to be beneficial, the high NO
concentrations produced by iNOS in some pathologies can be detrimental. For
example, high NO output from iNOS expressed in vascular smooth muscle cells
(VSMCs) and endothelial cells in response to bacterial endotoxins produces global
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vasodilatation and vascular collapse as a result of hyporesponsiveness to the
vasoconstrictor, noradrenaline, during sepsis (Paya et al. 1995; Parratt 1998).
Subtrate-deficient iNOS has been demonstrated to generate 02~ (Xia and
Zweier 1997; Xia et al. 1998) and this 02~ has been found to contribute to the
vascular hyperactivity seen in a rat model of chronic heart failure (Miller et al. 2000).
Furthermore, iNOS gene deficiency in the apolipoprotein E null (Apo E~'~) mouse
model of atherosclerosis results in reduced lesion development, due to decreased
ONOO" production (Detmers et al. 2000; Kuhlencordt et al. 2001). These studies
suggest that far from being beneficial, elevated levels of iNOS may contribute to, and
exacerbate, the pathogenesis of these conditions. However, genetic deficiency of
iNOS (iNOS~/~) alone is not sufficient to reduce diet-induced atherosclerosis in mice
wild type for the Apo-E gene (Niu et al. 2001), and administeration of L-Arg to
replenish iNOS substrate levels negates the protective effects of iNOS gene deficieny
in double knockout Apo-E'/iNOS'1' mice (Chen et al. 2003). However, the
possibility exists that the concentration of L-Arg administered may not have been
sufficient to totally replenish substrate levels, or the enzyme may also have been
deficient in additional co-factors, such as tetrahydrobiopterin. Alternatively, other
sources of ROS may have been sufficient to counteract any additional NO
production.
Inflammatory cells are potentially a major source of iNOS-derived NO as
iNOS is up-regulated during non-selective host defence against invading pathogens
and, therefore, may contribute substantially to the inflammatory response (Vane et al.
1994; Luss et al. 1996; Salvemini et al. 1996; Salvemini and Marino 1998).
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However, the majority of studies examining the impact of iNOS on various
conditions use primarily rodent models and although rodent inflammatory cells
produce high levels of NO, this is not necessarily the case in human inflammatory
cells. Despite the fact that human macrophages express iNOS messenger ribonucleic
acid (mRNA) and protein, the output of NO in these cells is exceeding low or absent
(Albina 1995; Weinberg et al. 1995; Thomassen and Kavuru 2001; Schneemann and
Schoedon 2002)
Recently, it has been suggested that iNOS transcription may be crucial to the
cytoprotective/cytotoxic balance of NO. Transcription of iNOS is controlled by the
transcription factor, nuclear factor kB (NFkB), the activation of which can be
regulated by NO. Hattori et al propose that NO suppresses, but ONOO" maintains
NFkB activation (Hattori et al. 2004). Therefore, ONOO" is able to drive the
production of iNOS-derived NO and, in cells that are already under oxidative stress,
the NO generated will go on to form further ONOO", hence establishing a cycle of
ONOO" production.
1.3 Apoptosis
Apoptosis, or programmed cell death, is a highly regulated, fundamental
biological process governing cell survival. First described by Kerr et al in 1972
(Kerr et al. 1972), apoptosis differs from necrosis in that the cell is required to
expend energy during apoptosis and the cell membrane remains intact, preventing the
release of the cellular contents prior T> removal by phagocytosis. A large number of
pro- and anti-apoptotic mediators are contained within the cell, and it is the net
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balance of these mediators that determines whether the cell undergoes apoptosis or
remains viable.
Research interest in apoptosis has increased significantly in recent years
following the discovery that many diseases are characterised by dysregulation of
apoptotic pathways, including those with a chronic inflammatory component, such as
atherosclerosis.
1.3.1Characteristics and Pathways ofApoptosis
During the apoptotic process, cells undergo a number of characteristic
morphological changes including membrane blebbing, chromatin condensation,
nuclear fragmentation and cell shrinkage (Uren and Vaux 1996; Wyllie 1997). Cell
surface changes, such as exposure of phosphatidylserine on the outer cell membrane,
allow recognition by phagocytes (Fadok et al. 1992; Fadok et al. 2001; Hoffmann et
al. 2001; Huynh et al. 2002). There are two principal apoptotic pathways: the death
receptor pathway and the 'stress' or mitochondrial pathway.
1.3.1.1 Caspases
Caspase enzymes are aspartate-specific cysteine proteases which are
the central effectors of apoptosis (Alnemri 1997; Miller 1997; Nicholson and
Thornberry 1997). Regardless of whether apoptosis is initiated by the mitochondrial
pathway or the death receptor pathway, caspases are the ultimate effectors of
apoptosis. Caspases have the ability to auto-activate, or to be activated by other
members of the caspase family, as part of an amplification cascade (Zimmermann et
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al. 2001). Caspases-2, -8, -9, and -10, are generally classed as apoptotic initiators,
whilst caspases-3, -6, and -7 are the apoptotic executioners. In non-apoptotic cells,
caspases exist as inactive procaspases until initiation of apoptosis results in
proteolytic cleavage and activation of the enzymes (Thomberry 1997; Kidd 1998).
In addition, caspase activity is also controlled by natural caspase inhibitors present in
cells, called inhibitors of apoptosis proteins (IAPs; Liston et al. 1996; Roy et al.
1997; Deveraux and Reed 1999; Deveraux et al. 1999).
The targets of caspases are the proteins involved in cell homeostatis and
maintenance of the cell structure. For example, caspase-3 cleaves the inhibitor of
caspase-activated deoxyribonuclease (iCAD) allowing the active enzyme, caspase-
activated deoxyribonuclease (CAD), to cut the chromatin, resulting in DNA
fragmentation (Liu et al. 1997; Enari et al. 1998; Sakahira et al. 1998). In addition to
their role in DNA degradation, caspases are also responsible for the disassembly of
the cytoskeleton through cleavage of structural proteins such as actin and fodrin,
resulting in the dissociation of the cyoskeleton from the plasma membrane (Martin et
al. 1995; Vanags et al. 1996). DNA degradation and disassembly of the cytoskeleton
and nucleus result in the membrane blebbing, cell shrinkage and nuclear
condensation characteristic of apoptosis (Thornberry 1997).
24
Chapter One: Introduction
1.3.1.2 Death Receptor Pathway ofApoptosis
The death receptor pathway of apoptosis is triggered when ligands such as
tumour necrosis a (TNF-a), Fas ligand (Fas-L), or TNF-related apoptosis-inducing
ligand (TRAIL), activate their corresponding 'death receptors' - TNF receptor 1
(TNF-R1), the Fas receptor or the TRAIL receptor respectively. Death receptors are
characterised by an extracellular region of cysteine-rich repeats, plus an intracellular
amino acid sequence at the carboxy terminus of the receptor termed the 'death
domain' (DD; Zimmermann et al. 2001). The DD is responsible for coupling the
death receptor to a cascade of caspases, initiating apoptosis.
Ligation of a death receptor causes rapid formation of the death-inducing
signalling complex (DISC). Adaptor proteins such as Fas-associated protein with
death domain (FADD), or TNF-Rl-associated protein with death domain (TRADD),
are then recruited to the receptor death domain (Erickson 1997; Zimmermann et al.
2001; Algeciras-Schimnich et al. 2002). Adaptor proteins such as FADD also
contain a death effector domain (DED) that is able to recruit procaspase-8
(Zimmermann et al. 2001; Boatright and Salvesen 2003). Procaspase-8 monomers
undergo dimerisation to yield the active caspase-8 enzyme (Boatright and Salvesen
2003; Donepudi et al. 2003), which goes on to trigger the apoptotic caspase cascade
via proteolytic cleavage of procaspase-3, -6 and -7 (Stennicke et al. 1998). Caspase-
8 can also activate the mitochondrial pathway of apoptosis by causing Bid
translocation to the mitochondria (see section 1.3.1.3; Zimmermann et al. 2001).
Caspase-8 activation is additionally controlled by FLICE-like inhibitory protein
(FLIP; caspase-8 was initially known as FLICE). FLIP can be both pro- and anti-
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apoptotic depending on its concentration within the cell: at low levels of expression
(close to those expected in a normal cell) FLIP enhances receptor-induced caspase-8
activation at the DISC, whilst at supraphysiological levels of expression FLIP can
inhibit caspase-8 activation (Chang et al. 2002; Boatright and Salvesen 2003).
1.3.1.3 Mitochondrial Pathway ofApoptosis
Mitochondria play an essential role in apoptosis by releasing pro-apoptotic
molecules, such as cytochrome c, into the cytoplasm which then go on to induce
apoptosis (Green and Reed 1998). The mitochondrial pathway is broadly controlled
by members of the Bcl-2 family of proteins (Kluck et al. 1997; Yang et al. 1997).
Bcl-2 proteins can be both anti- and pro-apoptotic. Anti-apoptotic Bcl-2 proteins
include (amongst others) Bcl-2, Bcl-XL, and Bcl-w, whilst the pro-apoptotic
members include Bid, Bad, Bim and Bik (Zimmermann et al. 2001). Anti-apoptotic
Bcl-2 members promote cell survival by preventing cytochrome c release from the
mitochondria (Kluck et al. 1997; Yang et al. 1997); pro-apoptotic members initiate
cytochrome c release.
During apoptosis, the pro-apoplotic Bcl-2 proteins are activated and
translocate to the mitochondria where they trigger the release of cytochrome c into
the cytoplasm. Following cytochrome c release, the 'apoptosome', consisting of
cytochrome c, apoptotic protease activating factorl (Apaf-1) and procaspase-9, forms
(Zou et al. 1999). The binding of Apaf-1 to procaspase-9 in the apoptosome results
in activation of procaspase-9 (Rodriguez and Lazebnik 1999; Stennicke et al. 1999),
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Figure 1.5 Schematic Representation of the Pathways of Apoptosis
Engagement of death receptors (eg TNFR-1) causes DISC formation and activation of
caspase-8, which in turn activates the effector caspases-3,6 & 7 to trigger apoptosis.
Additionally caspase-8 is able to initiate the mitchondrial pathway by causing translocation
of the Bcl-2 protein, Bid, to the mitochondria. Pro-apoptotic Bcl-2 members cause
cytochrome c release from the mitochondria. Cytochrome c combines with apoptotic
protease activating factorl (Apaf-1) and procaspase-9 to form the apoptosome, resulting in
generation of active caspase-9. Caspase-9 activates caspases-3,6 & 7 to trigger apoptosis.
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1.3.2 Inflammatory Cell Apoptosis
Because inflammatory cell apoptosis occurs without disruption of the cell
membrane and ensuing release of histotoxic and pro-inflammatory mediators from
the cytoplasm (Meagher et al. 1992; Stem et al. 1996; Lawrence et al. 2002),
apoptosis represents a non-inflammatory mechanism for the removal of cells from a
site of tissue damage, and hence, is critical to the successful resolution of the
inflammatory response (Haslett 1997; Madema and Godson 2003; Taylor et al. 2003;
Rossi et al. 2004). Apoptotic cells are instantly recognised by phagocytes, such as
macrophages, and removed from the site of inflammation (Savill et al. 1989; Fadok
et al. 1992; Savill et al. 1993). Failure of inflammatory cells to undergo apoptosis, or
failure of the subsequent phagocytic removal of apoptotic cells, for example, if the
population of phagocytes is overwhelmed by the number of apoptotic cells,
incomplete resolution of the inflammatory response can occur (figure 1.6). This
happens because apoptotic cells remaining in situ undergo secondary necrosis, during
which the cell membrane ruptures and the pro-inflammatory, histotoxic granule
contents are released into the surrounding tissue, causing an exacerbation of the
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Figure 1.6 Non-Inflammatory and Pro-Inflammatory Fate of Inflammatory Cells
During apoptosis the cell membrane is maintained and the histoxic cell contents retained
within the cell. Apoptotic cells are recognised by phagocytes and removed from a site of
inflammation. Failure, or overwhelming of phagocytic clearance mechanisms leads to
secondary necrosis. During necrosis the cell membrane is disrupted, causing release of the
histotoxic cell contents into the surrounding tissue and resulting in an exacerbation of the
inflammatory response.
NO can be both pro- and anti-apoptotic in many cell systems. As apoptosis
involves manifold pathways and signalling cascades, it is likely there are multiple
NO-dependent targets for the regulation of apoptosis, depending on the nature of the
target cell. Current evidence suggests that lower NO concentrations produced
1.3.3 NO as a Mediator ofApoptosis
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constitutively by eNOS and nNOS are cytoprotective via primarily cGMP-dependent
mechanisms, whilst higher, supraphysiological concentrations generated in some
pathologies by iNOS mediate apoptosis via mechanisms independent of cGMP
(Nicotera et al. 1997). For example, high concentrations of either exogenous or
endogenous iNOS-derived NO have been shown to induce apoptosis in various cell
types including macrophages, endothelial cells and smooth muscle cells (Albina et al.
1993; Sarih et al. 1993; Muhl et al. 1996; Bennett and Boyle 1998), and this has been
demonstrated to occur independently of cGMP signalling (Wang et al. 1999). The
precise downstream effectors of NO-induced apoptosis remain to be elucidated, but
there is some evidence to suggest that NO causes a profound down-regulation of LAP
proteins (Manderscheid et al. 2001). However, this effect is cell type specific,
occurring in macrophages but not mesangial cells. Alternatively, NO may act to
enhance, or sensitise cells to Fas/Fas-L mediated apoptosis (Garban and Bonavida
1999; Boyle et al. 2002).
Conversely, pre-treatment of RAW 264.7 cells (a mouse macrophage cell
line) with relatively low concentrations of exogenous NO, delivered by synthetic NO
donor compounds, confers cGMP-dependent protection against cell death upon
subsequent exposure to concentrations of NO which would normally be sufficient to
be cytotoxic (von Knethen et al. 1999; Yoshioka et al. 2003). Similarly, endogenous
eNOS and iNOS-derived NO inhibits apoptosis in various cell types, possibly by
regulating levels of death receptor ligands such as TNF-a and Fas-L (Furuke et al.
1999; Hatano et al. 2001). S-Nitrosothiols have also been demonstrated to decrease
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apoptosis by directly inhibiting caspase-3 activation via S-nitrosation of thiol groups
on the enzyme (Kim et al. 1997; Mohr et al. 1997).
The dual effect of NO in apoptosis may be attributed to the chemistry of NO
and the ease with which it forms various NO-related species (see section 1.2.3). A
critical reaction of NO in vivo is that with O2, resulting in the formation of ONOO".
The precise role of ONOO" in inflammatory cell apoptosis remains to be elucidated.
There is some evidence to suggest that at high concentrations (100-300 pM), ONOO"
induces apoptosis in RAW 264.7 cells (Sandoval et al. 1997), whilst at lower
concentration (30-50 pJM) it may have a protective effect against lipopolysaccharide
(LPS) and interferon (IFN)-y-induced apoptosis in these cells (Scivittaro et al. 1997).
Brockhaus et al have demonstrated that over-expression of copper/zinc SOD
(CuZnSOD) can protect RAW 264.7 cells against apoptosis initiated by NO, either
exogenous or iNOS-derived, suggesting ONOO" may be the mediator of NO-induced
apoptosis (Brockhaus and Brune 1999). Similarly, delivery of exogenous ONOO"
has recently been shown to induce apoptosis in human neutrophils (Taylor et al.
2004).
Whilst endogenous macrophage iNOS-derived NO has been shown to induce
apoptosis in animal models, this is not necessarily the case in human macrophages,
where NO production is exceedingly low or absent (Albina 1995; Weinberg et al.
1995; Thomassen and Kavuru 2001; Schneemann and Schoedon 2002). However,
despite this reduced capability to produce endogenous NO, human macrophages do
undergo apoptosis in response to exogenous NO and NO-related species. For
example, the NO donors S-nitrosoglutathione (GSNO) and spermine
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diazeniumdiolate (SPER/NO) induce apoptosis in primary human monocytes-derived
macrophages (von Knethen et al. 1999).
Phagocyte (e.g., macrophage) Ingesting phagocyte
Endothelial cell
Figure 1.7: The Pro- and Anti-Apoptotic Actions of NO
High concentrations of NO synthesised by iNOS in phagocytes, such as macrophages,
induce apoptosis in neighbouring cells. In addition, apoptosis can also be induced by
ONOO" generated as 02~ produced by phagocytes reacts with NO. Apoptotic cells are
subsequently recognised and ingested by phagocytes, thus aiding the resolution of
inflammation. Conversely, low concentrations of NO produced constitutively by eNOS in




Atherosclerosis is characterised by the formation of lipid-rich plaques in the
sub-endothelial space of large conduit blood vessels (Badimon et al. 1993; Ross
1993; Ross 1999a; Ludewig et al. 2002). These plaques, which are the hallmark of
the disease, are usually eccentric (occupying one side of the vessel; figure 1.8) and
consist of a necrotic core of lipid-laden inflammatory cells encapsulated by a fibrous,
collagen-rich cap made up of vascular smooth muscle cells (VSMC) and
extracellular matrix (Ross 1993; Davies 1997; Ross 1999a). Advanced lesions may
also be vasculised by new blood vessels (O'Brien et al. 1994; Kumamoto et al. 1995)




one side of the vessel
Figure 1.8 Schematic Representation of the Eccentric Position of Atherosclerotic
Plaques
Atherosclerotic plaques form in the vessel wall and are usually eccentric - occupying one




Despite decades of arduous research efforts in both humans and animal
models of atherosclerosis, the underlying causes of atherogenesis remain largely
unknown. Atherosclerotic lesions are known to be initiated early in life: in 1953
Enos et al described advanced lesions in the coronary arteries of young soldiers
killed in the Korean War, whose average age at the time of death was just 23 (Enos
et al. 1953), and the earliest recognisable lesions of atherosclerosis, non-stenotic
'fatty streaks', have been observed in children, including neonates (McGill et al.
2000).
1.4.1.1Endothelial Dysfunction in Atherosclerosis
In healthy vessels, endothelium-derived NO contributes not only to control of
vascular tone but also to the maintenance of vessel wall integrity and to inhibition of
platelet and leucocyte activation (Radomski et al. 1987a; Radomski et al. 1987b;
Gauthier et al. 1994; Kanwar and Kubes 1995). A critical early event during
atherogenesis is believed to be endothelial cell injury and damage, resulting in
endothelial dysfunction. One of the major consequences of endothelial dysfunction
is a decrease in the net bioavailability of NO. This is seen in conditions predisposing
to atherosclerosis such as hypercholesterolaemia, diabetes and cigarette smoking.
Such conditions are associated with endothelial dysfunction, which is usually
assessed in terms of impaired of endothelium-dependent vasomotion that can be
reversed by delivery of exogenous NO (Osborne et al. 1989; Chowienczyk et al.
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1992; Kim et al. 1994; Zeiher et al. 1995b; Cooper and Heagerty 1998; Cosentino
and Luscher 1998; Poredos et al. 1999; De Vriese et al. 2000; Esen et al. 2004).
Endothelial dysfunction can result from oxidative stress and the retention in
the vessel wall of pathogenic oxidation-modified low density lipoproteins (ox-LDL -
see section 1.4.2.1; Simon et al. 1990; Tanner et al. 1991; Buckley et al. 1996;
Mougenot et al. 1997). Additionally, physical damage to endothelial cells can occur
as a result of abnormal shear stress within the vessel. Atherosclerotic plaques tend to
form in areas of the arterial tree exposed to particularly turbulent blood flow, such as
bifurcation points, or in areas exposed to particularly low shear stress (Ku et al.
1985; Salzar et al. 1995; Thubrikar and Robicsek 1995; Gnasso et al. 1997; Jiang et
al. 2000). Conversely, plaque initiation and progression is significantly decreased in
regions of laminar flow. This is thought to be because laminar flow is a stimulus for
transcription of atheroprotective genes, such as the genes for eNOS and SOD (Busse
and Fleming 1998; Traub and Berk 1998; Silacci et al. 2000; Berk et al. 2001), and
because shear stress is a major activator of NOS (Gallis et al. 1999; Fisslthaler et al.
2000; Busse and Fleming 2003; Fleming and Busse 2003)
1.4.1.2 Inflammation in Atherosclerosis
It is now broadly accepted that there is an inflammatory component to
atherosclerosis (Badimon et al. 1993; Vogel 1997; Ross 1999a; Ross 1999b; Berk et
al. 2001; Libby 2002; Robbins and Topol 2002). This was first described in 1989
when Hanson et al detected activated T-lymphocytes in human atherosclerotic
plaques excised from carotid endarterectomy specimens and proposed a mechanism
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for the involvement of the immune system in atherosclerosis (Hansson et al. 1989a;
Hansson et al. 1989b). Since then, this hypothesis has been widely accepted and
atherosclerosis is now considered to be the consequence of a chronic low-grade
inflammatory process which, over time, comes to constitute the disease process itself
(Badimon et al. 1993; Vogel 1997; Ross 1999a; Ross 1999b; Berk et al. 2001; Libby
2002; Robbins and Topol 2002).
The inflammatory response, widely acknowledged to be initiated by the
retention of pathogenic lipids in the vessel wall and consequent endothelial injury, is
characterised by the expression of numerous cytokines and adhesion molecules for
mononuclear leucocytes on the surface of activated endothelial cells (Ross 1999a;
Ross 1999b; Libby 2002). These molecules, including integrins, immunoglobulins,
and selectins and their ligands, are responsible for the recruitment of leucocytes to
the site of inflammation through a series of events involving leucocyte rolling along
the endothelial surface, firm leucocyte adhesion and activation at the site of
inflammation, followed by diapedesis through the endothelium to the vessel intima
(Lefer and Granger 1999; Huo and Ley 2001). A variety of studies in both
atherosclerosis-prone mice and human excised arteries containing plaques have
demonstrated that the endothelium in lesion-prone areas, or that overlying pre¬
existing plaques, expresses many leucocyte adhesion molecules, which include P-
and E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell
adhesion molecule-1 (VCAM-1; Davies et al. 1993; Ramos et al. 1999; Collins et al.
2000; Dong et al. 2000; Huo et al. 2000; Huo et al. 2001). Of these, VCAM-1, a
member of the cytokine-inducible Ig superfamily which bind leucocyte integrins, has
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been identified as playing a critical role in early atherogenesis and one which is
distinct from the structurally and functionally similar ICAM-1 (Cybulsky et al.
2001). The importance of leucocyte adhesion and migration during atherogenesis
has been further illustrated in studies in which the gene for various adhesion
molecules or chemokines have been deleted in mice already genetically susceptible
to atheroma, such as the apolipoprotein E null (Apo E'1'), or the LDL receptor null
(LDLrmouse models of the disease. In these studies, the double knockout mice
have markedly reduced lesion area and show greatly reduced monocyte accumulation
within the plaque compared to their single knockout Apo E~'~ or LDLr7" controls
(Boisvert et al. 1998; Boring et al. 1998; Gu et al. 1998; Huo and Ley 2001).
Once resident in the intima, monocytes differentiate into macrophages under
the influence of various colony stimulating factors, such as macrophage colony-
stimulating factor (M-CSF; Takahashi et al. 2002). M-CSF expression is elevated in
both human and animal plaques and, when deleted in atherosclerosis-prone mice,
lesion development is greatly retarded due to decreased macrophage accumulation
(Clinton et al. 1992; Rosenfeld et al. 1992; Smith et al. 1995). Following
differentiation, macrophages express scavenger receptors facilitating the
internalisation of ox-LDL (Henriksen et al. 1981; Parthasarathy et al. 1986;
Haberland et al. 1992; Parthasarathy et al. 1992; Hazell and Stacker 1993).
Accumulation of ox-LDL is allowed to continue unchecked because, unlike the
native LDL receptor, scavenger receptors are not down-regulated once the cell is
cholesterol-replete (Brown and Goldstein 1983). This results in the formation of
cytosolic droplets of cholesterol and cholesterol esters within macrophages. In this
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lipid-laden condition, macrophages are known as foam cells and it is an
accumulation of foam cells which characterises the earliest recognisable
atherosclerotic lesions, known as 'fatty streaks' (Schwartz et al. 1991; Ross 1993).
However, scavenger receptors can also regulate cholesterol efflux from the cell and,
therefore, foam cell formation is a dynamic process and the net result of total
cholesterol flux within the cell (Schwartz et al. 1991).
1.4.1.2.1 NO as an Anti-Inflammatory Agent in Atherosclerosis
Following the establishment of inflammation as a critical process during
initiation, progression and complication of atherosclerotic plaques (Ross 1999a; Ross
1999b; Libby 2002; Libby et al. 2002; Robbins and Topol 2002), many studies have
demonstrated an anti-inflammatory role for NO. Pharmacological inhibition of NOS
to limit NO production has been demonstrated to increase monocyte adhesion and
infiltration into vessels in animal models of atherosclerosis, whilst administration of
L-Arg or NOS gene transfer to boost NO production decreases inflammatory cell
adhesion (Tsao et al. 1994; Tomita et al. 1998; Qian et al. 1999). Similarly,
leucocyte rolling and leucocyte-endothelial interactions are increased in eNOS and
nNOS deficient mice (Lefer et al. 1999). Delivery of exogenous NO to human
endothelial cell cultures results in a decreased expression of adhesion molecules,
such as VCAM-1, and chemokines, such as monocyte chemoattractant protein-1
(MCP-1), which are thought to be critical for the migration of monocytes into the
intima at sites of atherosclerotic lesion formation (De Caterina et al. 1995; Zeiher et
al. 1995a; Tomita et al. 1998).
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1.4.2 Atherosclerotic Plaque Progression
Once the fatty streak has been established, the plaque evolves and develops
into a complicated lesion consisting of a necrotic core of lipid-laden inflammatory
cells encapsulated by a layer of VSMC, forming a fibrous cap over the lesion surface
(Ross 1993; Davies 1997; Ross 1999a). Plaque growth occurs as the ox-LDL
accumulated in macrophage-derived foam cells is released into the surrounding
tissue following necrosis of foam cells and this causes further endothelial damage
(Simon et al. 1990; Tanner et al. 1991; Buckley et al. 1996; Mougenot et al. 1997)
and is chemoattractant for additional inflammatory cell recruitment (Quinn et al.
1987; McMurray et al. 1993; Ruan et al. 1996; Wang et al. 1997a; Wang et al.
1997b). Hence, a perpetual cycle of endothelial damage, monocyte recruitment and
peroxidation and accumulation of lipids is established.
1.4.2.1 Lipid Peroxidation in Atherosclerosis
Peroxidation of lipids was proposed as a key step in atherogenesis following
the observation that oxidative modification of LDL by cells, or by oxidising species
generated in vivo, could cause LDL to become cytotoxic (Hessler et al. 1983; Morel
et al. 1983; Morel et al. 1984). Internalisation and accumulation of lipids in the form
of cholesterol and cholesterol esters is a central feature of atherosclerosis, with lipid-
laden cells eventually becoming necrotic and releasing their contents to form the
plaque core. However, native lipids do not accumulate in cells because the native
LDL receptor is down-regulated once the cell becomes cholesterol-replete (Brown
and Goldstein 1983). Lipids only accumulate once they have been modified,
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rendering them recognisable by scavenger receptors which are not down-regulated
by cholesterol loading in the cell (Henriksen et al. 1981; Parthasarathy et al. 1986;
Haberland et al. 1992; Parthasarathy et al. 1992; Hazell and Stacker 1993). The LDL
particle consists of an apolar core of cholesteryl esters and triglycerides, surrounded
by a monolayer of phospholipids, unesterified cholesterol and the protein molecule
apolipoprotein B 100 (Orlova et al. 1999; Rubbo and O'Donnell 2005). In addition,
lipophilic antioxidants, including a-tocopherol (vitamin E) and carotenoids are also
present in the LDL particle (Rubbo and ODonnell 2005). Modification of LDL can
occur by acetylation, and, possibly most importantly in the context of atherosclerosis,
oxidation. Polyunsaturated fatty acid residues (those that contain more than one
carbon-carbon double bond) in the LDL particle are more susceptible to oxidation, as
the carbon-hydrogen bond adjacent to the double bond is weaker and therefore, the
hydrogen atom is easier to abstract from the bis-allylic methylene (-CH2-) group.
Hydrogen atom abstraction results in the formation of a lipid peroxyl radical
(Holvoet and Collen 1994; Maxwell and Lip 1997). The peroxyl radical formed is
able to abstract a hydrogen atom from an adjacent unsaturated fatty acid producing a
second peroxyl radical which goes on to oxidise surrounding fatty acids. Thus, a
self-propagating chain reaction is established. This sequence of oxidation events can
be terminated by 'chain breaking' anti-oxidants, which react with reactive radicals to
form unreactive radicals. Such compounds, including glutathione, vitamin E,
vitamin C and ubiquinol-10, are electron rich compounds, which are sacrificed
(oxidised) when the cell is under oxidative stress (Carr et al. 2000b). Additionally,
enzymes such as SOD, catalase, and glutatione peroxidase remove damaging oxidant
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species from the cell. Only when oxidative stress within a cell has overcome the
intracellular anti-oxidant defence capacity, will damaging oxidation occur. Such an
event might occur as a result of increased generation of oxidants or depletion or
down-regulation of antioxidant defences, as has been demonstrated recently in a
study showing that glutathione synthesis is depleted in advance of lipid peroxidation
and detectable atheroma in ApoE'1' mice (Biswas et al. 2005).
The initiators of lipid peroxidation in vivo are still not fully established, but
possible oxidising candidates include copper (and other transition metal) ions, either
free or bound in prosthetic groups of proteins, for example the haem group in
proteins such as haemoglobin (Heinecke et al. 1984; Heinecke 1997a). Metal ions
are able to react with H202 in the Fenton Reaction to generate powerful oxidising
OH* radicals (Valko et al. 2005). However, given that these ions are present under
normal physiological conditions, perhaps more likely is decreased anti-oxidant
capacity within the cell, occurring in combination with the generation of powerful
oxidising free radical species present in vivo (Heinecke 1997a; Maxwell and Lip
1997). There are numerous sources of oxidising free radical species present in the
vessel wall including xanthine oxidase (Terada et al. 1991; White et al. 1996;
Houston et al. 1999; Sawa et al. 2000; Spiekermann et al. 2003), co-factor deficient
NOS (Vasquez-Vivar et al. 1998; Vasquez-Vivar et al. 1999a; Vasquez-Vivar et al.
1999b), and the mitochondrial electron transport chain (Zhang et al. 1998; Liu 1999;
Staniek et al. 2002; Nohl et al. 2003). Additionally, activated inflammatory cells
present in the vessel wall express enzymes capable of producing oxidising species
usually associated with host defence against invading pathogens (for example, the
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family of NADPH oxidases and myloperoxidase (MPO; Klebanoff 1980; Mohazzab
et al. 1994; Pagano et al. 1995; Somers et al. 2000; Forman and Torres 2001; Souza
et al. 2002)). MPO, a member of the haem peroxidase superfamily generates various
species implicated in the oxidation of lipids, including H2O2, hyperchlorous acid
(HOC1), and the products of L-tyrosine oxidation - tyrosyl radical and p-
hydroxyphenylacetaldehyde (pHA; Savenkova et al. 1994; Heinecke 1997b; Yang et
al. 1999; Carr et al. 2000a; Heller et al. 2000; Jerlich et al. 2000; Podrez et al. 2000).
The presence of the MPO enzyme has been demonstrated in human atherosclerotic
lesions (Daugherty et al. 1994), and specific markers of MPO-mediated lipid
modification, for example 3-chlorotyrosine and dityrosine, have been isolated from
both animal and human atherosclerotic plaques, suggesting that this may be the most
physiological relevant mechanism of lipid peroxidation during atherogenesis (Hazen
and Heinecke 1997; Leeuwenburgh et al. 1997b; Heinecke 1999; Hazen et al. 2000;
Heller et al. 2000).
1.4.2.1.1 Pro-OxidantRole ofNO in Lipid Peroxidation
The role of NO in lipid peroxidation is complex due to its ability to form
various NO-related species. NO can be both pro- and anti-oxidant towards lipids,
depending on the redox balance of the microenvironment. NO alone is not a strong
enough oxidising agent to initiate the peroxidation chain reaction (Darley-Usmar et
al. 1992; Rubbo et al. 1994; Hogg and Kalyanaraman 1999). However, mass
spectrometric studies have revealed significantly elevated levels of nitrotyrosine (a
marker for protein damage by reactive nitrogen species (van der Vliet et al. 1996;
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Halliwell 1997)) in LDL recovered from human atherosclerotic aortae compared to
LDL isolated from plasma of healthy donors (Leeuwenburgh et al. 1997a). NO in
combination with 0{ results in the formation of ONOO" (see section 1.2.3.3) which
is a powerful oxidising agent and able to initiate LDL oxidation (Radi et al. 1991;
Darley-Usmar et al. 1992; Hogg et al. 1993a; Hogg et al. 1993b; Leeuwenburgh et al.
1997a). Furthermore, this ONOO-mediated modification leads to recognition by
scavenger receptors and rapid accumulation in macrophages (Graham et al. 1993).
Graham et al propose that ONOO" may act to modify lipids by altering the protein,
lipid and anti-oxidant composition of LDL, most notably, by depleting the anti¬
oxidant vitamin E content of the particle via the conversion of a-tocopherol to a-
tocopherol quinone (Graham et al. 1993). Reactive nitrogen species are also
involved in MPO-mediated lipid oxidation (Byun et al. 1999; Hazen et al. 1999;
Schmitt et al. 1999), because nitrite (N02~) acts as a co-substrate for MPO and will
also react with HOC1 to generate nitrating and chlorinating species (Eiserich et al.
1996; van der Vliet et al. 1997; Eiserich et al. 1998; Sampson et al. 1998). MPO-
generated reactive nitrogen species have been demonstrated to convert LDL into an
atherogenic form (Podrez et al. 1999) and lipids damaged by reactive nitrogen
species have been isolated from human atherosclerotic intima (Pennathur et al.
2004).
1.4.2.1.2 Anti-oxidant Role ofNO in Lipid Peroxidation
In addition to the pro-oxidant characteristics of NO-related species, there is
some evidence to suggest that NO is able protect against LDL oxidation, providing
the concentration is sufficient to counteract any other oxidising agents present in the
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cell. Relatively high NO concentrations (12 uM) generated by murine cytokine-
stimulated macrophages have been demonstrated to inhibit macrophage-driven lipid
peroxidation (Yates et al. 1992). Similarly, continuous NO release from NO donor
drugs inhibits LDL oxidation, possibly because NO is able to act as a chain breaking
anti-oxidant by reacting with lipid radicals such as alkyl (L/), alkoxyl (LO-) and
peroxyl (LOO-) radicals (Hogg et al. 1993c; Padmaja and Huie 1993; O'Donnell et
al. 1997; Hogg and Kalyanaraman 1999; O'Donnell and Freeman 2001).
1.4.2.2 The Plaque Cap
VSMC proliferation is an important component of vessel wall remodelling in
response to injury during atherosclerosis. Activated VSMCs undergo hypertrophy
and/or hyperplasia during the atherosclerotic process to form the plaque cap, which
also contains endothelial cells and fibroblasts (Ross 1993). During this process,
VSMCs undergo phenotyptic alteration from the adult vascular contractile
phenotype, to a synthetic phenotype usually seen in developing vessels, and the
VSMCs of the plaque cap are now considered to have a distinct phenotype (Bonin et
al. 1999; de Vries et al. 2000; Blindt et al. 2002; Zhang et al. 2002; Mulvihill et al.
2004). However, characterisation of VSMCs into only two distinct phenotypes is a
vast over-simplification. A wide spectrum of diverse, intermediary, phenotypes with
differential gene expression, exist under different physiological and
pathophysiological conditions, without a clear distinction between phenotypes. This
is especially true when VSMCs are undergoing phenotypic transition and there may
be several sub-populations of VSMCs present within the plaque at any given time
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(Owens et al. 2004). In a synthetic phenotype, VSMCs have the ability to proliferate
and produce connective tissue and extracellular matrix macromolecules including
elastin and collagen (Newby and George 1996). These molecules form a mesh over
the fatty streak and, following calcification, form the fibrous cap over the plaque,
encapsulating the highly thrombogenic lipid core and maintaining a barrier between
the plaque contents and the circulation (Badimon et al. 1993; Davies 1997).
There is currently some debate as to the origins of VSMCs present in the cap.
Initially they were thought to migrate from the media into the intima, however,
recently it has been proposed that there may be bone marrow-derived smooth muscle
progenitor cells circulating in the blood which are then recruited to the site of vessel
damage (Hillebrands et al. 2001; Sata et al. 2002; Simper et al. 2002; Deb et al.
2004).
1.4.2.2.1 The Role ofNO in VSMC Proliferation
Numerous studies have demonstrated that NO is able to inhibit VSMC
proliferation (Garg and Hassid 1989; Kariya et al. 1989; Nakaki et al. 1990;
Assender et al. 1992; Newby et al. 1992; Mooradian et al. 1995; Jeremy et al. 1999).
The exact mechanism of this inhibition remains to be elucidated, with some authors
reporting that the anti-proliferative of NO are cGMP-dependent (Garg and Hassid
1989), whilst others suggest cGMP-independent inhibition of the enzymes arginase
and ornithine decarboxylase is involved (Ignarro et al. 2001).
The ability of NO to inhibit VSMC proliferation has led to the hypothesis that
reduced NO bioavailability occurring as a result of endothelial dysfunction in
45
Chapter One: Introduction
atherosclerosis may contribute to the formation of the plaque cap. A number of
studies have reported that eNOS gene therapy inhibits luminal narrowing following
vascular injury by preventing VSMC proliferation (von der Leyen et al. 1995; Tzeng
et al. 1996; Janssens et al. 1998). However, these studies are not strictly a model of
atherosclerosis, and the presence of the cap may be a protective response, preventing
plaque rupture (see section 1.4.3).
1.4.3 Atherosclerotic Plaque Rupture
Although atherosclerotic lesions may be widespread by middle age, the vast
majority remain sub-clinical with only a small minority of plaques becoming
symptomatic (Rudd et al. 2005). The physical presence of a plaque within an arterial
wall may impinge on the vessel lumen causing partial occlusion of the vessel. Such
an occlusion may be sufficient to cause substantial blood flow restriction and tissue
ischaemia, which, if occurring in the coronary vessels, results in chronic stable
angina pectoris. However, arteries are dynamic rather than static and can remodel to
compensate for this, allowing a vessel to accommodate an expanding plaque without
a significant decrease in lumen diameter (Glagov et al. 1987). Thus, large
atherosclerotic lesions may be, and often are, considered 'stable' and remain
asymptomatic. Of far greater clinical significance are unstable, or ruptured plaques.
Plaque instability occurs if the cap is subject to mechanical breakdown or erosion,
increasing the propensity of a plaque to rupture.
In the stable plaque, the VSMC cap serves as a barrier to ensure the highly
thrombogenic contents of the plaque core are separated from the circulation. When
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the cap is compromised and the thrombogenic contents of the core are exposed to the
circulation, platelets are rapidly recruited and activated, and a thrombus forms.
Plaque rupture can occur several times and remain subclinical with the VSMC cap
reforming, or healing, over the top of the thrombus which becomes incorporated into
the growing lesion, resulting in a layering, or 'onion skin', effect within the plaque
(Mann and Davies 1999). However, if the resulting thrombus is sufficiently large, it
can further occlude the vessel in situ leading to the clinical symptoms of angina
pectoris. Alternatively, if the thrombus detaches form the plaque surface, the
resulting embolus can occlude smaller vessels downstream, leading to the acute
cardiovascular syndromes, such as myocardial infarction and stroke (Davies 1995;
Schroeder and Falk 1995; Dalager-Pedersen et al. 1998; Gutstein and Fuster 1999;
Zhou et al. 1999; Corti and Badimon 2002; Mitra et al. 2004).
The determinants of plaque vulnerability to destabilisation and rupture have
yet to be fully identified, but a growing body of evidence is emerging that points to a
critical role for both the thickness of the VSMC layer overlaying the core (Leskinen
et al. 2003) and to inflammatory processes occurring within the plaque (Libby 2002;
Robbins and Topol 2002; Lombardo et al. 2004). For example, a plaque containing a
large lipid pool, with a high inflammatory cell content and a thin fibrous cap
containing relatively few VSMCs is more prone to rupture than a plaque with a lower
inflammatory cell content and a thicker cap, containing a relatively high VSMC
density (Davies 1996; Felton et al. 1997).
Given that plaque rupture is now considered the critical determinant of acute
cardiovascular syndromes (Bonin et al. 1999; de Vries et al. 2000; Blindt et al. 2002;
47
Chapter One: Introduction
Zhang et al. 2002; Mitra et al. 2004; Mulvihill et al. 2004), a clinical need exists to
identify those individuals with potentially unstable plaques who are at high risk of
cardiovascular events (Stefanadis et al. 2003; Rudd et al. 2005).
1.4.3.1 The Role of Matrix Metalloproteinases in Plaque Rupture
Matrix metalloproteinases (MMPs) are a family of zinc-dependent
endopeptidases capable of cleaving components of the extracellular matrix including
collagen and elastin (Jones et al. 2003). Since their discovery in 1962, over 66
MMPs, including at least 20 in humans, have been identified (Ye 2000). The
presence of elevated levels and activity of MMPs within atherosclerotic plaques,
particularly at the shoulder region of the plaque cap (Henney et al. 1991; Galis et al.
1994; Halpert et al. 1996; Johnson et al. 1998), coupled with the observation that
patients with acute coronary syndromes have elevated levels of MMP-9 compared to
patients suffering stable angina (Nikkari et al. 1995; Sukhova et al. 1999; Inokubo et
al. 2001; Uzui et al. 2002; Blankenberg et al. 2003), has led to speculation that
MMPs might be involved in plaque rupture. The role of MMPs in atherosclerosis is
complex due to the large number of isozymes with overlapping specificities.
Numerous studies have suggested a role for various MMPs, particularly MMP-2 and
MMP-9, in plaque instability (Sapienza et al. 2004; Kong et al. 2005; Tziakas et al.
2005), and genetic deficiency of MMP-9 protects ApoE'1' mice against
atherosclerotic media destruction (Luttun et al. 2004). Furthermore, activated
macrophages have been demonstrated to induce collagen breakdown in the fibrous
cap of atherosclerotic plaques via activation of MMPs (Shah et al. 1995). However,
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a recent study comparing divergent effects of various MMPs on plaque stability,
found that whilst MMP-12 may act as a destructive protease promoting plaque
instability, MMP-9 and MMP-3 have a protective role in reducing thrombus size and
promoting smooth muscle-directed healing after plaque rupture (Johnson et al. 2005).
The authors suggest that elevated MMP-9 levels are a consequence, rather than
cause, of plaque rupture and that increased MMP-9 expression results in increased
stability of the newly re-formed cap (Johnson et al. 2005).
1.4.3.2 The Role ofApoptosis in Plaque Rupture
Apoptosis of several cell types, notably monocytes/macrophages, endothelial
cells and VSMCs, may play a pivotal role in atherosclerotic lesion progression and in
determining plaque rupture. Apoptosis of inflammatory cells within an
atherosclerotic lesion may result in their subsequent non-inflammatory, phagocytic
removal from the plaque core, hence aiding the resolution of inflammatory processes
occurring within the lesion, and potentially resulting in regression of the plaque
itself. However, apoptosis in endothelial cells may worsen pre-existing endothelial
dysfunction by removing any remaining functioning endothelial cells, whilst
apoptosis in the VSMC population of the plaque cap may increase the likelihood of
rupture in any given plaque.
1.4.3.1 Apoptosis ofInflammatory Cells inAtherosclerosis
Recruitment of inflammatory cells, particularly monocytes and macrophages,
is the major driving force behind plaque growth and development. However,
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atherosclerotic plaques are dynamic and inflammatory cells are constantly turning
over within the core. The identity of the cells responsible for clearing apoptotic
macrophages from the plaque remains to be confirmed. It is currently unclear
whether activated macrophages can themselves phagocytose populations of apoptotic
inflammatory cells, or whether this is done by a subset of specialised phagocytes.
It is well established that apoptotic cells are present in atherosclerotic
plaques. Apoptotic macrophages have been located by deoxynucleotidyl transferase
(TdT)-mediated dUTP-biotin nick end-labelling (TUNEL) staining in plaques from
animal models of atherosclerosis and in plaques excised from human vessels (Han et
al. 1995; Bjorkerud and Bjorkerud 1996; Haunstetter and Izumo 1998). The
apoptotic macrophages tend to be clustered in areas of the plaque most vulnerable to
rupture, in particular, the shoulder, or base, region, where the VSMC prevalence is
also decreased (Kolodgie et al. 2000). It is currently unclear why these areas of the
plaque are particularly susceptible to rupture, however, reduced VSMC localisation
in these areas of vulnerable plaques may indicate that apoptosis of a variety of cell
types, including VSMCs, plays a role in plaque instability (Kockx and Herman
1998).
Recently it has been suggested that macrophage MPO could have an
important role in determining plaque vulnerability to rupture. MPO generates ROS
including hypochlorous acid (HOC1) as part of its normal function during innate host
defences (Klebanoff 1980; Hazen and Heinecke 1997). Sugiyama et al have
described a strong co-localisation between macrophage MPO expression and HOC1-
modified proteins at sites of lesion rupture in patients who suffer acute cardiac events
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(Sugiyama et al. 2001). MPO-generated HOC1 at relatively high physiological
concentrations, but still within the range expected to be produced at areas of vascular
inflammation (30-50 pM), has been shown to promote endothelial cell death by
stimulating apoptotic pathways, including rapid caspase-3 activation and DNA
fragmentation (Sugiyama et al. 2004). This observation suggests that, prior to
undergoing apoptosis themselves, activated macrophages may induce apoptosis in
neighbouring endothelial cells through MPO expression, ultimately resulting in
plaque rupture.
1.4.3.2 Apoptosis of VSMCs In Atherosclerosis
Loss of VSMCs from the protective cap may be a major determinant of
plaque susceptibility to rupture. Because healthy endothelial cells secrete factors that
promote VSMC survival, a consequence of activated macrophage-induced
endothelial cell death is an increase in VSMC death (Gordon et al. 1990). In addition
to removing the protective presence of the endothelium, macrophages can also
influence VSMC apoptosis directly. Activated human monocytes/macrophages have
been found to be responsible for the death of human VSMC in vitro (Seshiah et al.
2002; Vasudevan et al. 2003). Seshiah et al have hypothesised that M-CSF, a
haematopoietic growth factor supporting survival and differentiation of monocytes,
is secreted from VSMCs resulting in macrophage activation, and ultimately
triggering subsequent VSMC apoptosis (Seshiah et al. 2002). The exact mechanism
of this process remains to be fully understood, but it is thought that macrophages
prime VSMCs to respond to apoptotic stimuli, for example by triggering the
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expression of death receptor ligands such as TNF-a (Mayr and Xu 2001). Direct
induction of VSMC apoptosis in the ApoE'1' null murine model of atherosclerosis
also induces both rupture and thrombosis of the plaque, independently of
macrophage involvement, (von der Thusen et al. 2002).
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Figure 1.9 Processes Involved in Atherosclerosis
(A) During atherogenesis, circulating monocytes translocate to the sub-endothelial space
where thay accumulate modified lipids to form an atherosclerotic plaque that becomes
overlain with a fibrous cap of VSMCs and extracellular matrix fibres such as collagen
(B) Apoptosis can be induced in a variety of cell by NO. Apoptotic inflammatory cells are
cleared by phagocytes, aiding resolution of the inflammatory response, stabilising the
plaque and leading, ultimately, to plaque regression.
(C) Apoptosis of VSMCs may be detrimental, causing degradation of the lesion cap,
particularly at the shoulder regions of the plaque, which can lead to plaque rupture,
thrombus formation and ultimately to the acute clinical consequences of atherosclerosis,
such as myocardial infarction and stroke.
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1.5 NO and Apoptosis in the Resolution of
Inflammation During Atherosclerosis
Given that apoptosis is now thought to be key to the successful resolution of
the inflammatory response, pharmacological manipulation of apoptosis in a variety
of cell types, particularly inflammatory cells, may represent a novel therapeutic
strategy for the treatment of chronic inflammatory disorders (Ward et al. 1999;
Gilroy et al. 2004). Inducing apoptosis in atherosclerosis could potentially delay
disease progression, or even promote disease regression.
1.5.1 Therapeutic Potential of NO in Atherosclerosis
NO is a promising candidate for use in the treatment of atherosclerosis
because its ability to induce apoptosis and aid inflammatory resolution has already
been demonstrated in several animal models. In a mouse model of kidney
inflammation, activated macrophages have been shown to induce apoptosis in
neighbouring mesangial cells prior to ingestion by phagocytes (Duffield et al. 2000).
The ability of the activated macrophages to induce apoptosis is greatly reduced in the
presence of the NOS inhibitor, NG-monomethyl-L-arginine (L-NMMA), indicating
that the rnacrophage-directed apoptosis of mesangial cells occurs via a NO-
dependent mechanism (Duffield et al. 2001). Similarly, several studies have
demonstrated that activated macrophages infiltrating murine tumours induce
apoptosis via a NO-dependent pathway in both activated anti-tumour T cells and in
the tumour cells themselves (Saio et al. 2001; Chattopadhyay et al. 2002). Thus, it
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appears that macrophages have the capacity to induce apoptosis of nearby cells by
the liberation of NO, or an NO-related species, to enhance the clearance of apoptotic
cells.
Inducing apoptosis in inflammatory cells within an atherosclerotic lesion is
an attractive prospect as it may represent a mechanism to resolve vascular
inflammation, thereby stabilising the plaque and halting disease progression.
Reducing the number of activated macrophages present in the plaque would have
multiple consequences. Firstly, the physical presence of the plaque in the vessel
would be decreased, reducing stenosis. Secondly, because activated macrophages
induce apoptosis in neighbouring endothelial cells and VSMCs, reducing the number
of activated macrophages may help to preserve endothelial function and maintain the
integrity of the plaque cap, hence reducing the likelihood of plaque rupture.
Considered in combination with the additional powerful anti-atherogenic
characteristics of NO, including inhibition of platelet and inflammatory cell
activation, these potentially beneficial pro-apoptotic properties of NO make this
molecule an appealing prospect as a mechanism to regress atherosclerosis.
Support for the hypothesis that manipulation of apoptosis by NO could be
used to reverse atherosclerosis is emerging from animal studies. For example, L-
arginine (the substrate for NOS) or the NO donor sodium nitroprusside (SNP),
administered to hypercholesterolemic rabbits increases the number of apoptotic
macrophages present in intimal lesions by three fold (Wang et al. 1994; Wang et al.
1999). This increase in apoptosis was accompanied by a significant reduction in
intimal thickening, demonstrating that manipulation of the NO synthase pathway, or
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delivery of exogenous NO, may be a way to boost NO availability in order to
stabilise, or even regress, the plaque via an apoptotic mechanism (Wang et al. 1994;
Wang et al. 1999). However, such treatments are by no means selective for
macrophages, and as already discussed, NO will induce apoptosis in endothelial cells
and VSMCs. This could have several serious detrimental consequences for the
plaque: firstly, additional loss of endothelial function would occur leading to further
exacerbation of the disease process. Secondly, because VSMCs are essential for
maintaining the integrity of the plaque cap, loss of cells in vulnerable regions of the
lesion could destabilise the plaque and cause rupture. The potential benefit of
regressing the plaque in this manner must also be offset against the cost of reducing
the size of the macrophage population available for scavenging existing apoptotic
macrophages, endothelial cells and VSMCs, which, if remaining in situ, will undergo
secondary necrosis, thereby increasing the thrombogenicity of the plaque as a whole.
In the study by Wang et al described above, apoptosis is quantified by the number of
apoptotic nuclei per area of plaque, rather than as a percentage of the total
macrophage population. Therefore, it is not possible to draw any conclusions as to
whether the phagocytosis capacity of the plaque has been affected in this case.
Although human macrophages appear unable to generate the
supraphysiological concentrations that murine cells produce (Albina 1995; Weinberg
et al. 1995; Thomassen and Kavuru 2001; Schneemann and Schoedon 2002), human
macrophages will respond to exogenous NO delivered by synthetic NO donor
compounds, suggesting that NO could potentially be used to manipulate rates of
apoptosis in human atherosclerosis. However, global, non-selective delivery of NO
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concentrations sufficient to induce apoptosis are likely to cause systemic
hypotension. Additionally, indiscriminate pro-apoptotic events could have serious
adverse consequences for the plaque dynamic, resulting in a greater propensity to
rupture, and thereby increasing the risk of myocardial infarction and stroke. It is
therefore essential to target any therapeutic intervention to specific cell types within
the plaque, and in particular, to appropriate cell types within those plaques
vulnerable to rupture.
1.5.2 NO Donor Drugs
Organic nitrates have been used for over a century to treat angina (Parker and
Parker 1998). However, the development of nitrate tolerance prevents the
continuous use of this class of drugs (Csont and Ferdinandy 2005; Munzel et al.
2005). The mechanisms underlying development of tolerance and subsequent loss of
therapeutic effect remain unclear. A number of hypotheses to explain these
phenomena have been put forward but no consensus amongst investigators has been
reached. Possibilities include impaired bioactivation (Sage et al. 2000), excessive
compensatory levels of potent vasoconstrictors such as endothelin-1 (Munzel et al.
1995) and angiotensin II (Kamajian and Tilley 1975; Wada et al. 2002; Hirai et al.
2003), increased 02" production (Munzel and Harrison 1997; Fayers et al. 2003), and
a desensitisation of sGC (Artz et al. 2002). Similarly SNP has been used to treat
acute hypertension but its therapeutic potential is limited by a host of difficulties in
the clinical setting, including the necessity for intravenous administration, difficulties
with dose titration, and the accumulation of toxic cyanide metabolites (Friederich
57
Chapter One: Introduction
and Butterworth 1995; Megson 2000). Such problems with traditional NO donor
drugs, together with the observation that endogenous NO production is often
decreased in cardiovascular disease, has led to the development of several categories
of novel synthetic NO donor compounds with the aim of delivering exogenous NO,
stimulating sGC, or elevating cGMP levels within cells. The development of such
compounds represents not only the prospect of potential therapies for conditions
associated with decreased endogenous NO production, but also provide invaluable
experimental tools in the quest to elucidate the mechanisms underlying such
conditions.
Cell specificity will be critical to the success of any NO-based therapy in
atherosclerosis. Existing NO donor drugs are not selective for particular cell types;
commonly used organic nitrates, such as glyceryl trinitrate (GTN), tend to have an
unfavourable selectivity profile when considered in the context of atherosclerosis
(veins > arteries > platelets; MacAllister et al. 1995; Kojda et al. 1998; Barba et al.
1999). In order to use NO donor drugs as effectors of apoptosis in atherosclerosis,
compounds that are able to discriminately act on, for example macrophages, but not
endothelial cells or VSMCs, will have to be developed in the future. One possibility
may be to target macrophage iNOS. However, whilst human macrophages do
express iNOS mRNA and protein (Weinberg et al. 1995), so too do VSMCs and
endothelial cells present in atherosclerotic plaques (Wilcox et al. 1997; Yan and
Hansson 1998).
In addition to selectivity, another major consideration when contemplating
the use of NO donor drugs for the treatment of atherosclerosis is that of delivery. A
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global, non-selective release of NO throughout the circulation may have various anti-
atherosclerotic actions, but dosing will be limited by concurrent vasodilatation,
resulting in systemic hypotension. The challenge, therefore, is to generate high local
concentrations of NO in the immediate vicinity of a plaque. Possible means of
achieving this include the use of NO donor drugs that are selective for areas of
endothelial damage, such as RS-N=0 (see section 1.5.2.2), or use of NO-eluting
stents to prevent restenosis following angioplasty. Angioplasty is a common clinical
intervention to improve blood flow through stenosed (or occluded) arteries, however,
restenosis of the vessel currently limits the success of the procedure (Liu et al. 1989;
Preisack and Karsch 1993). Given that NO inhibits VMSC proliferation (Newby et
al. 1992; Mooradian et al. 1995; Jeremy et al. 1999), NO-eluting stents may limit
restenosis by inhibiting intimal hyperplasia, as well as treating the underlying
condition by providing all the anti-atherogenic properties of NO in situ. There has
been some success to date in humans with the use of sirolimus (rapamycin)-eluting
stents in preventing the neointimal proliferation which leads to re-stenosis following
angioplasty, although the long-term effectiveness (>1 year) remains to be established
(Sousa et al. 2001). Nevertheless, this demonstrates that use of drug-eluting stents
may be a practical application in this specific clinical setting.
A further potential method of delivering high local concentrations directly to
the interior of the plaque may be to exploit the lipid environment of the core by
developing novel lipophilic NO donor drugs designed to induce apoptosis in the lipid




The diazeniumdiolate compounds, or 'NONOates', are complexes of NO
with nucleophilic adducts that are considered to be 'pure' NO donors. These
compounds release up to two molecules of NO per molecule of compound
spontaneously in solution and, unlike other NO donor drugs such as SNP, do not
require tissue thiol or enzymatic activation (Diodati et al. 1993; Megson 2000;
Megson and Webb 2002). Biological efficacy can be accurately predicted from their
in vivo rate of decomposition which follows first order kinetics, and is determined by
the nucleophilic adduct, temperature, and pH (Morley and Keefer 1993; Megson
2000). Varying the nucleophilic adduct has produced a diversity of compounds with
differing rates of decompositions, ranging from locally active drugs which release
their NO within minutes, for example, 2-(N,N-diethylamino)-diazenolate-2-oxide
(DEA/NO; tVz = 2 min; figure 1.10 A), to longer acting compounds which generate
NO over a period of several hours, for example (Z)-l-[2-(2-aminoethyl)-N-(2-









S-nitrosothiols, general formula RS-N=0, are formed endogenously and can
be synthesised by nitrosation (transfer of NO+) of reduced thiols (Butler and Rhodes
1997); examples include endogenous GSNO (figure 1.11 A) and the synthetic
compounds S-nitroso-N-acetlypenicillamine (SNAP) and S-nitroso-N-valeryl-
penicilliamine (SNVP; figure 1.11 B). The biological half-life of S-nitrosothiols is
unpredictable in solution and dependent on the R group of the compound (Mathews
and Kerr 1993). The exact mechanism of decomposition and subsequent NO release
from S-nitrosothiols, both endogenous and synthetic, is not fully known. However,
decomposition is greatly accelerated in the presence of copper I (Cu+) ions (Gordge
et al. 1995; Dicks and Williams 1996; Gorren et al. 1996; Singh et al. 1996).
Interestingly, the enzyme sGC contains one mole of copper per mole of holoenzyme
dimer (Ignarro 1992), which may act as a catalyst to trigger NO release from
endogenous S-nitrosothiols. In vivo, S-nitrosothiols are thought to act via transfer of
NO+ to reduced tissue thiols without the release of free NO radical (Broillet 1999).
A recent study has shown that the cell surface protein, disulfide isomerase, may act
as a chaperone molecule to transfer S-nitrosothiol-derived NO from extra-cellular S-
nitrosothiols into the cell cytosol (Ramachandran et al. 2001).
S-Nitrosothiols are generally accepted to be platelet-selective NO donor
drugs (de Belder et al. 1994) and some have been shown in vitro to have vasodilator
actions which are selective for areas of experimentally denuded endothelium
(Megson et al. 1997; Megson et al. 1999; Sogo et al. 2000b). Furthermore, in a
rabbit balloon angioplasty model of vascular injury, SNVP. in contrast to the
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traditional organic nitrate, GTN, reduced the adhesion or radiolabeled platelets in
areas of endothelial damage without significantly affecting systemic blood pressure
(Miller et al. 2003). This indicates that S-nitrosothiols may have advantages over
other NO donor drugs for the treatment of atherosclerosis, as they are able to
discriminate areas of endothelial damage, which is an important precursor to plaque
development.
B
Figure 1.11 The Chemical Structures of GSNO (A) and SNVP (B)
1.5.2.3 Mesoionic Oxatriazole Derivatives
The mesoionic oxatriazole derivatives and sydnonimines are not strictly NO
donors but are generators of the NO-related species, ONOO". Molsidomine is the
precursor of 3-morpholinosyndnonimine (SIN-1). Although originally considered to
be a NO donor, SIN-1 is now widely accepted to be a ONOO" generator on account
of concomitant generation of equivalent concentrations of NO and O2" which rapidly
combine to form ONOO" (Feelisch et al. 1989). Mesoionic 3-aryl, 5-imino-
oxatriazole derivatives, for example GEA-3162 (figure 1.12), represent a novel class
of NO donors which are structurally very similar to the sydnonimines (Megson 2000;
Megson and Webb 2002). Until recently, GEA-3162 was regarded as a pure NO
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donor (Kankaanranta et al. 1996; Holm et al. 1998), but there is now clear evidence
that, in common with the structurally similar SEN-1, GEA-3162 is a ONOO"
generator rather than an NO donor (Taylor et al. 2004).
Figure 1.12 The Chemical Structure of GEA-3162
1.5.2.4 NO-independent Stimulators of sGC
Due to the uncertainty regarding the exact NO-related species responsible for
many of the effects of NO, coupled with the drawbacks of existing NO-based
therapies, major efforts have been made to develop NO-independent stimulators of
sGC. 3-(5'-hydroxymethyl-2'-furyl)-l-benzyl-indazol (YC-1) was the first such
compound developed which displayed anti-platelet properties via elevation of
intracellular cGMP (Ko et al. 1994; Wu et al. 1995). More recently, following the
discovery of an NO-independent regulatory site on sGC, BAY 41-2272 (figure 1.13)
was developed (Stasch et al. 2001). BAY 41-2272 is a pyrazolopyridine, which has
been reported to potently stimulate sGC through the NO-independent, haem-
dependent regulatory site on the ai-subunit of the enzyme in order to produce both
anti-platelet actions and the ability Ao decrease blood pressure in a rat model of





of both YC-1 and BAY 41-2272 have been attributed to the synergistic effects of
inhibition of the cGMP-inactivator, phosphodiesterase 5 (PDE V), coupled with
sensitisation of sGC toward endogenous NO (Friebe et al. 1998; Mullershausen et al.
2004).
Whilst compounds such as these may overcome some of the difficulties
associated with more traditional NO donor drugs, it should be noted that NO is able
to exploit pathways independently of cGMP signalling and that these additional
pathways would be unavailable to NO-independent stimulators of sGC.
Atherosclerosis has a highly complex pathogenesis and is a condition that
evolves over many years. Initiated by the retention of pathogenic lipids and
consequent insult to the endothelial cell layer of blood vessels, the disease progresses
via activation of a chronic inflammatory response involving the recruitment and




activation of inflammatory cells, such as macrophages, which go on to internalise ox-
LDL and accumulate in the sub-endothelial space of the vessel to form a fatty streak.
The fatty streak progresses to the hallmark atherosclerotic plaque through the
recruitment and activation of further inflammatory cells, which become encapsulated
by a cap of VSMCs and fibrous matrix. The VSMC cap acts as barrier between the
highly thrombogenic core of the plaque and the circulation. The major determinant
of outcome in atherosclerosis is now considered to be plaque rupture. The
mechanisms involved in plaque vulnerability to rupture are not yet fully understood
but are thought to include inflammatory processes occurring within the plaque, and
the thickness and ability of the cap overlaying the lesion to withstand mechanical
erosion.
Apoptosis is a fundamental biological process governing cell survival and is
thought to be critical to the successful resolution of the inflammatory response.
Apoptotic cells are removed from the site of inflammation by non-inflammatory
phagocytosis. Manipulation of apoptosis in a variety of cell types may aid the
resolution of the inflammatory response occurring in atherosclerosis, hence halting
the disease process or even aiding plaque regression.
The endogenous free radical signalling molecule, NO, has a complex
chemistry and its effects may be elicited by a variety of intermediary NO-related
species that have biological actions of their own. The anti-atherogenic properties of
NO include regulation of vascular tone and inhibition of platelet and inflammatory
cell activation. In addition to this, NO can be both pro- and anti-apoptotic depending
on the NO-related species and cell type in question. NO-induced manipulation of
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apoptosis in atherosclerosis, particularly in macrophages, may be beneficial in terms
of reducing plaque size, but this benefit must be offset against the potential risk of
indiscriminate apoptotic events de-stabilising the plaque and causing rupture.
1.7 Thesis Aims
The aims of this thesis were to characterise the precise NO and NO-related
species liberated by various synthetic putative NO donor compounds and to examine
their role in various processes occurring in cell types relevant to atherosclerosis at
concentrations which might be predicted to be physiologically relevant.
The central hypotheses addressed will be:
1. Three different classes of putative NO donor compounds - diazeniumdiolates,
RS-N=0, and mesoionic oxatriazole derivatives - will decompose in solution to
generate different NO and NO-related species.
2. Different NO-related species will exert disparate effects on the proliferation of
VSMCs.
3. Variations in the actions NO-related specis can be exploited to differentially
induce apoptosis in different cell types, namely VSMC and human macrophages.
4. Elevating cGMP in VSMC and human macrophages will result in cellular
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2. Methods
2.1 Detection of NO
2.1.1 Electrochemical Detection of NO
NO released in solution from the NO donors DEA/NO, DETA/NO, SNVP,
GSNO, and GEA-3162, was measured using an isolated NO electrode (Iso-NO II,
World Precision Instruments, Stevenage, U.K), calibrated daily with DEA/NO (0.1 -
1.6 pM) in phosphate buffer (pH 4; 2ml; figure 2.1.A). DEA/NO has a rapid and
predictable rate of decomposition at pH 4 (Davies et al. 2001). Therefore, the change
in peak NO signal can be used to generate a calibration curve assuming a 2:1
stoichiometry of NO release from DEA/NO under the calibration conditions (Davies
et al. 2001) and fitting the curve by linear regression (figure 2.1.B). In order to
measure higher NO concentrations, the electrode sensitivity was decreased and re-
calibration was performed with DEA/NO (1-16 pM; pH 4 phosphate buffer; 2 ml).
In this situation, a slightly curved calibration graph was generated, therefore, the
slope was fitted by second order polynomial nonlinear regression (figure 2.1.C and
2.1.D). Data were captured via a MacLab 4/e analogue-digital converter and
displayed through Chart™ v 3.6/s software (AD Instruments, Sussex, U.K).
Prior to the addition of NO donor compounds, aliquots (2 ml) of tissue
culture media were pre-warmed (37°C) and stirred (600 rpm) until a stable electrode
baseline had been achieved. NO released from each NO donor compound was
measured in the presence or absence of Cu/Zn SOD (50 - 500 U.mf1). At the end of
each recording, the recognised NO scavenger, haemoglobin (Hb; 5 pM; Hille et al.
1977), was introduced into the electrode chamber to quench the signal and verify the
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presence of NO. The concentration of NO generated was calculated from the slope
of the calibration graph, or by solving the quadratic equation for the calibration curve








Figure 2.1 NO Electrode Calibration.
Example single calibration trace (A) and graph (B) with electrode at high sensitivity setting. In
order the measure higher concentrations of NO, the sensitivity was reduced and the
electrode re-calibrated (C), generating a curved calibration graph (D). DEA/NO (pM)
additions are indicated by arrows.
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2.1.2 Detection of NO2/NO3 by Griess Test
The total nitrite/nitrate (NO2/NO3"; NOx) concentration released by SNVP,
GSNO, and GEA-3162 (all 10 - 300 uM) in tissue culture media in presence of
bovine aortic smooth muscle cells (BAoSMC) or human monocyte-derived
macrophages, and that released by human monocyte-derived macrophages stimulated
by lipopolysaccharide (LPS; 1 pg.ml"1), was measured by Griess Test (R&D
Systems, Abington, U.K). It was not possible to measure NOx generation from
DEA/NO and DETA/NO by Griess reaction because reagents are acidified during the
protocol and NO release from diazeniumdiolate compounds is pH dependent (Davies
et al. 2001).
The Griess reaction allows colourimetric detection of N02~ as an azo dye
product that absorbs light at 540 nm. N02" in the sample reacts with sulfanilic acid
to produce the diazonium ion, which is then coupled to N-(naphthyl)
ethylenediamine to form the chromophoric azo derivative. Measurement of total
NOx is achieved by enzymatic conversion of N03" to N02" by nitrate reductase prior
to addition of Greiss reagents.
Aliquots (200 pi) of tissue culture media were aspirated at lh, 6h, and 24h
time points from tissue culture plates containing BAoSMC or human monocyte-
derived macrophages (see sections 2.2.3 and 2.2.2.1) in the presence or absence of
NO donor compounds, or human monocyte-derived macrophages stimulated with
LPS (1 pg.ml"1). Aliquots were frozen immediately on dry ice and stored (-70°C) for
approximately 1 week prior to performing the assay. For the N02" assay, absorbance
(540nm) was measured in 96-well, flat-bottomed microtiter plates following
incubation (10 min; room temperature; RT) with Griess Reagent I (sulfanilamide in 2
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M hydrochloric acid; HC1) and Greiss Reagent II (A-(l-naphthyl) ethylenediamine 2
M in HC1). For the NOx assay, samples were incubated (37°C; 30 min) in the
presence of the enzyme nitrate reductase and its substrate P-nicotinamide adenine
dinucleotide (NADH) in 96-well, flat-bottomed mircotiter plates. Following this
incubation period, samples were assayed as for NO2" as above. The absorbance (540
nm) of the relevant tissue culture media was measured and this value was used as a
blank that was subtracted from all readings. The concentration of total NOx was
calculated from the slope of standard curves generated daily by serial dilution of
known concentrations of sodium nitrite (3.12 - 200 pM) and sodium nitrate (3.12 -
100 pM; figure 2.2). All standards and samples were assayed in duplicate. Optical
densities (540 nm) were measured by a Multiskan Ascent plate reader and data
captured using Ascent™ v 2.6 software (Thermo Labsystems, South Trentham,
U.K).
Figure 2.2 Standard Curves Generated for the Calculation of N02 /N03" Concentration
Example standard curves generated by the absorbance (540 nm) of sodium nitrite (0 - 200
pM; A) and sodium nitrate (0-100 pM; B) following conversion to N02" by nitrate reductase.
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2.1.3 Detection of NO2/NO3 by High Performance
Liquid Chromatography
Concentrations of NO2 /NO3" below the limit of detection of the Griess test
(<3 pM) were measured by fluorescence high-performance liquid chromatography
(HPLC), which allows detection of NO2" in the nM range . The fluorometric assay is
based on the reaction of N02" with 2,3-diaminonaphthalene (DAN) under acidic
conditions to yield the fluorescent product, 2,3-naphthotriazole (NAT), which is
stable under alkaline conditions (Misko et al. 1993; Li et al. 2000; Woitzik et al.
2001; Gharavi and El-Kadi 2003).
Aliquots (500 pi) of tissue culture media were aspirated from wells
containing LPS- stimulated (1 pg.ml"1; 24 h) human monocyte-derived macrophages.
Aliquots were frozen immediately on dry ice and stored (-70°C) for approximately
one week prior to performing the assay.
Prior to detection of N02", samples were filtered through pre-washed
ultrafilter centrifuge tubes (12 kD pore size) in order to remove any protein. NO2"
was detected by incubation (10 min; RT; light proof conditions) of each sample with
DAN under acidic conditions (0.125 pg.ml1 in 0.7 M HC1). Following this period,
the pH of each sample was raised by addition of sodium hydroxide (NaOH; 1.7 M),
and the sample stored (5°C) prior to analysis by HPLC. In order to calculate the
concentration of NO2", a calibration curve was generated daily from the fluorescence
peak area of serial dilutions of known concentrations of sodium nitrite (0.1 - 1.0 pM;
figure 2.3). Due to difficulties with the solubility of DAN, a curved calibration graph
was generated, therefore the line was fitted by second order polynomial nonlinear
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regression and the concentration of N02~ generated in subsequent experiments
calculated by solving the quadratic equation of the curve.
NO3" would normally be measured following chemical conversion to N02" by
copper-coated cadmium prior to analysis by HPLC. However, this reaction did not
occur in the tissue culture media in which the human monocyte-derived macrophages
were cultured. To overcome this problem, an attempt was made to combine
enzymatic conversion (nitrate reductase) of NO3", with fluorescence HPLC detection
of N02\ Each sample was incubated (37°C; 30 min) in presence of nitrate reductase
(1 U.mr1) and its substrate nicotinamide adenine dinucleotide phosphate (NADPH;
80 pM). Serial dilutions of known concentrations of sodium nitrate (1-10 pM) were
also treated in this manner in order to generate a standard curve. Following this
incubation period, samples were assayed for N02~ as described above. However, the
detection of N02" following this system of converting NO3" to N02" was
unsuccessful. This is likely due to interference by the nitrate reductase co-factors,
NADP+/NADPH, with NAT, resulting in a quenching of the fluorescence signal
(Woitzik et al. 2001). This interference could potentially be avoided during future
attempts to convert NO3" to N02" enzymatically by addition of D-glucose-6-
phosphate monosodium salt and glucose-6-phosphate dehydrogenase, which act to
aid the recycling NADP+ to NADPH. This system has been successfully employed
by others to prevent the interference, and subsequent reduction in fluorescence
formation by NAT, caused by NADP+ (Woitzik et al. 2001). However, as this
system was not used here, it was not possible to measure NO3" by this HPLC method.
The HPLC system consisted of a multi wavelength fluorescence detector
(2475 model, Waters, Massachusetts, USA; X excitation = 365 nm, X emission = 425
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nm). The mobile phase, 65% borate buffer: 40% acetonitrile, was pumped through
the system at a flow rate of 1 ml.min1 using a Waters 2695 Separations Module with
integrated autosampler (Waters, Massachusetts, USA). An Xterra column and a
HPLC guard-column insert packed with C18 (Waters, Massachusetts, USA) were
used for the assay. Data were captured and recorded using Empower™ 2 software
(Waters, Massachusetts, USA). All solutions were of HPLC grade quality.
[NCV]/pM
Figure 2.3 Standard curve generated for the calculation of N02" concentration
Example standard curve generated from the fluorescence peak area produced by sodium
nitrite (0.1 - 1 pM)
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2.1.4 Electron Paramagnetic Resonance
The concentration of oxidising free radical species generated by DEA/NO,
DETA/NO, SNVP, GSNO, and GEA-3162 in tissue culture media was assessed by
electron paramagnetic resonance (EPR) spectrometry. This technique uses a
chemical spin-trap, which reacts with free radical species to form a stable radical
adduct. EPR spectrometry then measures the absorption of electromagnetic
(microwave) radiation by the stable radical adduct when it is placed in a strong
magnetic field. In these studies, the chemical spin-trap used was Tempone-H
hydrochloride (l-Hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine . HC1), which reacts
with oxidising species to form the stable radical adduct 4-oxo-tempo. Tempone-H
has previously been demonstrated to be an effective spin-trap for oxidising radical
species such as 02\ and has also successfully been used for the detection of ONOO"
in biological systems (Dikalov et al. 1997a; Dikalov et al. 1997b).
Each NO donor compound (10 - 300 pM) was incubated (37°C; 30 min) in
tissue culture media in the absence or presence of Cu/Zn SOD (500 U.mr1) together
with the recognised spin trap for oxidising radical species, Tempone-H (1 mM;
prepared in 10 mM ethylene diamine tetraacetic acid (EDTA) solution to minimise
metal ion-induced auto-oxidation of the spin trap). Aliquots (50 pi) were removed
from the incubation vessels at timed intervals (1, 10, and 30 min) and the intensity of
signal corresponding to formation of the radical adduct 4-oxo-tempo (triplet centred
around 3360 G) recorded by EPR spectrometry. EPR signals were measured using a
Miniscope MS100 X-band spectrometer (Magnettech, Berlin, Germany) with the
following parameter settings: field sweep 51.2 G, microwave frequency 9.5 GHz,
microwave power 20 mW, modulation amplitude 1500 mG. Data were captured,
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recorded, and manipulated via Multiplot™ 2.24 and Analysis™ 2.02 software
(Magnettech, Berlin, Germany). Control experiments in the absence of NO donor, or
radical-generating compounds were conducted in all cases and small signals were
detected due to the auto-oxidation of Tempone-H to 4-Oxo-Tempone. This
phenomenon was minimised by preparation of the spin trap, Tempone-H, in EDTA
solution, which protected the spin trap against metal ion-induced oxidation. Control
signals generated by auto-oxidation of Tempone-H were subtracted from the
corresponding experimental signals.
2.2 Cell Culture
2.2.1 THP-1 Macrophage Cell Culture
Cells of the human monocyte/macrophage cell line, THP-1, were cultured
(37°C; 95% 02: 5% C02; 75 cm2 tissue culture flasks) from cyropreserved stocks in
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with penicillin
(100 U.ml"1), streptomycin (100 U.ml"1), L-glutamine (200 mM) and heat inactivated
foetal calf serum (FCS; 10% v:v). Prior to experimental assay, cell suspensions of
this non-adherent cell line were aspirated from the flasks and a cell pellet obtained by
centrifugation (220 g; 5 min). The pellet was then re-suspended (lml; RPMI 1640
medium plus supplements) and viable cell yield obtained by trypan blue exclusion
and use of a bright line haemocytometer. An aliquot (10 pi) of the cell suspension
was mixed with trypan blue (190 pi: 1:20 dilution) and an aliquot (10 pi) of the
resulting solution placed under the haemocytometer cover slip. Cells excluding
trypan blue in the outer four corners of the haemocytometer were counted by light
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microscopy (xlO magnification; figure 2.4). The number of cells present in 1 ml was
then calculated according to the equation shown in figure 2.4.
Cells were then re-suspended at a density of 0.75 x 106 cells/ml and seeded
(150 pl/well; 1.125 x 103 cells/well) in 96-well, round-bottomed, Flexiwell plates
(BD Falcon) in the presence and absence of each NO donor compound or in the




Figure 2.4 Assessment of Viable Cell Yield by Trypan Blue Exclusion
Cells excluding trypan blue are counted by light microscope (x10 magnification) and the cell
yield calculated according to the equation shown.
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2.2.2 Isolation of Human Mononuclear Cells
Human mononuclear cells were isolated from peripheral blood of healthy
volunteers aged between 21 and 64. Venous blood (40 ml) was drawn from the
antecubital fossa through a 19 gauge needle into 50 ml polypropylene tubes (BD
Falcon) containing sterile sodium citrate (0.38% final concentration). Platelet rich
plasma (PRP) was separated from whole blood by centrifugation (350 g; 20 min) and
aspirated from the leucocyte/erythrocyte-rich layer (figure 2.5). Autologous serum
was prepared in sterile glass tubes by incubating PRP (37°C; -30 min) in the
presence of calcium chloride (CaCl2; 20 pM), which caused the platelets to
aggregate. At the end of this incubation period the autologous serum was aspirated
from the plug of aggregated platelets and stored (4°C) in polypropylene tubes.
Sedimentation of erythrocytes from the remaining cellular fraction was
carried out by addition of 2.5 ml of pre-warmed (37°C), Dextran T500 (6%) per 10
ml haematocrit. Following addition of the appropriate volume of Dextran, the total
volume of each tube was adjusted to 50 ml with pre-warmed (37°C) saline solution
(0.9%). Erythrocytes were allowed to sediment for no longer than 30 minutes (RT),
following which the leucocyte-rich upper layer was gently aspirated into 50 ml
polyproylene tubes and the volume adjusted to 50 ml with pre-warmed (37°C) saline
solution (0.9%). The leucocyte pellet was then obtained by centrifugation (350 g; 6
min).
Isotonic Percoll solution was prepared as a 9:1 (v:v) ratio of Percoll: lOx
phosphate buffered saline (PBS) without calcium (Ca2+) or magnesium (Mg2+). The
resulting solution was then used to prepare further solutions of 55%, 68%, and 81%
isotonic Percoll in lx Ca2+/Mg2+-free PBS. Discontinuous gradients were prepared
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by layering 3 ml of 68% Percoll solution onto 3 ml of 81% Percoll solution in 15 ml
polypropylene tubes. The leucocyte pellet was then re-suspended in 3 ml of the 55%
Percoll solution and layered on top of the 68% solution to form the upper layer of the
gradient. Sub-populations of leucocytes were separated by centrifugation of the
gradients (720 g; 20 min; deceleration 0). Mononuclear cells were harvested at the
55:68% interface and washed twice in lx PBS without Ca2+/Mg2+ ions by
centrifugation (220 g; 6 min). Granulocytes were harvested at the 68:81% interface.
Following the final wash, the isolated mononuclear cells were re-suspended
(lx Ca2+/Mg2+-free PBS; 50 ml) and cell yield assessed by use of a bright line
haemocytometer. An aliquot (10 pi) of the cell suspension was placed under the
haemocytometer cover slip, the number of mononuclear cells in the central 25
squares counted by light microscopy (xlO magnification) and the cell yield
calculated according to the equation shown in diagram 2.6. When the total yield had
been obtained, the cells were centrifuged (220 g; 6 min), the PBS supernatant
discarded and the cells re-suspended at a density of 4 x 106 cells/ml in Iscove's
Modified Dulbecco's Medium (IMDM) supplemented with penicillin (100 U.mf1)
and streptomycin (100 U.mf1). The typical mononuclear yield was approximately
100 xlO6 cells from 160 ml whole blood, although this varied considerably between
donors.
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Antecubital fossa venous sampling
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containing sodium citrate (0.38%)
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CaCI2 (1 mM; 37°C)
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in PBS (50 ml) prior to counting
Figure 2.5 Isolation of Human Mononuclear Cells.
Whole blood was separated into platelet-rich plasma (PRP) and erythrocytes by
centrifugation. Leucocytes were separated from erythrocytes by Dextran sedimentation.
Finally, leucocyte sub-populations were separated by centrifugation through discontinuous
Percoll gradients and the mononuclear cells re-suspended in PBS prior to assessment of
cell yield.
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Cells re-suspended in 50 ml
Ca2+/Mg2*-free PBS
\J
10 pi placed under
haemocytometer cover slip
















Figure 2.6 Assessment of Total Mononuclear Cell Yield
Cells present in the central 5 squares of the haemocytometer were counted by light
microscopy (x10 magnification), and the cell yield calculated by the equation shown prior to
re-suspension of the cells in IMDM (4x106 cells/ml).
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2.2.2.1 Human Mononuclear Cell Culture
Re-suspended cells (4 x 106 cells/ml in IMDM) were seeded in 48-well tissue
6 5 2culture plates at a density of 2 x 10 cells/well (2.1 x 10 cell/mm") and incubated
(37°C; 95% O2: 5% CO2) for 1 hour. During this initial incubation period the
monocyte cell population adheres to the plate. After 1 hour the tissue culture
medium was aspirated and the adherent cells washed twice with Hank's Balanced
Salt Solution (HBSS; containing Ca2+/Mg2+ ions but without phenol red) in order to
remove non-adherent cells and any contaminating lymphocytes. After the final
wash, IMDM (0.5 ml/well) supplemented with penicillin (100 U.mr1) and
streptomycin (100 U-ml"1) plus 10% (v:v) autologous serum. Cells were incubated
(37°C; 95% O2: 5% C02) for 24 h prior to experiments on monocytes. Alternatively,
cells were cultured (37°C; 95% 02: 5% CO2) for 5 - 7 days to allow monocyte
differentiation into monocyte-derived macrophages. During this 5-7 day
incubation, the IMDM (plus supplements) was replaced on day 3 and again
immediately prior to any experimental protocol.
2.2.3 Bovine Aortic Smooth Muscle Cell Culture
Commercially available bovine aortic smooth muscle cells (BAoSMC; Cell
Applications Incorporated, San Diego, USA) were cultured (37°C; 95% 02: 5% CO2)
in tissue culture flasks of increasing size (15 cm2 up to 162 cm2) from cyropreserved
stocks in Dulbecco's Modified Eagle Medium (DMEM) supplemented with
penicillin (100 U.mr1), streptomycin (100 U.mr1), L-glutamine (200 mM) and heat
inactivated FCS (10% v:v). When a confluent monolayer of cells had formed, cells
were removed from the flasks (0.25 % typsin solution with EDTA) and a cell pellet
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obtained by centrifugation (35Og; 5 min). The pellet was then re-suspended (1 ml;
DMEM plus supplements) and viable cell yield obtained by trypan blue exclusion as
described in section 2.2.1 and figure 2.4. Following assessment of viable cell yield,
cells were then re-suspended at a density of 0.5 x 106 cells/ml (DMEM; plus
supplements), seeded in 48 well flat-bottomed tissue culture plates at a density of 10
x 103 cells/well (1 x 103 cells/mm2), or in 96 well flat-bottomed tissue culture plates
at a density of 2.5 x 103 cells/well (8 x 102 cells/mm2) and incubated (37°C; 95% O2:
5% C02) for 24 hr (in order to allow cells to adhere to the plate) prior to the relevant
experimental assay.
2.3 Assessment of Cell Viability
2.3.1 Cell Morphology
THP-l cells were seeded as described in section 2.2.1 in 96-well round-
bottomed, Flexiwell plates (BD Falcon) and incubated (37°C; 95% 02: 5% C02; 2, 4,
6, and 16 h) in the absence and presence of NO donor compounds (DEA/NO, SNVP,
GEA-3162; all 100 pM), or in the presence of the maximum concentration of drug
vehicle (DMSO; 1%). Additionally, the known apoptotic agent, gliotoxin (1 pg.ml"
]), was used a positive control. Following incubation, recovered cells (100 pi) were
aspirated from the 96-well plate and cyto-centrifuged (200 rpm; 2 min) in duplicate.
Resultant slides were fixed in methanol (100%; 1 min) and stained using Diff-
Quik™ physiological stain prior to observation by light microscopy (x 100
magnification). Apoptotic cells were identified as those with a darkly stained,
condensed, pyknotic nucleus, whilst necrotic cells were identified as those with a
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2.3.2 Lactate Dehydrogenase Assay
The cytotoxic impact of DEA/NO, DETA/NO, SNVP, GSNO, and GEA-
3162, on BAoSMC, was assessed by measuring the quantity of the enzyme lactate
dehydrogenase (LDH) released from cells with a damaged plasma membrane. LDH
is a stable cytoplasmic enzyme present in all cell types which is rapidly released
from the cell following damage to the plasma membrane. The Cytotoxicity
Detection Kit (Roche) allows quantification of the amount of LDH released from
damaged cells into the culture supernatant by exploiting a two-step reaction in which
LDH catalyses conversion of a tetrazolium salt to coloured formazan salt which
absorbs light at 490 nm. Therefore, absorption at 490 nm is proportional to the
number of damaged cells. Remaining viable cells are then lysed in order to calculate
the proportion of dead cells as a percentage of the total cell population as indicated
below.
Absorbance 490 mn supernatant
Absorbance 490 mn
K. (supernatant + lysed cells) J
X 100 = % Cytotoxicity
BAoSMC were seeded (2.5 x 103 cells/well) in 96-well, flat-bottomed
microtiter plates and incubated (DMEM plus supplements; 37°C; 95% O2: 5% CO2)
for 24 h as described in section 2.2.3. Following this initial incubation period, the
DMEM was replaced and the cells incubated (37°C; 95% O2: 5% CO2) in the absence
and presence of the each NO donor compound (10 - 300 pM) or in the presence of
the maximum concentration of drug vehicle (DMSO; 1%) for a further 24 h, at the
end of which the cell culture supermuants were aspirated from each well and plated
in a separate 96-well, flat-bottomed, microtiter plate. LDH activity in the
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supernatant was measured by determining the optical density (490 nm) following
incubation (20 min; RT; light proof conditions) with the tetrazolium salt solution (at
the end of the incubation period the reaction is stopped using 0.2 M HC1). Total
LDH activity was assessed by lysing the remaining cells (2% Triton-X 100 prepared
in DMEM) prior to determining LDH activity as above. The absorbance of each
concentration of the NO donor compounds, or that of the vehicle (DMSO; 1%), was
measured and subtracted from the appropriate supernatant reading, as was the
absorbance of DMEM. For the cell lysis measurements, the absorbance of 2%
Triton-X 100 in DMEM was subtracted from each well. All samples were assayed in
duplicate. Optical densities (490 nm) were measured by a Multiskan Ascent plate
reader and data captured using Ascent™ v 2.6 software (Thermo Labsystems, South
Trentham, U.K).
2.3.3 Flow cytometry
In order to characterise cell death induced by DEA/NO, DETA/NO, SNVP
GSNO, and GEA-3162, as either apoptosis or necrosis, flow cytometric analysis was
carried out to measure the percentage of cells positive for specific cell surface
markers of apoptosis and the percentage of cells with a disrupted membrane (necrotic
cells). Flow cytometry is a method of characterising individual particles, or cells,
based on how they fluoresce and scatter light as they are passed in suspension though
a laser beam. The light scatter can be used to measure the size and granularity of a
cell: forward scatter (FS) provides information on the relative size of a cell, and side
scatter (SS) provides information about the relative granularity. For example, when
a cell becomes apoptotic it shrinks, therefore the forward scatter decreases compared
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to cells remaining viable. Additionally, cell surface changes can be detected by use
of cell permeable dyes, or of fluorescent-conjugated antibodies raised against
specific cell surface markers. For example, during apoptosis, phosphatiylserine (PS)
translocates from the inner, to the outer, leaflet of the plasma membrane. Once
exposed to the extracellular environment, binding sites on PS become available for
Annexin V - a binding protein with a high affinity for PS. Apoptosis can therefore
be quantified by measuring fluorescein isothiocyanate (FITC)-conjugated Annexin V
binding (Vermes et al. 1995). Alternatively, when cells undergo necrosis (or during
the later stages of apoptosis) the cell membrane is disrupted, allowing dyes such as
propidium iodide (PI) to penetrate the cell. Therefore, necrotic or late apoptotic cells
can be identified as those positive for PI staining. Cells that are negative for both
Annexin V binding and PI staining are considered healthy, viable cells. Those that
are positive for Annexin V binding in the absence of PI staining are considered to be
undergoing early apoptosis, whilst those that are positive for PI staining or for both
Annexin V binding and PI staining are considered to have undergone necrosis or to
be in the late stage of apoptosis. Annexin-V positive cells are detected in the F1 1
channel of the flow cytometer (figure 2.6), and PI positive cells are detected in the F1
3 channel (figure 2.6).
Human monocytes, monocyte-derived macrophages or BAoSMC were
seeded in 48-well, flat-bottomed tissue culture plates as described in section 2.2.2.1
and 2.2.3 respectively. Cells were incubated (6h or 24h; 37°C; 95% O2: 5% C02) in
the presence and absence of each NO donor compound (100 - 300 pM for human
monocyte-derived macrophges; 10 - 300 pM for BAoSMC), or in the presence of the
maximum drug vehicle concentration (DMSO; 1%), or the known apoptotic agent
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gliotoxin (1 pg.mF1). At the end of this incubation period, the cell culture
supernatant was aspirated and discarded and the cells removed from the tissue
culture plate (0.25 % typsin with EDTA). The recovered cell suspensions were
removed to flow cytometry tubes and incubated (4°C; 10 min) in the presence of
FITC-conjugated Annexin V in Annexin V-binding buffer (prepared as a 1:500
dilution of FITC-conjugated Annexin V in HBSS containing 5 mM CaCU).
Following this incubation, PI (2 (xg.mF1 final concentration) was introduced to the
cell suspension/Annexin V binding buffer mix and incubated (4°C; 1 min) prior to
analysis by flow cytometry. Flow cytometric analysis was carried out using a
Coulter EPICS XL flow cyometer (Beckman Coulter, California, USA) and data
captured using EXPO™ 32 v 2.1 analysis software (Beckman Coulter, California,
USA).
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Figure 2.8 Assessment of Apoptosis and Necrosis by Flow Cytometry
Human monocyte-derived macrophages were incubated (24 h; 37°C; 95% 02: 5% C02) in
the absence of any treatment (A), and the presence of gliotoxin (1 pg.ml-1; B) or GEA-3162
(300 pM; C). Flow cytometry data are shown as two dimensional dot plot diagrams (left
panel) and histogram plots of cells detected in the Fl 1 channel (Annexin V-positive cells;
centre panel) and the Fl 3 channel (Pl-positive cells; right panel).
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In order to verify that a large population of apoptotic cells had not been
discarded in the culture supernatant due to loss of adherence of dead cells, a sample
of tissue culture supernatants was also analysed by flow cytometry. Supernatants
were found to contain both healthy and apoptotic cells in low numbers, but
importantly, the pattern of cell death in the supernatants correlated with that of the
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Figure 2.9 Ceil Death in Human Monocyte-Derived Macrophages
Cell death in cells present in the culture supernatant is representative of those remaining
adhered to the tissue culture plate (n=2).
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2.4 Assessment of Cell Proliferation
Cell proliferation induced by DEA/NO, DETA/NO, SNVP, GSNO, and
GEA-3162 (all 10 - 300 pM) in BAoSMC was assessed by bromodeoxyuridine
(BrdU) assay. BrdU is a thymidine analogue which becomes incorporated into the
newly synthesised DNA of actively proliferating cells. The BrdU Cell Proliferation
Assay (Calbiochem, Merck Biosciences, Darmstadt, Germany) allows detection and
quantification of BrdU, following partial denaturation of the DNA double strand by
use of a detector monoclonal anti-BrdU antibody to bind to any BrdU incorporated
into cells. Horseradish peroxidase-conjugated goat anti-mouse IgG antibody is then
used to bind to the detector antibody and catalyse the conversion of the chromogenic
substrate tetra-methylbenzidine (TMB) to form a coloured product that absorbs light
at dual wavelengths of 450nm and 540nm. The intensity of the coloured product is
directly proportional to the amount of incorporated BrdU present in the cells.
BAoSMC were seeded in 96-well, flat-bottomed microtiter plates at a
density of 2.5 x 103 cells/well (8 x 102 cells/mm2) and incubated (37°C; 95% 02: 5%
C02) for 24 hr to allow cells to adhere to the plate as described in section 2.2.3. This
density of cells was found to be sufficient to produce approximately 70% confluence
in the individual wells after the initial 24 h incubation, but was insufficient to
produce 100% confluence, thereby avoiding cell-cell contact inhibition of cell
proliferation. After this initial period, cells were incubated (37°C; 95% 02: 5% C02)
for a further 24 h in the presence of BrdU together with each NO donor compound
(10 - 300 pM), or the maximum concentration of drug vehicle (DMSO; 1%). At the
end of this incubation period, the cells were fixed and denatured according to the
assay kit instructions prior to incubation (1 h; RT) with the anti-BrdU antibody,
91
Chapter Two -Materials andMethods
followed by incubation (30 min; RT) with horseradish peroxidase-conjugated goat
anti-mouse IgG. Finally, the cells were incubated (15 min; RT; light proof
conditions) with TMB. After 15 min, the reaction was stopped (sulphuric acid; 2.5
M) and the optical densities (dual wavelengths 450nm and 540nm) measured by a
Multiskan Ascent plate reader and data captured using Ascent v 2.6 software
(Thermo Labsystems, South Trentham, U.K). The absorbance of cells without the
BrdU label, and that of the tissue culture media (DMEM), were measured and
subtracted from each reading. All samples were assayed in duplicate.
In order to verify that any observed reduction in cell proliferation was not due
to an increased cytotoxicity resulting from the drug vehicle, DMSO, the effect on cell
proliferation of the final concentrations of DMSO (0.01 - 1%) was investigated as
described above. DMSO was not found to have a significant impact on the levels of
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Figure 2.10 The Effect of DMSO on Cell Proliferation
DMSO (0-1%) has no impact on cell proliferation (P>0.05; unpaired, one-way ANOVA; n=6)
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2.5 Measurement of cGMP
Levels of cGMP produced by human monocyte-derived macrophages and
BAoSMC in response to treatment with DETA/NO (10 - 100 pM) in the absence and
presence of the NO-independent sGC-stimulator, BAY 41-227 (1 pM), or GEA-3162
(100 pM) were measured by an enzyme-linked immunosorbant (ELISA) cGMP
assay (R&D Systems Abingdon, UK). cGMP present in the sample competes with a
pre-existing, fixed amount of cGMP for binding sites on a goat anti-rabbit polyclonal
antibody coated to the microtiter plate. The level of bound enzyme is determined by
addition of />-nitrophenol phosphate (pNPP) substrate, which produces a coloured
product that absorbs light at 405 nm. The intensity of the colour produced is
inversely proportional to the amount of bound antibody. Low levels of cGMP are
measured by acetylation of the sample with acetic anhydride and triethylamine at low
pH.
Human monocyte-derived macrophages or BAoSMC were seeded in 48-well,
flat-bottomed tissue culture plates as described in section 2.2.2.1 and 2.2.3
respectively. Cells were incubated (37°C; 95% O2: 5% CO2; 24 h) in the presence of
NO-donor compounds plus the non-specific phosphodiesterase (PDE) inhibitor 3-
isobutyl-l-methylxanthine (IBMX; 250pM) to prevent cGMP breakdown.
Following this incubation, the cell culture supernatants were aspirated from the
wells, frozen immediately on dry ice and stored (-70°C). Adherent cells were lysed
(300 pl/well Triton X 100 (2%) prepared in phenol red-free HBSS containing
Ca2+/Mg2+) and the recovered solution divided into two aliquots of 225 pi for the
cGMP assay and 75 pi for a protein assay (see section 2.6 below). The aliquots for
the cGMP assay were acidified (HC1; 0.1 M) and then both aliquots frozen
93
Chapter Two -Materials andMethods
immediately on dry ice and stored (-70°C) for approximately one week prior to
performing the assay.
Each sample was acetylated according to the cGMP assay kit
instructions prior to incubation (2h; horizontal orbital shaker (500 ± 50 rpm); RT)
with the cGMP conjugate and the cGMP antibody. At the end of this time, the
substrate pNPP was added to the wells and the plate incubated for a further hour
(RT) before the reaction was stopped (trisodium phosphate) and the absorbance (405
nm) measured. Optical densities (405 nm) were measured by a Multiskan Ascent
plate reader and data captured using Ascent™ v 2.6 software (Thermo Labsystems,
South Trentham, U.K). Non-specific binding (NSB) was determined by addition of
the cGMP conjugate and cGMP antibody to wells coated with the goat anti-rabbit
polyclonal antibody in absence of any sample and this absorbance value subtracted
from the absorbance of all samples. The concentration of cGMP was calculated from
a standard curve produced daily from serial dilutions of known concentrations of
cGMP (0.08 - 50 pmol.ml"1; figure 2.9). Standards were acetylated as described
above for the samples. All standards and samples were assayed in duplicate.
Log [cGMP]/ pmol.ml'1
Figure 2.11 Standard Curve Generated for the Calculation of cGMP Concentration
Example standard curve generated from the absorption (405 nm) of known concentrations
of acetylated cGMP (0.08 - 50 pmol.ml"1)
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2.6 Measurement of Protein
In order to account for variability in the densities of the cell populations
seeded in tissue cultures plates, the total amount of protein present in each well was
measured by bicinchoninic acid (BCA) colorimetric protein assay (Pierce, Illinois,
USA). During this assay, Cu2+ is reduced to Cu+ by protein in an alkaline medium
(the biuret reaction). Cu+ ions are then detected by the reaction of the assay substrate
containing BCA to form a coloured product that absorbs light at 562 nm. Aliquots
of human monocyte-derived macrophages and BAoSMC cell lysates (see section 2.5)
were plated out in 96-well, flat-bottomed microtiter plates. Cell lysates were
incubated (37°C; 30 min) in the presence of the assay substrate containing BCA
prior to determining the absorbance (562 nm) of each sample. Optical densities were
determined using a Dynatech MRX plate reader (Dynatech Laboratories
Incorporated, Virginia, USA). Total protein concentration of each well was
calculated from a calibration graph generated daily from the absorbance (562 nm) of
known concentrations of bovine serum albumin (BSA; 0 - 1000 pg.ml"1) diluted in
Triton X 100 (2%; prepared in phenol red-free HBSS containing Ca2+/Mg2+), with
the curve fitted by first order polynomial nonlinear regression (figure 2.12). The
absorbance of the Triton X 100 solution was recorded as a blank and this value
subtracted from the readings of all standards and samples. All standards and samples
were assayed in duplicate.
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[BSA]/n.mr1
Figure 2.12 Standard Curve Generated for the Calculation of Total Protein in Cell
Lysates
Example calibration graph generated from the absorbance (562 nm) of known
concentrations of bovine serum albumin (BSA; 0 - 1000 |ig.mr1).
2.7 Functional Studies in Isolated Rat Aortae
To test the efficacy of DETA/NO, the NO-independent sGC stimulator, BAY
41-2272, and the non-specific PDE inhibitor, IBMX, relaxation in response to each
compound was measured as isometric tension in isolated rat aortic rings using a
fixed-mount myogragh.
Male Wistar rats (Charles River) were housed and terminated in accordance
with the Animals (scientific Procedures) Act 1986 (UK Home Office). Adult male
rats were terminated by cervical dislocation and thoracic aortae harvested into
physiological solution (PSS; 4°C) containing (mM) NaCl (119); KCL (4.7);
CaCl2.2H2Q (2.5); MgS04.7H20 (1.17); NaHC03 (25); KH2PQ4 (1.18); EDTA
(0.027) and glucose (5.5). Aortae were cleaned of connective tissue and fat in PSS
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(4°C), before being divided into aortic ring sections (approximately 3 mm). Aortic
rings were suspended between two intraluminal wires in four parallel myograph
chambers (10 ml) containing oxygenated (95% 02: 5% C02) PSS (37°C). In order to
model intraluminal pressure generated in vivo, tension was applied to each vessel in
stepwise increments to obtain a resting tension of 17 mN. This isometric tension was
measured in a Multi Tissue Bath System 700MO (Danish Myo Technology,
Copenhagen, Denmark) and data captured via a MabLab/4e analogue-digital
converter and displayed through Chart™ v 3.6/s software (AD Instruments, Sussex,
UK).
Prior to each experimental protocol, maximum receptor-independent
contraction in response to potassium (K+) was obtained by contracting each vessel
three times with high potassium PSS (KPSS) containing 123.7 mM KC1.
Subsequently, cumulative concentration-response curves fitted by second order
polynomial nonlinear regression were obtained in each vessel for phenylephrine (PE;
0.001 - 1 pM) and a suitable concentration selected to produce -80% contraction
(ECso; 0.1 pM; figure 2.11). Following precontraction with ECgo PE (0.1 pM),
responses to DETA/NO (0.001 - 100 pM) and DETA/NO (10 pM) in the presence of
BAY 41-2272 (1 pM) or IBMX (1 pM) were measured. Contractions are expressed
as a percentage of the maximum contraction in response to KPSS and relaxations as
a percentage of the contraction in response to EC80 PE. Data are expressed as the
average of four aortic rings for each animal.
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Figure 2.13 Determining the EC80 for Phenylephrine
Isometric tension in response to PE (0.001 - 1pM) was measured in isolated rat aortic rings
and the concentration of PE giving 80% of maximum contraction selected as the ECS0 PE.
Contractions are expressed as a percentage of the maximum contraction in response to
KPSS. Data are expressed as mean ± SEM, (n=4)
2.8 Statistics
Statistical analyses are stated in experimental chapters. Data were analysed
using GraphPad Prism software v 3.03 (GraphPad Software Inc., San Diego, USA).
Degrees of significance are abbreviated throughout as follows: *** = P < 0.001; ** =
P < 0.01; * = P < 0.05 or by symbols as indicated in experimental chapters. In all
cases, P > 0.05 was not considered to be statistically significant (ns; not significant).
Data are expressed throughout as mean ± standard error of the mean (SEM).
log [PE]
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2.9 Materials
NO Donor Compounds
GEA-3162, SNVP, GSNO and BAY 41-2272 were prepared and stored (-
20°C) as stock solutions (104 M) in DMSO. Immediately prior to use, these
compound were diluted in PBS. DEA/NO and DETA/NO were prepared and stored
(-20°C) as stock solutions (10~2 M) in NaOH (0.01 M), and diluted prior to use in
PBS. Additionally, an appropriate volume of DMSO was added to each
concentration of DEA/NO and DETA/NO such that the final experimental
concentration of DMSO was equal for all NO donor compounds and not greater than
1%, which was experimentally inert, thus removing the vehicle as a source of
variability.
GEA-3162, DEA/NO, and DETA/NO were purchased from Axxora (Axxora Ltd,
Nottingham, UK). GSNO was purchased from Sigma (Sigma Aldrich, Poole, UK).
SNVP was synthesised by a previously published method (Megson et al. 1997) and
kindly supplied by Drs A.R Butler and N.P Botting, University of St Andrews (St
Andrews, UK). BAY 41-2272 was kindly supplied by Bayer (Leverkusen,
Germany).
Met-Hb was reduced to the ferro-form with sodium dithionite as previously
described (Martin et al. 1985), and aliquots (1 mM) stored (-20°C) for less than one
month.
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Tissue Culture
Tissue culture materials were supplied as follows:
Becton Dickinson Falcon (Oxford, UK)
All tissue culture plasticware including tissue culture flasks (15 - 162 cm ),
microtiter (96-well) plates, multi-well tissue culture plates (48- & 96-well) and 96-
well Flexiwell™ plates were supplied sterile.
Gibco Life Technologies Paisley, UK)
Tissue culture media (RPMI 1640; IMDM; DMEM) were supplied sterile, endotoxin
free, at pH 7. Trypsin (0.25%) EDTA solution and tissue culture supplements
penicillin/ streptomycin solution and L-glutamine solution were stored (-20°C) in
aliquots. Foetal calf serum was heat inactivated by heating (50°C; 1 h) in a sterile
water bath before addition to media.
PBS (lx and lOx) and HBSS both with and without Ca2+/Mg2+ as required, were
supplied sterile, endotoxin free, at pH 7.
All tissue culture solutions were stored (4°C) and pre-warmed (37°C) in a sterile
water bath prior to use.
Pharmacia (Milton Keynes, UK)
Percoll was stored (4°C) as 100% solution and diluted to 90% solution immediately
prior to use in lOx PBS (without Ca2+/Mg2+). 90% Percoll solution was further
diluted as required in lx PBS (without Ca2+/Mg2+). Dextran T500 was stored (4°C)
in aliquots.
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Additional Reagents
Additional reagents were supplied and prepared as follows:
Sigma Aldrich (Poole, UK)
SOD was prepared (5000 U.ml"1 in PBS) and stored (-20°C) in aliquots. IBMX was
prepared (10~2 M in DMSO), stored in aliquots (-20°C) and diluted immediately prior
to use in PBS. LPS was prepared (1 mg.ml"1 in PBS) and stored (-20°C) in aliquots.
DAN was prepared freshly immediately prior to use in HC1 (0.7 M). Gliotoxin was
prepared (1 mg.ml"1 in DMSO), stored (-20°C) in aliquots and diluted prior to use in
PBS (to give a final DMSO concentration equal to that of the NO donor compounds).
NADPH was prepared freshly immediately prior to use in PBS. Nitrate reductase
was prepared (10 U.ml"1 in PBS) and stored in aliquots (-20°C). FITC- conjugated
Annexin V was stored (-20°C) in aliquots and diluted prior to use in Annexin V
binding buffer (prepared as HBSS plus 5 pM CaCU). PI was prepared (1 mg.ml"1 in
H20) and stored (4°C) in aliquots. Trypan Blue was stored at room temperature.
Fisher Scientific (Loughborough, UK)
Triton X 100; DMSO.
General laboratory reagents including buffer salts; EDTA; NaOH; HC1.
Ultrafilter centrifuge tubes (12 kD pore size)
Axxora Ltd (Nottingham, UK)
Tempone-H was prepared (0.1 M in 10 mM in EDTA solution) and stored (-20°C) in
aliquots. 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide .
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potassium salt (carboxyPTIO) was prepared (103 M in PBS) immediately prior to
use.
Tocris Cookson (Bristol, UK)
ODQ was prepared (10~2 M in DMSO) and stored (-20°C) in aliquots.
Rathburn (Walkerburn, UK)
HPLC-grade reagents: H2O; Acetonitrile; NaOH; HC1
Charles River (Kent, UK)
Wistar male rats were housed and terminated according to The Animals (Scientific
Procedures) Act 1986 (UK Home Office).
British Oxygen Company (Surrey, UK)
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3. Characterisation of NO Donor
Compounds
3.1 Introduction
NO is often reported to have paradoxical actions in many biological settings.
For example, the literature contains numerous reports of NO being both antioxidant
and pro-oxidant (Goss et al. 1995; Rubbo et al. 1995; Struck et al. 1995; Joshi et al.
1999; Wei et al. 2000), cytotoxic and cytoprotective (Polte et al. 1997; Stefanelli et
al. 1999; Mason et al. 2000; Keira et al. 2002; Hattori et al. 2004) and having both
pro- and anti-apoptotic characteristics (Ward et al. 2000; Kim et al. 2001; Fiscus et
al. 2002). Such apparent contradictions may be explained, at least in part, by the
ease with which the NO radical forms intermediary, NO-related species in vivo. NO-
related species can be biologically active independent of the liberation of NO per se
and, therefore, the net outcome of any NO-induced response will be critically
dependent on the concentration and precise NO-related species generated in the
microenvironment, as well as the nature of the target cell.
Numerous synthetic NO donor compounds are available both for possible use
in the clinical setting and as experimental tools. Each class of compound has unique
chemical properties and varying mechanisms of NO release, ranging from
compounds capable of spontaneously liberating NO radical in solution to those
requiring more complex enzymatic degradation, or the presence of tissue thiol groups
(Megson 2000). Such differences can be exploited in vitro to examine the precise
NO-related species responsible for mediating particular biological actions of NO.
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The diazeniumdiolate class of NO donor are considered 'pure' NO donors
and are capable of releasing up to two molecules of NO spontaneously in solution
without the requirement for enzymatic or tissue-dependent activation (Smith et al.
1996; Megson 2000; Megson and Webb 2002). NO is released predictably and by
first order kinetics with the rate of release dependent on the nature of the nucleophile
to which the [N(0)NO] group is attached, as well as temperature and pH (Davies et
al. 2001). Varying the nucleophilic adduct in the molecule has produced a variety of
compounds in which the rates of decomposition range from seconds to many hours
(Megson 2000; Megson and Webb 2002). This makes the diazeniumdiolates
particularly useful experimental tools because compounds can be selected on the
basis of their individual half-lives in order to deliver NO over a range of
concentrations and time periods. For example, a compound with a short half-life,
such as DEA/NO (ty2=2 min), can be used to deliver a short burst of NO, whereas
those with longer half-lives, such as DETA/NO (t>/2=20 h), can be used to provide a
prolonged and relatively sustained delivery of NO.
The S-nitrosothiol (RS-N=0) class of NO donors are formed both
endogenously and synthetically by nitrosation (transfer of NO+) of reduced cysteine
residues of proteins, or thiol groups of low molecular weight compounds (Butler et
al. 1995; Kharitonov et al. 1995; Butler and Rhodes 1997; Liu et al. 1998); examples
include endogenous GSNO and the synthetic compound, SNVP. The biological half-
life of S-nitrosothiols is unpredictable in solution and dependent on the R group of
the compound (Mathews and Kerr 1993). The exact mechanism of decomposition
and subsequent biological action of S-nitrosothiols, both endogenous and synthetic,
is not fully known and may occur without the liberation of NO per se (Kowaluk and
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Fung 1990; Ceron et al. 2001), but via rapid transnitrosation reactions resulting in the
transfer of NO+ from one thiol moiety to another (Scharfstein et al. 1994; Askew et
al. 1995; Liu et al. 1998; Hogg 1999). However, release of free NO from S-
nitrosothiols does occur when the rate of decomposition is greatly accelerated due to
the presence of copper ions or exposure to light (Sexton et al. 1994; Askew et al.
1995; Gordge et al. 1995; Dicks and Williams 1996; Gorren et al. 1996; Singh et al.
1996; Al-Sa'doni et al. 1997).
Mesoionic 3-aryl, 5-imino-oxatriazole derivatives, for example GEA-3162,
are a novel class of NO donors which are structurally very similar to the
sydnonimines (Megson 2000; Megson and Webb 2002). Sydnonimines, for example
SEN-1, are not strictly NO donors but are considered generators of the NO-related
species, ONOO", on account of concomitant generation of NO and O2", which rapidly
combine to form ONOO" (Feelisch et al. 1989). Early investigations with the
mesoionic 3-aryl-substitued oxatriazole-5-amine derivatives initially reported this
class of compound to be pure NO donors (Kankaanranta et al. 1996; Holm et al.
1998). However, recent evidence has suggested that, in common with the
structurally similar compound SIN-1, GEA-3162 is in fact a ONOO" generator, rather
than an NO donor (Taylor et al. 2004).
In order to use this variety of NO donor compounds as useful experimental
tools, it is essential to characterise precisely which NO-related species is generated
during an assay. Because the profile of NO release and rate of decomposition from
such compounds depends on the composition of the environment into which they are
introduced (e.g. pH, temperature), it is prudent to characterise the NO-related species
generated by each compound in conditions as close as possible to those prevalent
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during subsequent experimental assays. This is particularly true for cell culture
experiments as components of the tissue culture medium may affect NO (Keynes et
al. 2003). Therefore, the aim of these studies was to fully characterise the NO, or
NO-related species, generated under conditions used during subsequent biological
investigations involving the diazeniumdiolates, DEA/NO and DETA/NO; the S-
nitrosothiols, SNVP and GSNO; and the mesoionic 3-aryl-substitued oxatriazole-5-
amine derivative, GEA-3162.
1.1 3.2 Methods
3.2.1 Electrochemical Detection of NO
NO released in solution was measured using a calibrated isolated NO
electrode (see chapter 2.1.1). The NO donor compounds DEA/NO (10 pM),
DETA/NO (300 pM), SNVP (300 pM) and GSNO (300 pM) were added in the
presence or absence of SOD (500 U.ml"1) to aliquots (2 ml) of pre-warmed (37 °C),
stirred (600 rpm) DMEM plus supplements (as described in chapter two, section
2.2.3) or IMDM plus supplements but without serum (see chapter two, section
2.2.2.1), and the signal from the electrode recorded for 30 minutes (figures 3.1 &
3.3). For those experiments conducted in the presence of SOD, the signal from the
NO electrode was recorded for 1 min in the presence of SOD (500 U.mF1) alone
prior to the addition of NO donor compounds. At the end of this time, the NO
scavenger, Hb (5 pM), was introduced to the electrode chamber. GEA-3162 (300
pM) was added to aliquots of pre-warmed (37 °C), stirred (600 rpm) DMEM or
IMDM and the signal recorded for 1 min prior to the introduction of stepwise
increments of SOD (50 - 500 U.ml"1). When a final concentration of 500 U.mF1 had
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been reached, Hb (5 pM) was introduced to the electrode chamber. Alternatively,
GEA-3162 (300 pM) and SOD (500 U.ml"1) were added simultaneously to aliquots
of pre-warmed (37 °C), stirred (600 rpm) DMEM or IMDM and the NO release
recorded until the signal had decayed to baseline.
The above recordings were also performed in H2O buffered with sodium
bicarbonate (NaHC03) to mirror the buffering of DMEM or HEPES to mirror that of
IMDM (see appendix one), and in IMDM containing heat inactivated FCS (10% v:v)
in addition to the supplements described in chapter two (see section 2.2.2.1).
3.2.2 Electron Paramagnetic Resonance
Oxidising free radical species generated by each NO donor compound (10 -
300 pM) were measured in DMEM and IMDM in presence and absence of SOD
(500 U.mr1) using the chemical spin-trap, Tempone-H, as described in chapter 2.1.4.
Only those signals where the signal-to-noise ratio was >3 were considered to genuine
signals. Despite preparation of the spin trap in EDTA (10 mM) to minimise the
phenomenon, relatively small signals were generated in control experiments
(Tempone-H (1 mM) in each medium) due to auto-oxidation of the spin trap. These
signals have been subtracted from the corresponding experimental signals detected in
the presence of NO donor compounds.
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3.3 Results
3.3.1 NO Electrode Studies
NO release from DEA/NO (10 pM) was rapid and short-lived in both media,
reaching a maximum signal by approximately 5 min in DMEM and 2.5 min in
IMDM, with the signal decaying to baseline by approximately 30 min in both media
(figures 3.1 & 3.3). In DMEM, a maximum concentration of 11.2 ± 2.2 pM NO was
attained from DEA/NO, and this was unaffected by the presence of SOD (500 U.ml"
*), when the peak concentration was 11.1 ± 1.8 pM (figure 3.3 & table 3.1). Analysis
of the area under the curve (AUC; figure 3.3) by unpaired, two-tailed t-test revealed
this difference to be non-significant (P>0.05; n=6). Similarly, in IMDM, the peak
NO concentration attained from DEA/NO was 8.9 ± 1.0 pM (figure 3.3 & table 3.1),
and this was not significantly affected by SOD (10.3 ± 0.6 pM; P>0.05; unpaired,
two-tailed t-test of AUC; n=6). Analysis of AUC of DMEM compared to IMDM
(comparison of the graphs in figure 3.3) revealed the release of NO from DEA/NO
was not significantly altered between the two media, both in the absence and
presence of SOD (P>0.05; unpaired, two-tailed, Mest AUC; n=6; table 3.1).
DETA/NO (300 pM) produced a slower, more prolonged NO release in both
media, with the maximum signal reached at approximately 10 min, and then
remaining steady for the duration of the 30 min recording (figure 3.2 & 3.3). Hb (5
pM) completely abolished the signal from DETA/NO at the end of the 30 min
recording (figures 3.2 & 3.3). The release of NO from DETA/NO was unaffected by
SOD (500 U.mf1) in both media (maximum concentrations of 3.9 ± 0.1 pM vs 4.1 ±
0.4 pM; P>0.05 for DMEM and 2.6 ± 0.2 pM vs 2.6 ± 0.2 pM; P>0.05 for IMDM,
unpaired, two-tailed t-test of AUC; n=6 for both media; figure 3.3). However,
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analysis of AUC (figure 3.3) by unpaired, two-tailed /-test revealed the total amount
of NO released from DETA/NO was significantly greater in DMEM compared to
IMDM over the 30 min incubation period, both in the absence (P < 0.01) and
presence of SOD (P < 0.05; table 3.1).
The S-nitrosothiols, SNVP and GSNO (both 300 pM), released only low
concentrations of NO in solution (figures 3.4 - 3.6). SNVP released significantly
more NO in DMEM compared to IMDM (maximum concentrations of 2.4 ± 0.8 pM
vs 0.4 ± 0.1 pM; P < 0.01; unpaired, two-tailed t-test of AUC; table 3.1). Hb (5 pM)
abolished the signal from SNVP when it had not already decayed to base line by the
end of the 30 min recording (figures 3.4 & 3.6). The presence of SOD significantly
increased the release of NO from SNVP in both DMEM (P < 0.05) and IMDM (P <
0.001; unpaired, two-tailed /-test AUC; n=6; for both media; figure 3.6). Similarly,
GSNO released significantly more NO in DMEM compared to IMDM (maximum
concentrations of 5.1 ± 0.2 pM vs 2.0 ± 0.2 pM; P < 0.001; unpaired, two-tailed, /-
test AUC; n=6; table 3.1). Hb abolished the signal from GSNO at the end of the 30
min recording (figures 3.5 & 3.6). The presence of SOD did not significantly affect
the amount of NO released from GSNO in either media (for both media P >0.05;
unpaired, two-tailed, /-test AUC; n=6; figure 3.6).
Both SNVP and GSNO, regardless of the absence or presence of SOD,
generated a biphasic NO release profile consisting of a rapid immediate peak, which
then decayed superimposed on a second slower and more sustained phase of NO
release. This occurred in both media, but was more pronounced for GSNO than
SNVP and more marked in DMEM than IMDM (figures3.4 - 3.6)
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Figure 3.1 NO Release from DEA/NO in DMEM and IMDM
Example traces from the NO electrode showing NO release from DEA/NO (10 p) in DMEM
and IMDM in the absence and presence of SOD (500 Urnf1). Arrows show addition of
compounds as described indicated.
Ill







Figure 3.2 NO Release from DETA/NO in DMEM and IMDM
Example traces from the NO electrode showing NO release from DETA/NO (300 pM) in
DMEM and MDM in the absence and presence of SOD (500 U.mr1). The signal in all cases
was abolished by addition of Hb (5 pM). Arrows show addition of compounds as indicated.
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Figure 3.3 NO Release from DEA/NO and DETA/NO
NO release from DEA/NO (10 |iM) and DETA/NO (300 pM) was measured by calibrated
isolated NO electrode in DMEM (left panel) and IMDM (right panel) in the absence (closed
symbols, solid lines) and presence of SOD (500 U.ml1; open symbols, dashed lines). Hb (5
pM) abolished the signal from DETA/NO in both media. Arrows show addition of compounds
as indicated. Analysis of the area under the curve (AUC) by unpaired, two-tailed f-test
revealed SOD did not significantly affect NO release (ns = P>0.05; n=6).
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Figure 3.4 NO Release from SNVP in DMEM and IMDM
Example traces from the NO electrode showing NO release from SNVP (300 pM) in
DMEM and IMDM in the absence and presence of SOD (500 U ml"1). Hb (5 pM)
abolished the signal when it had not already decayed to baseline. Arrows show addition
of compounds as indicated.
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Figure 3.5 NO Release from GSNO in DMEM and IMDM
Example traces from the NO electrode showing NO release from GSNO (300 pM) in DMEM
and IMDM in the absence and presence of SOD (500 U ml"1). Hb (5 pM) abolished the signal
in both media. Arrows show addition of compounds as indicated.
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Figure 3.6 NO Release from SNVP and GSNO
NO release from SNVP and GSNO (both 300 |jM) was measured by calibrated isolated NO
electrode in DMEM (left panel) and IMDM (right panel) in the absence (closed symbols, solid
lines) and presence of SOD (500 U.ml"1; open symbols, dashed lines). Hb (5 pM) abolished
the signal when it had not already decayed to basline. Arrows show addition of compounds
as indicated. Analysis of the AUC by unpaired, two-tailed f-test revealed SOD significantly
increased NO release from SNVP in DMEM (* = P<0.05) and IMDM (*** = P<0.001; n=6) but
did not affect NO release from GSNO in either media (ns = P >0.05; n=6 for both
compounds in both media).
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DEA/NO (10 pM) 11.2 ± 2.2 192.0 ±35.5 8.94 ± 1.0 120.1 ± 16.1 P = ns
DEA/NO (10 pM) +
SOD (500 U.mr )
11.1 ± 1.8 176.9 ± 22.7 10.3 ±0.6 127.7 ± 15.2 P = ns
DETA/NO (300 pM) 3.9 ±0.1 97.7 ± 2.8 2.6 ± 0.2 67.1 ± 6.4 P<0.01
DETA/NO (300 pM)
+ SOD (500 U.ml"1)
4.1 ± 0.4 104.0 ± 10.2 2.6 ±0.2 70.7 ± 5.4 P < 0.05
SNVP (300 pM) 2.4 ± 0.8 42.3 ± 9.2 0.4 ± 0.1 4.3 ± 1.3 P< 0.01
SNVP (300 pM) +
SOD (500 U.ml"1)
4.0 ± 0.8 85.9 ± 13.1 0.94 ± 0.1 22.9 ± 1.7 P< 0.01
GSNO (300 pM) 5.1 ± 0.2 113.2 ± 5.8 2.0 ±0.2 40.9 ± 9.3 P< 0.001
GSNO (300 pM) +
SOD (500 U.ml"1)
5.0 ±0.1 122.8 ± 4.8 2.7 ±0.3 53.3 ± 10.8 P< 0.001
Table 3.1 NO Release from NO Donor Compounds in DMEM and IMDM
NO release from each compound in DMEM and IMDM was measured by isolated NO
electrode. Table 3.1 shows a summary of the maximum concentration of NO release (pM)
together with the area under the curve (AUC; arbitrary units; figures 3.3 and 3.6) for each NO
donor compound in the presence and absence of SOD (500 U.mr1). Analysis of the AUC by
unpaired, two-tailed f-test revealed differences between the NO release from each NO donor
compound in DMEM compared to IMDM as shown in the final column (n=6 for all
compounds in both media).
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Unlike the diazeniumdiolate and the RS-N=0 compounds, GEA-3162 (300
pM) failed to release NO in solution except in the presence of SOD (50 - 500 U.mT1;
figures 3.7 & 3.8), when significantly more NO was released in DMEM compared to
IMDM (NO concentrations in the presence of maximum concentrations of SOD of
2.3 ± 0.2 pM vs 1.6 ± 0.1 pM; P < 0.001, unpaired, two-way analysis of variance
(ANOVA); n=6; figure 3.8). Hb (5 pM) abolished the signal from GEA-3162 in the
presence of the final concentration of SOD (figures 3.7 & 3.8). Additionally, the
release of NO from GEA-3162 (300 pM) in the presence of SOD (500 U.ml"1) was of
shorter duration in DMEM compared to IMDM (figures 3.9). In DMEM, GEA-3162
in the presence of SOD produced a greater initial release of NO with the signal
decaying to baseline by approximately 100 min, whereas in IMDM, the initial release
of NO from GEA-3162 was blunted in comparison, but more prolonged overall, with
the signal persisting until approximately 260 min (figures 3.9).
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Figure 3.7 NO Release from GEA-3162 in the Presence of SOD in DMEM and IMDM
Example traces from the NO electrode showing NO release from GEA-3162 (300 pM) in the
presence of SOD (50 -500 U.mr1) in DMEM and IMDM. Arrows show addition of
compounds as indicated. Final SOD concentrations (U.mr1): SOD1 = 50; SOD2 = 150;
SOD3 = 300; SOD4 = 500. Hb (5 pM) abolished the signal in both media when the
maximum concentration of SOD had been attained.
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Figure 3.8 NO Release from GEA-3162 in the Presence of SOD
NO release from GEA-3162 (300 pM; A) was measured by calibrated isolated NO electrode
in DMEM (solid symbols; solid line) and IMDM (open symbols; dashed line) in the presence
of SOD (50 - 500 U.mr1). Arrow indicates addition of the NO scavenger Hb (5 pM).
Unpaired, two-way ANOVA followed by post hoc Bonferroni test revealed GEA-3162 (300
pM) released significantly more NO in DMEM compared to IMDM (*** = P<0.001; n=6).
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Figure 3.9 Release Profile of NO from GEA-3162 in the Presence of SOD
Example traces from the NO electrode (A) and average graph (B; n=6) showing release profile
of NO from GEA-3162 (300 pM) in the presence of SOD (500 U.ml-1) in DMEM and IMDM.
GEA-3162 and SOD were introduced simultaneously into the electrode chamber and the
signal recorded until it had decayed to baseline. Arrows show addition of compounds as
indicated.
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In summary, NO release from all the NO donor compounds, with the
exception of DEA/NO, varied accorded to the medium in to which they were
introduced. In all cases where differences were observed, the measurable NO release
was greater, (and shorted lasting in the case of GEA-3162) in DMEM compared to
IMDM. In order to investigate if these differences were due to different means of
buffering between the two media - NaHC03 for DMEM and HEPES for IMDM (see
appendix one), pilot experiments were conducted to measure NO release from each
compound in NaHC03-buffered H20 and HEPES-buffered H20.
In NaHCOg- buffered H20 (DMEM equivalent), DEA/NO (5 pM) released a
peak NO concentration of 7.4 pM at approximately 5 min, which had not completely
decayed to baseline at the end of the 30 min recording period (figure 3.10). In
HEPES-buffered H20 (IMDM equivalent), the peak signal from DEA/NO was
marginally greater (8.1 pM), occurred slightly earlier (at 2 min) and had decayed to
baseline by -20 min (figure 3.10).
DETA/NO (300 pM) released a peak concentration of 2.6 pM NO in
NaHCOs-buffered H20 compared to 1.4 pM NO in HEPES-buffered H20 (figure
3.10). The profile of NO release from DETA/NO was similar in both solutions,
reaching a plateau by approximately 10 min and remaining steady throughout the 30
min recording, at the end of which the signal was abolished by Hb (5 pM; figure
3.10).
NO release from SNVP (300 pM) was greater in HEPES-buffered H20
(IMDM equivalent) than in NaHC03-buffered H20 (7.7 pM vs 2.4 pM; figure 3.10).
Hb abolished the signal from SNVP at the end of the 30 min recording in both
solutions (figure 3.10). NO release from GSNO (300 pM) was limited in both
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solutions: 0.3 pM in NaHC03-buffered H2O and 0.1 pM in HEPES-buffered H2O
(figure 3.10). Hb abolished the signal to baseline at the end of the 30 min recording
in both solutions (figure 3.10).
In NaHC03-buffered H20 (DMEM equivalent), GEA-3162 (300 pM) in the
presence of SOD (500 U.ml"1) produced a maximum concentration of 4.9 pM NO by
approximately 2.5 min, which remained constant for approximately 80 min before
slowly decaying to baseline by approximately 160 min (figure 3.10). In HEPES-
buffered H20, the peak concentration of NO released from GEA-3162 in the
presence of SOD occurred at approximately the same time (2.5 min), but was slightly
greater (6 pM) and decayed rapidly during the first 30 min of recording (figure 3.10).
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Figure 3.10 NO Release in NaHC03 and HEPES Buffered H20
NO release from DEA/NO (5 |iM), DETA/NO, SNVP, GSNO, and GEA-3162 (all 300 )ilVl)
was measured by calibrated isolated NO electrode in NaHC03-buffered H20 (DMEM
equivalent; closed symbols; solid line) and HEPES-buffered H20 (IMDM equivalent; open
symbols; dashed line). Hb (5 pM) abolished the signal from DETA/NO, SNVP and GSNO at
the end of the 30 min recording (indicated by arrows). The signal from GEA-3162 was
measured in the presence of SOD (500 U.ml"). n=1 for both solutions.
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Since the different buffering methods did not fully account for the differences
observed in NO release between the two media, the effect of the presence of protein
in the media was investigated by repeating the recordings in IMDM plus 10% FCS
(as is supplemented to DMEM).
In IMDM containing FCS (10%), DEA/NO (5 pM) released a maximum
concentration of 6.5 pM NO, with the peak occurring at approximately 5 min and
decaying to baseline by approximately 20 min (figure 3.11). DETA/NO (300 pM)
released 10.8 pM NO in IMDM containing FCS, with the signal reaching a plateau
by approximately 15 min, and being abolished to baseline by Hb (5pM) at the end if
the 30 min recording period (figure 3.11).
SNVP (300 pM) released a maximum NO concentration of 2.8 pM in IMDM
containing FCS, with the peak signal occurring at approximately 10 min before
slowly decaying; Hb added at the end of the 30 min recording period abolished the
signal (figure 3.11). GSNO (300 pM) released a maximum NO concentration of 9.3
pM, with the peak signal occurring at approximately 2.5 min before slowly decaying
and being abolished to baseline by Hb at the of the 30 min recording period (figure
3.12.
In IMDM containing FCS, GEA-3162 (300 pM) in the presence of SOD (500
U.mF1) produced a maximum concentration of 7.4 pM NO by approximately 25 min,
which slowly decayed to baseline by approximately 260 min (figure 3.11).
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Figure 3.11 NO Release in IMDM Containing 10% FCS
NO release from DEA/NO (5 |jM), DETA/NO, SNVP and GSNO (all 300 |jM) was measured
by calibrated isolated NO electrode in IMDM containing FCS (10%). Hb (5 gM) abolished the
signal from DETA/NO, SNVP and GSNO at the end of the 30 min recording (indicated by
-j
arrows). The signal from GEA-3162 was measured in the presence of SOD (500 U.ml" ).
n=1 for all compounds.
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3.3.2 EPR Studies
Detection of an EPR signal consistent with the production of the
radical adduct, 4-oxo-tempone, was observed only from GEA-3162 (10 - 300 pM) in
DMEM and IMDM (figures 3.12-3.14). The signal generated by GEA-3162 was
significantly attenuated by SOD (500 U.mr1), which typically reduced the intensity
of the signal by approximately half in both media (figure 3.12 - 3.14). Levels of
oxidising radical species generated by GEA-3162 were significantly greater in
DMEM compared to IMDM (P < 0.001; unpaired, two-way ANOVA followed by
post hoc Bonferroni's test; n=6; figure 3.15).
The diazeniumdiolate compounds, DEA/NO (10 - 100 pM) and DETA/NO
(10 - 300 pM), and RS-N=0 compounds, SNVP and GSNO (both 10 - 300 pM),
failed to generate EPR signals of greater intensity than control and this was
unaffected by the presence of SOD (data not shown). The highest DEA/NO
concentration (300 pM) did generate a signal significantly greater than control, but
SOD failed to abrogate this signal in both media (5700 ± 770 vs 6385 ± 880; E>0.05
for DMEM and 4730 ± 380 vs 4450 ± 430; P>0.05 from IMDM; unpaired, two-tailed
t-test; n=6 for both media).
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Figure 3.12 Oxidising Radical Production by NO Donor Compounds in DMEM
Example EPR spectra showing the signal produced by the radical adduct, 4-oxo-tempo,
formed by reaction of the spin trap, Tempone-H (1 mM) with NO compounds (300 pM) as
indicated in the right hand legend. Recordings were performed in DMEM (plus
supplements) in the presence and absence of SOD (500 llml" ) as indicated in legends.
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Figure 3.13 Oxidising Radical Production by NO Donor Compounds in IMDM
Example EPR spectra showing the signal produced by the radical adduct, 4-oxo-tempo,
formed by the reaction of the spin trap, Tempone-H (1 mM) with NO compounds (300 pM)
as indicated in the right hand legend. Recordings were performed in IMDM (plus
supplements, but without serum) in the presence and absence of SOD (500 U.mr1) as
indicated in legends
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Figure 3.14 Oxidising Radical Production by GEA-3162 in DMEM and IMDM
GEA-3162 (10 - 300 pM; closed symbols, solid lines) generated significant levels of
oxidising radical species in DMEM and IMDM. Analysis by unpaired, two-way ANOVA
followed by post hoc Bonferroni's test revealed SOD (500 U.ml1; open symbols, dashed
lines) significantly attenuated the signal from GEA-3162 (* = P<0.05, ** = P<0.001; *** =
P<0.001; n=6 for both media).
130




u-| 1 1 1 I |
-5.5 -5.0 -4.5 -4.0 -3.5 -3.0
log[GEA-3162]/pM
Figure 3.15 Oxidsing Radical Production by GEA-3162 in DMEM and IMDM
Levels of oxidising radical species generated by GEA-3162 (10 - 300 pM) were significantly
greater in DMEM (closed symbols, solid line) compared to IMDM (open symbols, dashed
lines). *** = P < 0.001, unpaired, two-way ANOVA followed by post hoc Bonferrroni test; n =
6 for both media)
3.4 Discussion
These studies provide characterisation of the NO-related species liberated by
three different classes of putative NO donor compound. Variations in the
concentration and the release profile of NO and NO-related species in solutions of
varying composition justified the necessity to conduct such characterisation studies
in conditions closely reflecting those employed in subsequent biological studies.
Studies using the isolated NO electrode demonstrated that the
diazeniumdiolates spontaneously liberate NO radical in solution, with release
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profiles consistent with their half-lives and unaffected by the presence of SOD. In
common with previously published data on this class of compound (Fitzhugh and
Keefer 2000; Davies et al. 2001; Arnold et al. 2002), both DEA/NO and DETA/NO
released NO radical as would be predicted from their published half-lives, i.e. a rapid
and short burst of NO from DEA/NO (t i/2=2 min), and slower, more prolonged
delivery of NO from DETA/NO (t i/2=20 h). The NO-scavenger, Hb, verified that the
signal recorded from DETA/NO was indeed due to NO. These observations are
unsurprising because members of this class of compound are known to
spontaneously liberate NO in solution without the need for enzymatic activation, or
the presence of, for example, tissue thiol groups (Megson 2000; Megson and Webb
2002).
Unlike the diazeniumdiolate compounds, RS-N=Os liberate only very low
levels of NO radical spontaneously in solution, with the peak NO concentration
generated being several hundred fold lower, and bearing an unpredictable
relationship, to the concentration of the RS-N=0 compound. The small NO
electrode signals generated by SNVP and GSNO were confirmed to be due to NO by
the successful abolition of the signal by Hb.
Interestingly, both SNVP and GSNO generated a biphasic release profile of
NO with rapid initial spike, followed by a slower release of NO. This could result
from the combination of two separate phases of NO generation as illustrated in figure
3.16.
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" Overall release profile consisting of:
fast phase 1 ( — — ) and slow phase 2 ( )
Figure 3.16 Schematic Representation of NO Release from RS-N=0
NO release from RS-N=0 compounds occurred in a biphasic manner which may resulted
from a composite of two individual phases: an initial fast phase and a subsequent slow
phase as indicated.
The mechanism of RS-N=0 decomposition remains to be fully elucidated but
there are some interesting theories that could explain this biphasic phenomenon.
Firstly, decomposition of RS-N=0 compounds is greatly accelerated in the presence
of Cu+, which catalyses the breakdown of R8-N=0 to yield NO plus the
corresponding disulphide group (RS-SR) (Gordge et al. 1995; Dicks and Williams
1996; Gorren et al. 1996; Singh et al. 1996; Al-Sa'doni et al. 1997; Butler and
Rhodes 1997). Exceedingly low concentrations of trace metal ions, including those
present in distilled laboratory water and most buffers, are capable of accelerating RS-
N=0 decomposition (Butler et al. 1995). Additionally, reduction of Cu2+ bound in
proteins has been proposed as a mechanism to release NO from RS-N=0 in vivo
(Dicks and Williams 1996). Acceleration of decomposition due to protein-bound
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Cu2+ might explain why the level of NO generated by both GSNO and SNVP in
DMEM, which is supplement with bovine foetal calf serum (FCS; 10%) as a protein
source, is greater than that generated in 1MDM, which during NO electrode studies,
was protein-free. Indeed, pilot experiments in which IMDM was supplement with
10% FCS, resulted in an increase in the level of NO generated. Flowever, the
presence of protein may also influence NO release from RS-N=0 in additional ways.
For example, transnitrosation reactions, involving rapid transfer of NO+ from the RS-
N=0 to a reduced cyteine group of a protein, may yield a simpler S-nitrosothiol that
is more susceptible to Cu+-induced decomposition (Park 1988; Kowaluk and Fung
1990; Askew et al. 1995; Liu et al. 1998; Hogg 1999; Ceron et al. 2001).
Secondly, RS-N=0 may undergo enzymatic cleavage of a peptide bond to
yield the corresponding disulphide and an S-nitrosothiol that is more susceptible to
Cu+-induced decomposition (Askew et al. 1995). GSNO has been demonstrated to
be a substrate for the enzyme y- glutamyltranspeptidase (y-GT) (Askew et al. 1995;
Hogg et al. 1997), which is normally involved in the metabolism of glutathione (Tate
and Meister 1981; Keillor et al. 2005). Following catalytic breakdown by y-GT,
GSNO yields glutamic acid and the S-nitrosothiol, S-nitrosoglycylcysteine, from
which NO can be subsequently liberated by metal ion catalysis (Askew et al. 1995;
Hogg et al. 1997).
Finally, it has been demonstrated that decomposition of GSNO may not go to
completion, especially at high concentrations, due to the ability of the resulting
disulphide group (GS-SG) to act as a metal ion chelator, hence removing, or slowing,
metal ion-induced catalysis (Swift 1996; Noble and Williams 2000).
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Considered in combination, metal ion catalysis followed by chelation of
metal ions by the breakdown products, and transnitrosation and/or enzymatic
cleavage of a peptide bond, prior to subsequent metal ion catalysis, may account for
the biphasic release profile of NO from GSNO and SNVP presented in the current
study. In this model, metal ion catalysis could potentially induce the initial fast
phase, which then rapidly declines due to chelation of metal ions by the resulting
disulphide product. Transnitrosation or enzymatic cleavage of a peptide bond prior
to subsequent metal ion induced catalysis is then responsible for the second slower
phase of NO release. This phase proceeds despite chelation of metal ions by the
disulphide groups formed during the initial phase, because the simpler S-nitrosothiols
resulting from the transnitrosation or enzymatic cleavage are more susceptible to
metal ion catalysis, therefore, their decomposition can be catalysed by a lower
concentration of ions.
However, it is unclear whether the disulphide product resulting from SNVP
decomposition would be capable of chelating Cu+ or whether SNVP would be a
suitable substrate for y-GT. This may explain why the biphasic profile of NO release
is more pronounced for GSNO than SNVP. Additionally, no direct source of y-GT,
or similar peptidase enzymes have been identified in the reagents used in these
experiments. It is possible that such enzymes may be present in bovine FCS,
accounting for the more marked biphasic effect in DMEM that IMDM. However,
the FCS is heat inactivated (1 hour; 50°C; chapter two, section 2.2.3), which is likely
to have denatured any enzymes present. Furthermore, although addition of FCS to
IMDM in a pilot study did enhance the biphasic profile of NO release from GSNO, it
remained less pronounced than in DMEM and FCS failed to elicit a marked change
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in the release profile of SNVP. For these reasons, transnitrosation is possibly more
likely than enzymatic cleavage under the experimental conditions used in the current
study.
Metal ion catalysis is also likely to account for the observed increase in NO
release from SNVP in the presence of SOD. Given that low concentrations of Cu+
greatly accelerate the decomposition of RS-N=0, copper present in the Cu/Zn SOD
isoform used in these studies is likely to be sufficient to augment NO release from
RS-N=0 compounds. Although SOD tended to increase NO release from GSNO,
this trend did not reach significance, possibly due to metal ion chelation by the
disulphide production of GSNO decomposition, GS-SG (Swift 1996; Noble and
Williams 2000), which has previously been demonstrated to limit SOD-dependent
decomposition of GSNO (Singh et al. 1999).
GEA-3162 failed to liberate NO in solution except in the presence of SOD.
SOD converts 02~ to H2O2, thus preventing Of and NO combining to form ONOO"
(Beckman and Koppenol 1996). Although the reaction of NO and 02 is diffusion-
limited (k>109 M^S"1), (Huie and Padmaja 1993; Espey et al. 2000; Wolin et al.
2002), SOD is present at high concentrations in these experiments and likely to be in
excess. This allowed SOD to successfully compete with NO for Of, thus preventing
the formation of ONOO", and effectively 'unmasking' the NO generated by GEA-
3162. This 'unmasked' signal generated by GEA-3162 in the presence of SOD was
confirmed to be a genuine NO signal by the successful abolition of the unmasked
signal by the NO-scavenger, Hb. The duration of the NO signal in the presence of
SOD was in the region of several hours, therefore, it is reasonable to infer that GEA-
3162 decomposes over a period of several hours.
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These initial electrode studies suggested that GEA-3162 was generating NO
and 02 concomitantly. This was further illustrated by the EPR studies
demonstrating significant GEA-3162-induced oxidation of Tempone-H, forming the
radical adduct, 4-oxo-tempone. Tempone-H has successfully been used previously
as a method for the detection of O2" and ONOO" (Dikalov et al. 1997a; Dikalov et al.
1997b). There are two possibilities as to how GEA-3162 might bring about the
oxidation of Tempone-H to result in formation of 4-oxo-tempone and the consequent
EPR signal. Firstly, Tempone-H could be directly reacting with ONOO" in a two-
step process involving the production of NO2 as an intermediary, with the result that
one molecule of ONOO" finally forms two molecules of 4-oxo-tempone (reactions 1
and 2) (Dikalov et al. 1997a).
Tempone-H + ONOO" ► 4-oxo-tempone + *N02 + H2O (1)
Tempone-H + *N02 ► 4-oxo-tempone + HN02 (2)
Alternatively, if GEA-3162 releases NO and 02" concomitantly, then
Tempone-H could be competing with NO for 02", resulting in the oxidation of
Tempone-H by O2" (reaction 3), before NO and O2" combine to form ONOO".
Tempone-H + 02" ► 4-oxo-tempone + H2O2 (3)
Dikalov et al have calculated the overall rate constant for reaction 1 +
reaction 2 to be ki+2 = 6 x 109 M"1s"< and for reaction 3 to be k3 = 1.2 x 104 M'V1
(Dikalov et al. 1997a), whilst the rate constant for the reaction of NO with O2" is in
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the region of k > 109 IVfV1 (Huie and Padmaja 1993; Wolin et al. 2002). Given a
consistent Tempone-H concentration and the diffusion-limited rate constant of the
reaction of NO with Of, one might predict that reactions 1 + 2 are the more likely to
occur and that therefore, Tempone-H is oxidised by ONOO" rather than O2". SOD is
able to attenuate the EPR signal generated by GEA-3162 because this antioxidant
enzyme combines with O2" at a rate comparable with that of NO (Espey et al. 2000),
and is present at high enough concentrations to successfully compete with NO for
O2". Therefore, the O2" generated is scavenged by SOD, thus preventing the
formation of ONOO", and hence reducing the concentration of ONOO" available to
oxidise Tempone-H.
Taken together, these two lines of evidence demonstrate that GEA-3162
decomposes to co-generate NO and 02" concomitantly and should therefore, be
regarded as a ONOO" generator, rather than an NO donor. These observations
confirm earlier studies demonstrating similar results for both GEA-3162 and the
structurally similar compound, SIN-1 (Taylor et al. 2004). Although initial studies
demonstrated that GEA-3162, unlike SIN-1, was able to liberate NO in the absence
of 02" generation (Kankaanranta et al. 1996; Holm et al. 1998), these earlier studies
used indirect methods to measure both NO and 02~, rather then more direct and
accurate methods presented in the current study.
Somewhat surprisingly, at high concentrations, DEA/NO generated a
significant EPR signal, appearing to suggest the production of oxidising radical
species from this compound. However, SOD failed to attenuate the EPR signal,
therefore it seems likely that the signal generated by high concentrations of DEA/NO
indicates loss of specificity of the chemical spin-trap at high concentrations of any
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radical, rather than a genuine production of 02~ or ONOO. This does not occur at
high concentrations of DETA/NO because, as the NO electrode studies demonstrate,
the release of NO radical from DETA/NO is far slower than from DEA/NO, and
therefore unlikely to reach sufficient concentrations quickly enough to result in loss
of specificity of the spin-trap. Neither SNVP nor GSNO generated oxidising radical
species in either media. It would not be expected for this class of compound to
generate oxidising radicals, and there are no previous reports of them doing so.
Indeed, generation of free thiol groups during the decomposition RS-N=0
compounds might result in anti-oxidant properties, giving this group of compounds
additional anti-atherosclerotic benefits over and above NO generation.
Interestingly, the composition of the solution into which these putative NO
donor compounds were introduced had a significant impact on the concentration and
release profile of NO. On the whole, DMEM accelerated NO release (or oxidising
radical generation in the case of GEA-3162) compared to IMDM. With the
exception of DEA/NO, which displayed consistent release characteristics, NO
generation was sensitive to the composition of the medium - even the concentration
of NO released from DETA/NO, often described as releasing NO in a highly
predictable manner (Davies et al. 2001), was influenced by medium composition.
Pilot experiments designed to elucidate the components of the medium responsible
for this phenomenon demonstrated even something as basic as the method of
buffering a solution can influence NO release. DMEM is buffered with sodium
bicarbonate (NaHC03; 44.05 mM) and IMDM with HEPES (25.03 mM; appendix
one) but the pH of the media was identical (pH 7.3), therefore, the actual chemical
entities appear to alter the decomposition. HEPES has previously been demonstrated
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to blunt NO release from diazeniudiolates as a result of the formation of 02 during
HEPES oxidation (Keynes et al. 2003). However, given that SOD did not affect NO
release from DETA/NO in IMDM, and that NO release from DETA/NO was
increased in HEPES-buffered H20 compared to IMDM, this is perhaps not the
principle factor responsible for the differences observed between the two media.
Although, further pilot studies indicated that the presence of protein (FSC) may be
responsible for some of the differences observed between DMEM and IMDM during
the decomposition of the RS-N=0, neither the buffering method nor the presence of
protein fully rationalised the different pattern of NO release between the media.
Overall, these studies provide characterisation of the NO species liberated by
three different class of putative NO donor drug. The results from studies involving
the diazeniudiolate compounds support the notion that these compounds are pure NO
donors whose half-lives can be used to accurately predict NO release. The precise
mechanism of RS-N=0 decomposition has not been identified, but the low levels of
NO radical and lack of EPR signals generated by this group of compounds confirm
that the main mechanism of action or RS-N=0 is not via the release of NO radical or
oxidising radical species, but by another mechanism that likely involves the transfer
of NO1 and the generation of intermediate S-nitrosothiol species. Importantly, these
studies provide strong evidence that GEA-3162 decomposes to co-generate NO and
02~ and so should be regarded as a ONOO" generator, rather than an NO donor.
Finally, the somewhat surprising observation that NO release is sensitive to the
composition of the medium underlines the absolute requirement to conduct this type
of preliminary characterisation study. Furthermore, in order to be confident of the
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accuracy of this type of data, it is essential to conduct such studies under conditions
closely paralleling those employed in subsequent biological investigations.
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4. The Role of NO and NO-Related Species
in Vascular Smooth Muscle Cell
Proliferation and Viability
4.1 Introduction
Vascular smooth muscle cells (VSMCs) play an important role in the vascular
remodelling that occurs during the response to vessel injury in atherosclerosis.
VSMCs constitute the major cellular component of the fibrous cap that forms over
the developing atherosclerotic lesion, encapsulating the plaque and serving as a
barrier to separate the highly thrombogenic contents of the plaque core from the
circulation, thus maintaining the stability of the plaque (Ross 1993; Davies 1997).
Plaque instability and rupture are now considered to be the major determinant of the
acute clinical consequences of atherosclerosis such as unstable angina, myocardial
infarction, and stroke (Davies 1995; Schroeder and Falk 1995; Dalager-Pedersen et
al. 1998; Gutstein and Fuster 1999; Zhou et al. 1999; Corti and Badimon 2002; Mitra
et al. 2004). Plaque rupture occurs if the cap is disrupted, causing exposure of the
contents of the core to the circulation, and resulting in thrombosis. Although the
underlying causes of plaque rupture are yet to be fully identified, such events are
associated with a reduction in the thickness, and VSMC content, of the plaque cap
(Bauriedel et al. 1999; Leskinen et al. 2003). For example, those plaques with a thin
fibrous cap containing a relatively low density of VSMCs are considered to have a
greater propensity to rupture than those with a thicker cap containing a higher density
of VSMC (Davies 1996; Felton et al. 1997). Therefore, in order to maintain the
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stability of the plaque, it is essential to preserve the integrity of the VSMC cap by
maintaining the population of VSMC within it. Processes inducing cell death, such
as apoptosis or necrosis, will reduce the VSMC content of the cap and may have
serious consequences for plaque stability by promoting rupture (Kockx and Herman
1998; Bauriedel et al. 1999). Indeed this has been demonstrated in the ApoE'1' null
murine model of atherosclerosis, where direct induction of VSMC apoptosis induces
both rupture and thrombosis of plaques (von der Thusen et al. 2002).
The net balance between proliferation and cell death will determine the
VSMC content within the cap. NO can influence both of these processes, exerting an
inhibitory effect on proliferation (Garg and Hassid 1989; Kariya et al. 1989; Nakaki
et al. 1990; Assender et al. 1992; Newby et al. 1992; Garg and Hassid 1993;
Mooradian et al. 1995; Yu et al. 1997; Jeremy et al. 1999) and inducing cytotoxic
effects (Fukuo et al. 1995; Nakahashi et al. 1995), including apoptosis (Fukuo et al.
1996; Nishio et al. 1996; Pollman et al. 1996; Nicotera et al. 1997; Bennett 1999;
Lau 2003). The anti-proliferative actions of NO are largely considered to be brought
about by mechanisms involving cGMP signalling (Kariya et al. 1989; Nakaki et al.
1990; Cornwell et al. 1994; Yu et al. 1997), although a more recent report has
suggested a possible cGMP-independent pathway (Ignarro et al. 2001). The
mechanism of NO-induced cytotoxicity is less well defined, and in the past has
generally been considered to be a result of non-specific oxidative chemistry.
However, it is now emerging that this may not be the case, particularly in NO-
induced apoptosis where evidence is emerging to establish a more precise role for
NO, and active mechanisms that are generally cGMP-independent. For example, NO
may act to sensitise cells to apoptotic stimuli by promoting the up-regulation of cell
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surface receptors such as tumour necrosis factor receptor 1 (TNF-R1 - the receptor
for TNF-a; Boyle et al. 2003), or Fas (the receptor for Fas-L (Boyle et al. 2003).
The precise NO-related species responsible for these anti-proliferative and
cytotoxic/pro-apoptotic actions is not entirely clear in VSMCs. Various NO donors
have been used as tools to investigate the actions of NO in VSMC proliferation and
apoptosis, but most of the studies quoted above have failed to characterise either the
concentration of NO, or the NO-related species liberated by such compounds. Some
studies have demonstrated that NO-related species, as well as NO per se, can induce
these responses. For example, ONOO" has been shown to induce apoptosis in VSMC
(Li et al. 2003; Li et al. 2004) and recent studies have demonstrated a central role for
signalling by RS-N=0 during NO-mediated induction of apoptosis (Foster et al.
2003; Benhar and Stamler 2005; Hara et al. 2005). Due to the paradoxical effects of
NO in many settings, investigating NO-species variations in these processes will lead
not only to a greater understanding of the role of NO in such processes, but may also
offer the opportunity of selective targeting of either a particular cell type, or a
particular pathway.
Therefore, the aims of these studies were to investigate the effects of NO, RS-
N=0 and ONOO" on the proliferation and viability of VSMC, and to characterise the
role of apoptosis or necrosis in any induced cell death.
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4.2 Methods
4.2.1 Cell Culture
Bovine aortic smooth muscle cells (BAoSMC) were cultured as described in
chapter two (see section 2.2.3).
4.2.2 Detection ofNO2/NO3 by Griess Test
In order to measure NO2 /NO3" (NOx) generated from SNVP, GSNO and
GEA-3162 (all 10 - 300 pM) in the presence of cells, BAoSMC were seeded in 48-
well, flat-bottomed, tissue culture plates and cultured for 24 h (37°C; 95% O2; 5%
CO2; section 2.2.3) in DMEM. Following this initial 24 h period, the DMEM was
aspirated from the wells and replaced with phenol red free DMEM (containing the
same supplements as described in section 2.2.3) plus each NO donor compound (10 -
300 pM). This was necessary because the phenol red in DMEM gives the medium a
colour that absorbs light at the same wavelength as the Greiss Test, whereas phenol
red-free DMEM is colourless.
The total NOx concentration released by SNVP, GSNO and GEA-3162 in
tissue culture media in presence of BAoSMC was measured at 1 h, 6 h, and 24 h time
points by Griess Test (R&D Systems, Abington, U.K) as described in chapter two
(section 2.1.2).
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4.2.3 Assessment of Cell Proliferation
Cell proliferation induced by DEA/NO, DETA/NO, SNVP, GSNO and GEA-
3162 (all 10 - 300 pM) in BAoSMC was assessed by bromodeoxyuridine (BrdU)
assay (Calbiochem, (Merck Biosciences), Darmstadt, Germany) as described in
chapter two (section 2.4). The intensity of the coloured product generated is directly
proportional to the amount of incorporated BrdU present in the cells.
Cells were incubated (37°C: 95% O2; 5% CO2) for 24 h in the presence of
BrdU, together with each NO donor compound (10 - 300 pM), or the maximum
concentration of drug vehicle (DMSO; 1%: control). Additionally, the experiments
were repeated in the presence of the O2" scavenger, SOD (500 U.ml"1), the specific
sGC inhibitor, ODQ (20 pM), or the NO-specific scavenger 2-(4-Carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide.potassium salt (carboxy-PTIO; 500
pM). Results are expressed as absorbance units when comparing NO donor treated
cells to control, untreated cells. Alternatively, when comparing NO donor treatments
in the presence or absence of SOD, ODQ, or carboxy-PTIO, the results are expressed
as a percentage of the appropriate control in order to take into account the
absorbance of the inhibitor or scavenger itself.
4.2.4 Assessment of Cell Viability
4.2.4.1 Lactate Dehydrogenase Assay
The cytotoxic impact of DEA/NO, DETA/NO, SNVP, GSNO and GEA-
3162, (all 10 - 300 pM) on BAoSMC, was assessed by lactate dehydrogenase (LDH)
assay as described in chapter two (section 2.3.2). Additionally, the experiments were
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repeated in the presence of SOD (500 U.ml"1), ODQ (20 pM) or CarboxyPTIO (500
pM).
4.2.4.2 Flow Cytometry
Cell death induced by NO donor compounds (DEA/NO, DETA/NO, SNVP,
GSNO and GEA-3162; all 10 - 300 pM) was characterised as apoptosis or necrosis
by flow cytometry as described in chapter two (section 2.3.3).
4.3 Results
4.3.1 NO2/NO3 Measurements
The concentration of total NOx generated in the presence of BAoSMC was
similar for SNVP, GSNO and GEA-3162, although at higher concentrations total
NOx generated by GSNO and GEA-3162 tended to be greater than that produced by
SNVP. Statistical analysis (unpaired, one-way ANOVA followed by post hoc Tukey
test) revealed a high degree of variability and no overall clear pattern of significant
differences between compounds (analyses not shown). The proportion of total NOx
consisting of nitrate (NO3") was exceedingly low and approximately equal to that
present in DMEM, therefore, the vast majority of NOx generated by the NO donor
compounds was nitrite (N02~; figures 4.1 & 4.2).
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Figure 4.1 NOx Generation by SNVP, GSNO and GEA-3162 in the Presence of
BAoSMC
Total NOx production from SNVP, GSNO and GEA-3162 (10 pM and 30 pM) in the
presence of BAoSMC was measured by Greiss Test at 1 h, 6h, and 24 h time points. The
proportion of N02" is indicated by lower, hatched sections of bars. n= 5 for all compounds at
all time points.
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Figure 4.2 NOx Generation by SNVP, GSNO and GEA-3162 in the Presence of
BAoSMC
Total NOx production from, SNVP, GSNO and GEA-3162 (100 pM; and 300 pM) in the
presence of BAoSMC was measured by Greiss Test at 1 h, 6h, and 24 h time points. The
proportion of N02" is indicated by lower, hatched sections of bars. n= 5 for all compounds at
all time points.
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4.3.2 The Effect of NO-Related Species on Cell
Proliferation in BAoSMC
The maximum concentration of drug vehicle (DMSO; 1%) had no effect on
the level of cell proliferation compared to control, untreated cells (P>0.05; unpaired
one-way ANOVA; n=6; figure 4.3). Similarly, the diazeniumdiolate compound,
DEA/NO, and the RS-N=0 compounds, SNVP and GSNO (all 10 - 300 pM) had no
effect of BAoSMC proliferation (P>0.05; unpaired, one-way ANOVA; n=6; figure
4.3). DETA/NO inhibited cell proliferation, but this inhibition only reached
significance at the highest concentration tested (300 pM; P<0.05; unpaired, one-way
ANOVA followed by post hoc Dunnett's test). The ONOO" generator, GEA-3162,
produced a concentration-dependent decrease in the level of cell proliferation
(P<0.01; unpaired, one-way ANOVA followed by post hoc Dunnett's test; figure
4.3; n=6).
The specific sGC inhibitor, ODQ (20 pM), or the O2" scavenger, SOD (500
U.ml"1), had no further impact on cell proliferation in those NO donor treatments
which failed to affect cell proliferation (DEA/NO and the RS-N=0 compounds; data
not shown). ODQ significantly attenuated the inhibition in cell proliferation induced
by DETA/NO (P<0.05; two-way ANOVA; n=6; figure 4.4), but did not effect GEA-
3162 induced inhibition of mitogenesis (P>0.05; two-way ANOVA; n=6; figure 4.4).
SOD had no effect on the decrease in cell proliferation induced by DETA/NO or
GEA-3162 (P>0.05 for both treatments; two-way ANOVA; n=6; figures 4.5).
It was not possible to assess the impact of the NO-specific scavenger,
carboxy-PTIO, on cell proliferation as the compound interfered with the BrdU assay
resulting in the absence of a signal in all cells treated with carboxy-PTIO.
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Figure 4.3 The Effect of NO Donor Compounds on BAoSMC Proliferation
The maximum concentration of drug vehicle (DMSO; 1%), DEA/NO, SNVP and GSNO (all
10 - 300 pM) had no significant impact on cell proliferation in BAoSMC compared to control,
untreated cells (P>0.05; unpaired, one-way ANOVA; n=6). DETA/NO (300 pM) caused a
significant reduction in cell proliferation (* = P<0.05). GEA-3162 (10 - 300 pM) caused a
concentration-dependent decrease in cell proliferation compared to control cells (** =
P<0.01; unpaired, one-way ANOVA followed by post hoc Dunnett's test; n=6).
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Figure 4.4 The Effect of ODQ on DETA/NO and GEA-3162 Induced Inhibition of Cell
Proliferation in BAoSMC
ODQ (20 (jM; open symbols, dashed line) significantly attenuated the inhibition of cell
proliferation induced by DETA/NO (closed symbols, solid line) but had no effect on GEA-3162
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Figure 4.5 The Effect of SOD on DETA/NO and GEA-3162 Induced Inhibition of Cell
Proliferation in BAoSMC
SOD (500 U.ml1; open symbols, dashed line) had no effect on the inhibition of cell
proliferation induced by DETA/NO (closed symbols, solid line; A;) or GEA-3162 (closed
symbols, solid line; B). P<0.05 for both treatments; two-way ANOVA; n=6
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4.3.3 The Effect of NO-Related Species on Cell
Viability in BAoSMC
Although DETA/NO and GEA-3162 appeared to cause a concentration-
dependent decrease in cell proliferation, this could in fact be due to cytotoxic
properties of the compounds rather than a genuine decrease in proliferation. In order
to further investigate this, the cytotoxic impact of all NO donor treatments was
assessed in BAoSMC by lactate dehydrogenase (LDH) assay and flow cytometric
analysis of cell surface markers of apoptosis and necrosis (annexin V binding to
phosphatiylserine (PS) and prodidium iodide (PI) staining respectively).
4.3.3.1 Lactate DehydrogenaseAssay
The maximum concentration of drug vehicle (DMSO; 1%) had no effect on
the level of cell viability compared to control, untreated cells (P>0.05; unpaired one¬
way ANOVA; n=6; figure 4.6). Similarly, the diazeniumdiolate compounds,
DEA/NO and DETA/NO, and the RS-N=0 compounds, SNVP and GSNO (all 10 -
300 pM) had no effect on BAoSMC viability (P>0.05; unpaired, one-way ANOVA;
n=14; figure 4.5). The ONOO" generator, GEA-3162, produced a concentration-
dependent increase in the level of cytotoxicity compared to control, untreated cells
(PcO.Ol; unpaired, one-way ANOVA followed by post hoc Dunnett's test; figure
4.6; n=14).
The O2 scavenger, SOD (500 U.mF1), the specific sGC inhibitor, ODQ (20
pM), and specific NO scavenger, carboxyPTIO (500 pM), had no further impact on
cytotoxicity in those NO donor treatments which failed to affect cytotoxicity (the
diazeniumdiolate and RS-N=0 compounds; data not shown). SOD significantly
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attenuated the concentration-dependent increase in cytotoxicity induced by GEA-
3162 (PO.OOl; two-way ANOVA followed by Bonferroni post hoc test; n=6; figure
4.7). ODQ and carboxyPTIO had no effect on the GEA-3162 induced cyotoxicity
(/*>().05 for both treatments; two-way ANOVA; n=6; figure 4.7).
DEA/NO DETA/NO SNVP ' GSNO GEA-3162
NO Donor Treatment/jiM
Figure 4.6 Cytotoxic Impact of NO Donor Compounds on BAoSMC
The maximum concentration of drug vehicle (DMSO; 1%), DEA/NO, DETA/NO, SNVP and
GSNO (all 10 - 300 pM) had no significant impact on cell viability in BAoSMC compared to
control, untreated cells (P>0.05; unpaired, one-way ANOVA; n=14). GEA-3162 (10 - 300
pM) caused a concentration-dependent increase in cytotoxicity compared to control cells (**
= P<0.01; unpaired, one-way ANOVA followed by post hoc Dunnett's test; n=14).
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Figure 4.7 The Effect of SOD, ODQ and CarboxyPTIO on GEA-3162 Induced
Cytotoxicity in BAoSMC
Cytotoxicity induced by GEA-3162 (10 - 300 |jM; closed symbols, solid line) was
significantly attenuated by SOD (500 U.ml"1; open symbols, dashed line). * = P<0.05, ** =
P<0.01, *** = P<0.001 (two-way ANOVA followed by post hoc Bonferroni's test; n=6). ODQ
(20 pM; open symbols, dashed line) and carboxyPTIO (500 pM; open symbols, dashed line)
failed to abrogate GEA-3162 induced cytotoxicity (ns = P>0.05; two-way ANOVA; n=8 for
ODQ and n=6 for carboxyPTIO).
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4.3.3.2 Flow Cytometric Characterisation of Cell Death
in BAoSMC
Analysis by flow cytometry confirmed that the maximum concentration of
drug vehicle (DMSO; 1%) together with the diazeniumdiolate compounds, DEA/NO
and DETA/NO, and the RS-N=0 compounds, SNVP and GSNO (all 10 - 300 pM),
had no effect on cell viability in BAoSMC. Following both a 6 and 24 h incubation
with the above treatments, the level of annexin V binding or PI staining was not
significantly altered compared to control, untreated cells (P>0.05 for all treatments at
both time points; unpaired, one-way ANOVA; n=6 at 6 h and n=7 at 24 h; figure
4.8).
GEA-3162 (10 - 300 pM) caused a concentration-dependent increase in the
number of cells positive for annexin V binding compared to control, untreated cells
at both 6 h and 24 h. This increase in annexin V binding occurred in combination
with an increase in the number of cells positive for PI staining (P values ranging
from <0.05 to < 0.001; unpaired, one-way ANOVA followed by post hoc Dunnett's
test; n=6 at 6 h and n=7 at 24 h; figure 4.8).
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Figure 4.8 Analysis of Cell Death in BAoSMC by Flow cytometry
The maximum concentration of drug vehicle (DMSO; 1%), DEA/NO, DETA/NO, SNVP and
GSNO (all 10 - 300 jjM) had no significant impact on the number of cells positive for
annexin V binding (solid bars) or PI staining (striped bars) following a 6 h or 24 h incubation
(P>0.05; unpaired, one-way ANOVA; n=6 at 6 h and n=7 at 24 h). GEA-3162 (10 - 300 pM)
caused a concentration-dependent increase in the number cells positive for annexin V
binding (* = P<0.05, ** = P<0.01, *** = P<0.001; unpaired, one-way ANOVA followed by
Dunnett's post hoc test; n=6 at 6 h and n=7 at 24 h), and this was accompanied by a
significant increase in the number of cells positive for PI staining (4 = P<0.05, 44 = P<0.01,
^4:4: = P<0.001; unpaired, one-way ANOVA followed by post hoc Dunnett's test; n=6 at 6 h
and n=7 at 24 h).
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4.4 Discussion
These studies demonstrate that, contrary to previous reports (Garg and Hassid
1989; Garg and Hassid 1993), RS-N=0 compounds have no effect on SMC
proliferation or viability. NO radical delivered as a burst of NO is similarly
incapable of affecting VSMC proliferation or viability, but a prolonged delivery of
NO inhibits cell proliferation in the absence of cytotoxic effects. The NO-related
species, ONOO", appears to inhibit cell proliferation, but further investigation
revealed that this is likely to be due to cytotoxic actions of ONOO", resulting in a loss
of cell number due to necrotic cell death.
Interestingly, Griess test measurements showed that SNVP, GSNO and GEA-
3162 release the majority of the NO, or NO-related species, during the initial hour of
the experiment, with levels of total NOx remaining relatively steady throughout the
subsequent incubation period, suggesting that a component of DMEM is accelerating
NOx generation. Previous experiments (chapter three) identified that NO release is
highly dependent on the chemical composition of the solution into which NO donor
compounds are introduced, with release profiles being sensitive to fundamental
chemical components, such as buffering means. Although the component(s) of
DMEM that might cause this initial acceleration of NO release has not been
identified in these studies, the observations further underline the necessity to conduct
such preliminary measurements under experimental conditions.
Overall, the results from the Greiss test experiments show that, although each
class of compound releases NO in a different chemical form, the total NOx generated
is comparable between the RS-N=0 compounds and the mesoionic oxatriazole
derivative. Although it was not possible to measure NOx generation from
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diazeniumdiolate compounds by Griess test, previous experiments (chapter three)
demonstrated that DEA/NO and DETA/NO release NO radical as would be predicted
from their respective half-lives - a rapid and short burst of NO from DEA/NO (b/2 =
2 min), and a prolonged and sustained generation of NO from DETA/NO (tVi = 20
h).
Despite previous reports demonstrating that NO, NO-related species, and
agents that act to elevate cGMP are capable of inhibiting VSMC proliferation (Garg
and Hassid 1989; Kariya et al. 1989; Assender et al. 1992; Newby et al. 1992; Garg
and Hassid 1993; Mooradian et al. 1995; Yu et al. 1997; Jeremy et al. 1999), the
results presented here show that, of a range of compounds capable of releasing
various NO and NO-related species, only a slow, prolonged delivery of NO radical or
ONOO", has an inhibitory effect on cell proliferation. Comparable concentrations of
NOx delivered by RS-N=0 compounds, or higher concentrations delivered as rapid
burst of NO radical by a short acting diazeniumdiolate compound, are incapable of
directly effecting VSMC proliferation or viability.
Inherent to anti-mitogenesis studies are the difficulties arising from
cytotoxicity of compounds. An apparent inhibition of proliferation may, in fact, be
due to decreasing cell number as a result of cytotoxic actions of a compound. Given
that GEA-3162 induces necrotic cell death (evidenced by LDH release and elevated
levels of PI staining) over the same concentration range as the apparent inhibition of
proliferation, it is likely that this is not a genuine inhibition of mitogenesis, but a loss
of overall cell number. However, whilst GEA-3162-induced cytotoxicity was
attenuated by SOD, the decrease in proliferation induced by this compound was
insensitive to SOD. This could indicate a residual, genuine anti-mitogenic effect
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being masked by the cytotoxic properties of GEA-3162. However, as cGMP is
widely accepted to be the downstream effector of inhibition of proliferation (Garg
and Hassid 1989; Kariya et al. 1989; Assender et al. 1992), the specific sGC
inhibitor, ODQ, would be expected to attenuate any remaining anti-mitogenic effects.
This was not seen and ODQ had no effect of the apparent GEA-3162-induced anti-
mitogenic effects. Alternatively, cGMP-independent pathways could be responsible
for any underlying cytostatic effects, however, considered in combination with the
LDH assay and flow cytometry results, these data strongly suggest that ONOO" is
cytotoxic, rather than genuinely anti-mitogenic. This potential difficulty in
interpreting the data from anti-mitogenesis studies has, to some extent, been
overlooked by previous investigators. For example, RS-N=0 compounds have been
demonstrated to inhibit SMC proliferation but this occurred at higher concentrations
of compound than used here (in the mM range) and interestingly, was attenuated by
SOD, suggesting that Of, or ONOO", is ultimately effector of this inhibition. It
seems likely that this observed inhibition of proliferation could, therefore, be due to
cytotoxicity of ONOO" formed as an intermediate species, which was not explored
fully (Garg and Hassid 1989). Similarly, SIN-1, which is structurally related to
GEA-3162 and now accepted to be a ONOO" generator, has been reported to inhibit
rabbit SMC mitogenesis, but no investigation into the cytotoxicity of this compound
was conducted (Assender et al. 1992). The demonstration that an apparent inhibition
of proliferation by GEA-3162 was, in fact, a result of necrotic cell death underlines
the absolute necessity to conduct cytotoxicity studies in conjunction with
mitogenesis studies.
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That cytotoxicity induced by ONOO" in BAoSMC was characterised by flow
cytometry to be necrosis, rather than apoptosis is perhaps unsurprising, as the
cytotoxic actions of NO have often been ascribed to non-specific oxidative
chemistry. However, ONOO" has previously been demonstrated to induce apoptosis
in rat VSMC (Li et al. 2003; Li et al. 2004). There are several possible explanations
as to why this phenomenon has not been demonstrated here. Firstly, the methods
used to characterise apoptosis in the published studies quoted above (trypan blue
exclusion and TUNEL staining) are not as sensitive or as specific as the flow
cytometry methods employed in this study, where markers of both apoptosis and
necrosis were examined in the same cell. Secondly, the ability of an agent to induce
apoptosis, rather than necrosis, in VSMC may be dependent on the precise phenotype
of the VSMC. A recent study has highlighted significant differences between the
ability of certain NO donors to induce apoptosis in VSMC of varying phenotypic
origin (Lau 2003). Although apoptosis was induced by sodium nitroprusside (SNP)
or the RS-N=0, 5-nitroso-V-acetylpenicillamine (SNAP), rather than ONOO", the
study by Lau emphasises how specifically apoptosis is regulated and suggests that
VSMCs are more susceptible to apoptotic cell death when they are of the
proliferative phenotype. Cells of a proliferative phenotype make up only a small
percentage of the VSMC population in healthy vessels, but come to dominate
following the phenotypic alterations that occur during vascular injury (including
atherosclerosis; Lau 2003). The cells examined in the current study were a bovine
aortic smooth muscle cell line harvested from the aortae of healthy animals.
Although VSMCs undergo phenotypic alteration during culturing (Absher et al.
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1989), it is not clear whether they develop a proliferative phenotype that is
susceptible to apoptotic stimuli.
Given the cytotoxic properties of ONOO", it is likely to have serious adverse
consequences for the atherosclerotic plaque. Due to the environment of elevated
oxidative stress, or more likely, due to a reduction in the anti-oxidant capacity of the
cell during atherosclerosis, any available NO, either endothelium-derived or
delivered by synthetic compounds, is likely to react rapidly with Of to form ONOO"
in situ. The cytotoxic properties of ONOO" would then result in a loss of cells from
the VSMC population of the plaque cap, increasing the likelihood of rupture. Plaque
rupture is associated with, and considered to be the underlying cause of, the acute
clinical consequences of atherosclerosis including myocardial infarction and stroke
(Davies 1995; Schroeder and Falk 1995; Dalager-Pedersen et al. 1998; Gutstein and
Fuster 1999; Zhou et al. 1999; Corti and Badimon 2002; Mitra et al. 2004).
Although the apparent anti-proliferative actions of ONOO" can largely be
ascribed to cytotoxicity, this is not the case for the anti-mitogenic actions of
DETA/NO, which was non-cytotoxic towards BAoSMC. The specific sGC inhibitor,
ODQ, partially attenuated DETA/NO-induced inhibition of proliferation,
demonstrating that these actions are, at least partly, cGMP-dependent. The precise
mechanism by which cyclic nucleotides bring about inhibition of proliferation
remains a source of some debate and likely involves multiple complex signalling
pathways. cGMP activates protein kinase G (PKG) which can then trigger signalling
pathways involving p42/44 mitogen-activated protein kinases (MAPK) and
extracellular signal-regulated kinases (ERK), leading ultimately to decreases in DNA
synthesis (Bauer et al. 2001; Koyama et al. 2001). Although ODQ significantly
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inhibited the cytostatic effects of DETA/NO, this inhibition was partial and a residual
inhibition of proliferation remained in the face of ODQ treatment. This could
potentially be due to incomplete inhibition of sGC, but this is unlikely as the
concentration of ODQ used in these studies has been demonstrated to be effective
during attenuation of NO-dependent inhibition platelet aggregation (Crane et al.
2005). It is therefore more likely that there is a cGMP-independent component to
anti-proliferative actions of DETA/NO. cGMP-independent pathways have been
implicated previously in the cytostatic actions of DETA/NO in rat aortic VSMC
(Ignarro et al. 2001), although the mechanism of such pathways remains to be
identified.
The observation that a burst of NO delivered by DEA/NO is insufficient to
inhibit cell proliferation in VSMC is in keeping with the findings of Mooradian et al
in a study into the effect on proliferation of the rate of release of NO (Mooradian et
al. 1995). Using a range of diazeniumdiolate compounds with varying half-lives,
Mooradian et al reported that DEA/NO and PAPA/NO (tVi = 15 min) had no effect
on proliferation, but that a slower, prolonged delivery achieved by use of DETA/NO
caused significant inhibition of rat aortic SMC proliferation, with the maximum
inhibition occurring following treatment for 3-5 days with a non-toxic concentration
(500 pM) of DETA/NO (Mooradian et al. 1995). The study by Mooradian et al,
together with the results presented in the current study, demonstrate that the total
concentration of NO delivered is not the critical factor in determining cytostatic
effects; rather the NO must be delivered over a prolonged period in order to sustain
cGMP concentrations at levels sufficient to inhibit proliferation. Therefore, short
acting diazeniumdiolate compounds fail to inhibit proliferation due to rapid decline
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in cGMP levels following the short burst of NO. Based on NO electrode recordings
(chapter three), a 300 pM concentration of DEA/NO can be crudely calculated to
release a peak NO concentration in region of 330 pM which would take
approximately 40 minutes to decay to nM range, whilst the same concentration of
DETA/NO might produce a peak release of approximately only 4 pM NO, but this
would take in the region of 180 hours to decay to similar nM concentrations. cGMP
production is thought to be triggered by NO in 5-100 nM range, with the half-life of
activation being 1-2 seconds (Condorelli and George 2001). Therefore, DETA/NO
will continue to generate levels of NO capable of sustaining cGMP production for
significantly longer than DEA/NO. The observation that cGMP production must be
sustained over a relatively long period, considered in combination with the Greiss
test results suggesting a component of DMEM accelerates the rate of NOx generation
from RS-N=0 compounds, may explain why these compounds failed to inhibit cell
proliferation. As already discussed, the RS-N=0 compounds generated the total
level of NOx during the first hour of delivery. Therefore, these compounds may not
stimulate sGC adequately to provide sufficiently elevated cGMP levels over a long
enough period to inhibit proliferation. That duration of cGMP production is the
critical factor for producing cytostatic effects is further evidenced by the observation
that inhibitors of PDEs (the enzyme responsible for cGMP breakdown), including the
cGMP-specific PDE-V inhibitor, Sildenafil, also possess anti-proliferative properties
in human pulmonary SMC (Tantini et al. 2005).
Of the compounds examined in these studies, the prolonged release of
relatively low concentrations of NO from DETA/NO could be considered to be the
most realistic model of physiological NO production by the healthy endothelium. In
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healthy blood vessels the NO released from the endothelium doubtless acts to
prevent uncontrolled proliferation of VSMCs, thus maintaining the vessel wall and
preventing hypertrophy. During atherosclerosis, the net production of NO decreases
and vascular remodelling occurs, resulting in a thickening of the vessel wall, to
which the removal of NO-mediated inhibition of proliferation may contribute.
During the later stages of atherosclerosis, when the vessel lumen can expand no
further to accommodate the growing lesion, this thickening of the vessel wall may
contribute to stenosis of the vessel. However, during the earlier stages of
atherogenesis, removing an inhibition of VSMC proliferation may be an initial
protective mechanism to maintain the integrity of the plaque cap, and hence prevent
lesion rupture.
In summary, the salient finding of these studies, is that, of a range of
compounds capable of releasing NO and various NO-related species, only the slow
release of NO radical is sufficient to cause inhibition of VSMC proliferation in the
absence of cytotoxicity. ONOO" is the only NO-related species to be cytotoxic
towards VSMC, inducing necrosis, but not apoptosis.
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5. The Effect of NO and NO-Related
Species on the Cell Viability of Human
Monocyte-Derived Macrophages
5.1 Introduction
Apoptosis is a fundamental process governing cell survival and differs from
necrosis in that it is an active, regulated process in which the cell is required to
expend energy prior to cell death. During apoptosis the cell undergoes a number of
characteristic morphological changes including membrane blebbing, chromatin
condensation, nuclear fragmentation and cell shrinkage (Uren and Vaux 1996;
Wyllie 1997). The externalisation of cell surface markers, such as
phosphatidylserine (PS), on the outer cell membrane, allows recognition of apoptotic
cells by phagocytes, leading ultimately to their clearance (Savill et al. 1989; Fadok et
al. 1992; Savill et al. 1993; Fadok et al. 2001; Hoffmann et al. 2001; Huynh et al.
2002). A crucial difference between apoptosis and necrosis is the preservation of the
intact cellular membrane. During the apoptotic process the cell membrane is
maintained, preventing the release of the cell contents into the surrounding tissue
(Meagher et al. 1992; Stem et al. 1996; Lawrence et al. 2001). Apoptosis of
inflammatory cells, therefore, represents a non-inflammatory mechanism for the
removal of cells from a site of tissue damage, thus preventing the exacerbation of
inflammatory responses which would occur if the histotoxic, pro-inflammatory
mediators contained within the cell were released (Haslett 1997; Madema and
Godson 2003; Taylor et al. 2003; Rossi et al. 2004). Hence, apoptosis of
168
Chapter Five - Effect ofNO-Related Species on Macrophage Viability
inflammatory cells is critical to ensuring the successful resolution of the
inflammatory response. Failure of inflammatory cells to undergo apoptosis, or
failure of phagocytic removal of apoptotic cells, can lead to incomplete resolution of
the inflammatory response because apoptotic cells remaining in situ undergo
secondary necrosis, resulting in rupture of the cell membrane, and the subsequent
release of the pro-inflammatory cell contents (Haslett 1997). Pharmacological
manipulation of apoptosis may aid the resolution of inflammation occurring in
chronic inflammatory disorders and, therefore, represents a novel therapeutic strategy
for the treatment of such conditions (Ward et al. 1999; Gilroy et al. 2004).
Atherosclerosis is now considered to be the consequence of a chronic, low-
grade inflammatory response (Ross 1999a; Ross 1999b; Berk et al. 2001; Libby
2002; Libby et al. 2002; Robbins and Topol 2002). Lipid laden macrophages, or
foam cells, retained in the vessel wall are the major constituent of the plaque core
(Ross 1993; Davies 1997) and recruitment of inflammatory cells, particularly
monocytes and macrophages, is the major driving force behind plaque growth and
development. Given that apoptosis of inflammatory cells results in their non¬
inflammatory phagocytosis, inducing apoptosis in macrophages within the plaque
core may aid resolution of vascular inflammation, and could potentially limit disease
progression, or even aid plaque regression.
NO is a possible candidate for use in the manipulation of apoptosis during
atherosclerosis. NO has previously been demonstrated to induce apoptosis and aid
subsequent inflammatory resolution in several animal models (Duffield et al. 2000;
Duffield et al. 2001; Saio et al. 2001; Chattopadhyay et al. 2002), including a rabbit
model of atherosclerosis (Wang et al. 1999). Although the production of NO by
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human macrophages remains debatable, such cells do respond to exogenous NO
delivered by synthetic NO donor compounds, indicating the potential of NO to
induce apoptosis in macrophages (Albina 1995; Weinberg et al. 1995; Thomassen
and Kavuru 2001; Schneemann and Schoedon 2002). The downstream effectors of
NO-induced apoptosis are not yet fully identified but are likely to be multiple, cell
type-specific, and are generally regarded to occur independently of cGMP signalling
(Nicotera et al. 1997; Garban and Bonavida 1999; Wang et al. 1999; Manderscheid et
al. 2001; Boyle et al. 2002). For example, NO may induce down-regulation of
intracellular caspase inhibitors such as the inhibitors of apoptosis proteins (IAPs;
Manderscheid et al. 2001), and/or increase the sensitivity of cells to apoptotic stimuli
such as Fas ligand (FasL; Garban and Bonavida 1999; Boyle et al. 2002)
Considered in combination with additional powerful anti-atherogenic
characteristics of NO, including inhibition of platelet activation (Deana et al. 1989;
Radomski et al. 1992) and various other anti-inflammatory properties (Tsao et al.
1994; De Caterina et al. 1995; Zeiher et al. 1995; Tomita et al. 1998; Qian et al.
1999), the potential beneficial pro-apoptotic actions of NO make this molecule an
appealing prospect as a means of regressing atherosclerotic plaques. However, the
success of such a therapeutic strategy relies on the ability to deliver NO with some
degree of selectivity in order to specifically target monocytes or macrophages within
the core, without triggering vascular collapse or indiscriminate pro-apoptotic events
in other cell types present in the plaque. For example, apoptosis of the VSMC
population in the plaque cap could have serious detrimental consequences, resulting
in plaque rupture (Bauriedel et al. 1999; Leskinen et al. 2003). A possible means to
achieve this necessary selectivity may be to exploit differences between the actions
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of NO-related species, delivering NO in a form that will induce apoptosis in one cell
type, whilst leaving other cell types unaffected. The main aim of these studies was
therefore to test the hypothesis that various NO-related species would differentially
induce apoptosis in human macrophages. A further aim was to examine the ability of
human monocyte-derived macrophages to generate NO in order to understand some
of the in vivo mechanisms underlying atherosclerosis.
5.2 Methods
5.2.1 Cell Culture
5.2.1.1 THP-1 Cell Culture
THP-1 cells (a human macrophage cell line) were cultured as described in
chapter two (section 2.2.1).
5.2.1.2 Isolation and Culture of Human Monocyte-Derived Macrophages
Human monocytes were isolated from peripheral blood of healthy volunteers
as described in chapter two (section 2.2.2). Experiments on monocytes were
performed following culture (37 °C, 95% O2: 5% CO2) for 24 hr after the initial
isolation. Alternatively, experiments on human monocyte-derived macrophages
were performed following culture for 5-7 days to allow monocyte differentiation into
monocyte-derived macrophages. At the end of these incubation periods the IMDM
was aspirated from the wells and replaced with fresh IMDM containing experimental
treatments.
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5.2.2 Detection of NO2/NO3
5.2.2.1 Detection of NO2/NO3 by Griess Test
In order to measure N027N03~ (NOx) generated by SNVP, GSNO and GEA-
3162 (all 10 - 300 pM) in the presence of cells, human monocytes were allowed to
differentiate into monocyte-derived macrophages in 48-well, flat-bottomed, tissue
culture plates for 5-7 days in IMDM (37°C, 95% 02: 5% C02; section 2.2.2). At the
end of this period, the IMDM was aspirated from the wells and replaced with phenol
red-free IMDM (containing the same supplements, including 10% autologous serum,
as described in section 2.2.2.1) plus each NO donor compound. This was necessary
because the phenol red in IMDM gives the medium a colour that absorbs light at the
same wavelength as the Greiss test, whereas as phenol red-free IMDM is colourless.
The total NOx concentration generated by SNVP, GSNO and GEA-3162 in
IMDM in presence of human monocyte-derived macrophages was measured at 1, 6,
and 24 h time points by Griess test (R&D Systems, Abington, U.K) as described in
chapter two (section 2.1.2). It was not possible to measure NOx generation from
DEA/NO and DETA/NO by Griess test because reagents are acidified during the
protocol and NO release from diazeniumdiolate compounds is pH dependent (Davies
et al. 2001).
In order to measure NOx generated by human monocyte-derived
macrophages, monocytes were allowed to differentiate into monocyte-derived
macrophages for 5-7 days. At the end of this period, IMDM was aspirated from the
wells and replaced with phenol red-free IMDM (plus supplements, including 10%
autologous serum). Cells were treated (24 h) in the absence and presence of
lipopolysaccharide (LPS; 1 pg.ml"1) in combination with the specific iNOS inhibitor,
172
Chapter Five - Effect ofNO-Related Species on Macrophage Viability
N-(3-(aminomethyl)benzyl) acetamidine dihydrochloride (1400W; 50 pM; Garvey et
al. 1997) or the non-specific NOS inhibitor, N-monomethyl-L-arginine (L-NMMA;
200 pM). Following the 24 h treatment period, supernatants were aspirated from the
wells and the concentration of NOx measured by Greiss test described in chapter two
(section 2.1.2).
5.2.2.2 Detection of NOf by Fluorescence High Performance Liquid
Chromatography
N02" generated by human monocyte-derived macrophages at concentrations
below the limit of detection of the Griess test (< 3 pM) were measured by
fluorescence high-performance liquid chromatography (HPLC) as described in
chapter two (section 2.1.3). Following differentiation, human monocyte-derived
macrophages were treated (24 h) in the absence and presence of LPS (1 pg.ml"1) in
combination with 1400W (50 pM) or L-NMMA (200 pM) in phenol red-free 1MDM
(plus supplements). Following treatment with LPS, supernatants were aspirated from
the wells and the concentration of N02~ measured by HPLC as described in chapter
two (section 2.1.3).
5.2.3Assessment of Cell Viability
5.2.3.1 Cell Morphology
Cell morphology, as an indicator of cell viability, was assessed in THP-1
cells as described in chapter two (section 2.3.1). Cells were cultured (37°C, 95% 02:
5% C02) in RPMI tissue culture medium (containing supplements described in
chapter two (section 2.2.1), including 10% heat-inactivated FSC and treated (2, 4, 6,
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16 h) in the absence and presence of the maximum concentration of drug vehicle
(DMSO; 1%), DEA/NO, SNVP, GEA-3162 (all 100 pM), or the acknowledged pro-
apoptotic agent, gliotoxin (1 pg.mF1). To investigate the influence of protein on cell
viability, the experiments were repeated at 6 h and 16 h time points in medium
containing FCS (10%) and FCS-free medium.
5.2.3.2 Flow Cytometry
Cell death induced by NO donor compounds was characterised in human
monocytes and monocyte-derived macrophages as either apoptosis or necrosis by
flow cytometry as described in chapter two (section 2.3.3). Cells were cultured
(37°C, 95% 02: 5% C02) in IMDM (containing supplements described in section
2.2.2.1, including 10% autologous serum), and treated (24 h) in the absence and
presence of the maximum concentration of drug vehicle (DMSO; 1%), DEA/NO,
DETA/NO, SNVP, GSNO and GEA-3162 (all 100 - 300 pM), or gliotoxin (1 pg.ml"
') prior to flow cytometric analysis of cell surface phosphatidylserine (PS) expression
(FITC-conjugated annexin V binding) and cell membrane integrity (propidium iodide
(PI) staining) as described in chapter two (section 2.3.3). In order to assess the
influence of oxidising radical species on the cytotoxic effects of NO donor treatment,
the experiments were repeated in the presence of SOD (500 U.mF1)
5.3 Results
5.3.1 NOx Generation By NO Donor Compounds
The concentration of total NOx generated in the presence of human
monocyte-derived macrophages was similar for GSNO and GEA-3162, and this was
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slightly greater than that generated by SNVP (figures 5.1 & 5.2). This general trend
occurred at all concentrations and time points, but was more pronounced at higher
concentrations (100 pM and 300 pM). Statistical analysis by unpaired, one-way
ANOVA followed by post hoc Tukey test revealed a high degree of variability with
no overall clear pattern of significance differences between compounds (analyses not
shown). The proportional of total NOx consisting of nitrate (NO3) was variable and
tended to be approximate a quarter to half for each compound.
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Figure 5.1 NOx Generation by SNVP, GSNO and GEA-3162 in the Presence of Human
Monocyte-Derived Macrophages
Total NOx production by SNVP, GSNO and GEA-3162 (10 pM and 30 pM) in the presence
of human monocyte-derived macrophages was measured by Greiss test at 1, 6, and 24 h
time points as indicated. The proportion of total NOx consisting of NOz" is indicated by
lower, hatched sections of bars. n= 5 for all compounds at each time point.
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Figure 5.2 NOx Generation by SNVP, GSNO and GEA-3162 in the Presence of Human
Monocyte-Derived Macrophages
Total NOx production from SNVP, GSNO and GEA-3162 (100 pM and 300 pM) in the
presence of human monocyte-derived macrophages was measured by Greiss Test at 1, 6,
and 24 h time points as indicted. The proportion of total NOx consisting of N02" is indicated
by lower, hatched sections of bars. n=5 for all compounds at each time point.
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5.3.2 NOx Generation by Human Monocyte-derived
Macrophages
5.3.2.1 Detection of NOx Greiss Test
NOx generated by human monocyte-derived macrophages was at the lower
limit of detection for the Greiss test. LPS (1 pg.ml^-stimulated human monocyte-
derived macrophages did not produce significantly greater levels of NOx compared
to control (un-stimulated), monocyte-derived macrophages (4.1 ± 1.4 vs 4.5 ±1.0
pM; P>0.05; matched, one-way ANOVA; n=5). The level of NOx generated by
monocyte-derived macrophages was unaffected by treatment with 1400W (50 pM)
or L-NMMA (200 pM; data not shown).
5.3.2.2 Detection of N02~ by Fluorescence High Performance Liquid
Chromatography
As with the Greiss test, levels of NO2" detected from un-stimulated
monocyte-derived macrophages were at the lower limit of detection by HPLC (2.2 ±
1.4 nM). It was not possible to make a comparison with NOx generated by LPS-
stimulated (1 pg.mP1) monocyte-derived macrophages, as NO2" was not detected
under these conditions (data not shown).
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5.3.3 The Effect of NO and NO-Related Species on
Cell Viability
5.3.3.1 The Effect of NO-Related Species on Cell Viability Assessed by
Morphology in THP-1 Macrophages
The maximum concentration of drug vehicle (DMSO; 1%) had no affect on
cell death in THP-1 macrophages compared to untreated cells following 2, 4, 6, or 16
h incubation (figures 5.3). DEA/NO and SNVP (100 pM) did not induce significant
cell death in THP-1 macrophages compared to vehicle treated cells at 2, 4 or 6 h
incubation (P>0.05; one-way ANOVA; n=4 at 2 h, n=5 at 4 h and n=6 at 6 h; figures
5.3 & 5.4). GEA-3162 (100 pM) induced significant levels of cell death compared
to vehicle treated cells at 4 and 6 h incubation (5.0 ± 1.7 vs 38.5 ± 8.4 %; n=5 at 4 h
and 15.5 ± 8.4 vs 59.5 ± 12.4 %; n=6; P<0.01 at both time points; one-way ANOVA
followed by post hoc Dunnett's test; figure 5.3). Following 16 h incubation,
DEA/NO, SNVP and GEA-3162 all induced significant levels of cell death
compared to vehicle treated cells. The maximum concentration of drug vehicle
(DMSO; 1%) induced 14.3 ± 3.4% cell death at 16 h compared to 60.4 ± 7.0 %
induced by DEA/NO (PcO.Ol), 44.4 ± 17.4% by SNVP (P<0.05) and 81.1 ± 10.2%
GEA-3162 (PcO.Ol; one-way ANOVA followed by post hoc Dunnett's test; n=6 for
all treatments; figure 5.3). The apoptotic agent, gliotoxin (1 pg.ml"1), induced
significant cell death compared to vehicle treated cells at 6 and 16 h incubation (15.5
± 8.4 vs 50.7 ± 10.9%; P<0.05 at 6 h and 14.3 ± 3.4 vs 90.8 ± 5.9%; PcO.Ol at 16 h;
unpaired, one-way ANOVA followed by post hoc Dunnett's test; n=6 at all time
points; figure 5.3).
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Figure 5.3 Cell Death Induced by NO Donor Compounds in THP-1 Macrophages
Cell death induced by drug vehicle (DMSO; 1%), DEA/NO, SNVP, GEA-3162 (all 100 gM)
and gliotoxin (1 pig.ml'1) was assessed in THP-1 cells by cell morphology following
treatment for 2 h, 4 h, 6 h, and 16 h as indicated. Analysis by unpaired, one-way ANOVA
followed by post hoc Dunnett's test revealed GEA-3162 induced significant cell death
compared to vehicle treated cells at 4, 6, and 16 h (** = P<0.01), DEA/NO and SNVP
induced significant cell death at 16 h (** = P<0.01 and * = P<0.05), and gliotoxin induced
significant cell death at 6 and 16 h (** = P<0.01). n=4 at 2 h, n=5 at 4, n=6 at 6 and 16 h.
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In order to investigate the influence of protein in the medium, the
experiments were repeated at 6 and 16 h incubation in presence and absence of heat
inactivated foetal calf serum (FCS; 10%). The absence of serum in the medium did
not significantly alter the level of cell death induced by any treatment at either time
point (P>0.05; unpaired one-way ANOVA; n=6 for all treatments at both
timepoints). The pattern of cell death was unchanged from that described above,
with DEA/NO and SNVP causing significant cell death following a 16 h incubation,
and GEA-3162 and gliotoxin being cytotoxic at earlier time points (figure 5.4).
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Figure 5.4 The Influence of FCS on Cell Death Induced by NO Donor Compounds in
THP-1 Macrophages
Cell death induced by drug vehicle (DMSO; 1%), DEA/NO, SNVP, GEA-3162 (all 100 pM) and
gliotoxin (1 pg.mf1) was assessed by cell morphology in the presence (solid bars) and
absence (striped bars) of heat inactivated foetal calf serum (FCS; 10%) in THP-1
macrophages following treatment for 6 h and 16 h as indicated. Analysis by one-way ANOVA
followed by post hoc Tukey test revealed GEA-3162 and gliotoxin induced significant cell
death compared to vehicle treated cells both in the presence and absence of serum 6 h and
16 h. DEA/NO and SNVP induced significant cell death compared to vehicle treated cells in
the presence and absence of serum at 16 h only. However, the presence or absence of
serum did not significantly affect the level of cell death induced by any treatment. * = P<0.05,
**
= P< 0.01 compared to vehicle treated in the presence of serum, and # = P<0.05, ## =
P<0.01 compared to vehicle treated cells in the absence of serum; ns = P >0.05; n=6 for all
treatments at both time points.
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5.3.3.2 Characterisation of Cell Death Induced by NO and NO-Related
Species in Human Monocyte-Derived Macrophages
The maximum concentration of drug vehicle (DMSO; 1%) had no effect on
annexin V binding (a marker of apoptosis) or PI staining (a marker of necrosis) in
either monocytes (figure 5.5), or monocyte-derived macrophages compared to
control, untreated cells (P>0.05; matched, one-way ANOVA; n=6; figure 5.6).
DEA/NO, DETA/NO, SNVP and GSNO (all 100 and 300 pM) did not induce
significant annexin V binding or PI staining in either monocytes (figure 5.5), or
monocyte-derived macrophages, compared to vehicle treated cells (P>0.05; matched,
one-way ANOVA; n=6; figure 5.6).
GEA-3162 (100 and 300 pM) and gliotoxin (1 pg.ml"1) markedly increased
the percentage of cells positive for annexin V binding compared to vehicle treated
cells in both monocytes (figure 5.5) and monocyte-derived macrophages (figure 5.6).
For example, in monocyte-derived macrophages, GEA-3162 (100 pM) increased the
percentage of cells positive for annexin V binding from 11.7 ± 4.5% (vehicle treated
cells) to 46.8 ± 11.9% (PcO.Ol; matched, one-way ANOVA followed by Dunnett's
post hoc test; n=6; figure 5.6). With the exception of the highest concentration of
GEA-3126 (300 pM), the increase in annexin V binding occurred in the absence of PI
staining (figures 5.5 & 5.6). P values quoted refer to statistical analyses performed
on results for monocyte-derived macrophages only. Statistical analyses were not
carried out on results for monocytes due to low n number (n=3).
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Figure 5.5 Apoptosis arid Necrosis Induced by NO and NO-Related Species in Human
Monocytes
Cell death induced by NO donor compounds (100 and 300 pM) was characterised as
apoptosis or necrosis in human monocytes flow cytometry. The percentage of cells positive
for annexin V binding is indicated by solid bars, and for PI staining by striped bars (n=3 for
both concentrations). Only GEA-3162 and gliotoxin (1 pg.ml"1) caused an increase in
annexin V binding which occurred in the absence of PI staining except at the higher
concentration of GEA-3162 (300 pM).
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Figure 5.6 Apoptosis and Necrosis Induced by NO and NO-Related Species in Human
Monocyte-Derived Macrophages
Cell death induced by NO donor compounds (100 and 300 pM) was characterised as
apoptosis or necrosis in human monocyte-derived macrophages by flow cytometry. The
percentage of cells positive for annexin V binding is indicated by solid bars, and for PI
staining by striped bars. Analysis by matched, one-way ANOVA followed post hoc
Dunnett's test revealed GEA-3162 and gliotoxin (1 ng.ml"1) caused a significant increase in
annexin V binding compared to DMSO (1%) treated cells (** = P<0.01) which occurred in
the absence of PI staining at 100 pM and in combination with significant PI staining at 300
pM (## = P <0.01; n=6 for both concentrations).
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SOD (500 U.mr1) had no affect annexin V binding or PI staining in
monocyte-derived macrophages compared to control (untreated) cells, or vehicle
treated cells (data not shown). Similarly, SOD had no further effect on those
treatments that did not affect cell viability (diazeniumdiolate and RS-N=0
compounds) or on the level of apoptosis induced by gliotoxin (data not shown).
The level of annexin V binding induced by GEA-3162 (10 - 300 pM) was
significantly increased by SOD (P<0.01; two-way repeated measures ANOVA
followed by post hoc Bonferroni's test; n=6; figure 5.7). PI staining remained
unaltered by the presence of SOD (P>0.05; two-way ANOVA; n=6; figure 5.7).
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Figure 5.7 The Effect of SOD on GEA-3162-lnduced Apoptosis in Human Monocyte-
Derived Macrophages
Annexin V binding and PI staining induced by GEA-3162 (10 - 300 pM) was assessed in the
absence (solid lines) and presence (dashed lines) of SOD (500 U.ml"1) by flow cytometry.
Analysis by matched, two-way ANOVA followed by post hoc Bonferroni's test revealed SOD
significantly increased the level of annexin V binding, but had no effect on PI staining (** =
P<0.01; ns = P>0.05; n=6).
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5.4 Discussion
The results of this study confirm that NO production by LPS-stimulated
human macrophages is exceedingly low or absent. Neither the Griess test nor the
HPLC method was sensitive enough to detect NOx generated by human
macrophages under these conditions. Fluorescence HPLC is capable of detecting
NO2 in the nM range (Misko et al. 1993; Li et al. 2000; Woitzik et al. 2001; Gharavi
and El-Kadi 2003), however, despite this enhanced sensitivity, levels of NO2"
detected from monocyte-derived macrophages remained below the limit of detection.
Human macrophages have previously been reported to be unable to generate
the supraphysiological NO concentrations produced by rodent cells (Albina 1995;
Schneemann and Schoedon 2002). However, despite this observed inability to
generate NO, iNOS mRNA and protein have been detected in human macrophages
isolated from atherosclerotic plaques (Buttery et al. 1996; Luoma et al. 1998; Luoma
and Yla-Herttuala 1999; Behr-Roussel et al. 2000). iNOS expression under these
circumstances is likely to be an induced response due to the inflammatory nature of
atherosclerosis (Ross 1999a; Ross 1999b; Libby 2002; Libby et al. 2002), and
therefore, treatment for 24 h with LPS alone may have been insufficient to cause
iNOS up-regulation to levels capable of generating detectable concentrations of NO.
Weinberg et al reported elevated levels of iNOS mRNA and protein, and of NO2"
/N03" (measured by Greiss test) in human peritoneal macrophages following LPS
stimulation (Weinberg et al. 1995). However, the cells were treated for 4 days,
rather than 24 h, and although NO27NO3" generation was augmented by treatment
with LPS, this was delivered in combination with interferon-y (INF-y), and remained
significantly below that produced by murine cells as part of the same study
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(Weinberg et al. 1995). A more successful strategy for future attempts to detect NO
from human monocyte-derived macrophages may therefore be to stimulate the cells
for a longer period of time with LPS in combination with a 'cocktail' of cytokines.
A further consideration is NOS substrate or co-factor deficiency. Substrate or co-
factor deficient NOS has previously been demonstrated to generate 02~, rather than
NO (Xia and Zweier 1997; Vasquez-Vivar et al. 1998; Xia et al. 1998; Vasquez-
Vivar et al. 1999a; Vasquez-Vivar et al. 1999b; Vasquez-Vivar et al. 2002).
However, the medium in which monocyte-derived macrophages are cultured
(IMDM) contains L-Arg (0.4 mM; appendix one), so it is perhaps unlikely that NOS
would be substrate deficient, unless there was a disorder of Arg transport.
Interestingly, Weinberg et al reported that although human peritoneal macrophages
did not contain the NOS co-factor, tetrahydrobiopterin (BH4); supplementation with
BH4 did not result in increased NO production, suggesting there may be additional
reasons underlying the inability of human macrophages to produce NO (Weinberg et
al. 1995).
Despite this apparent inability to generate NO, human macrophages do
respond to exogenous NO-related species. Therefore, although the contribution of
macrophage-derived NO to processes occurring within the atherosclerotic plaque
might be minimal, this cell type remains a realistic target for NO-based therapies in
the treatment of atherosclerosis. It is also worth noting that the macrophages used in
the current study were isolated from the peripheral blood of healthy volunteers and
given the inflammatory nature of atherosclerosis, macrophages within the plaque
may possess additional NO generating capacity as a result of inflammation-driven
iNOS up-regulation. iNOS up-regulation could potentially have implications for
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endothelium-derived NO or NO-based therapies. If macrophage iNOS becomes
substrate or co-factor deficient, resulting in 02, rather NO, generation, then any
available NO would combine with Of, forming ONOO" (Saran et al. 1990; Czapski
and Goldstein 1995; Goldstein and Czapski 1995; Reiter et al. 2000). This is
particularly important because the studies presented here examining the role of NO
in macrophage viability, demonstrated that of a range of compounds capable of
releasing various NO-related species, only the ONOO" generator, GEA-3162 is able
to induce apoptosis in both human monocytes, and monocyte-derived macrophages.
Comparable levels of NOx delivered via RS-N=0 (demonstrated by Griess test), or
elevated levels of NO radical, delivered either as a rapid and short burst (DEA/NO)
or in a prolonged and sustained manner (DETA/NO; chapter three), failed to induce
apoptosis in human monocytes and monocyte-derived macrophages.
Several previous reports have demonstrated that NO, delivered by both
diazeniumdiolate and RS-N=0 compounds, is capable of inducing apoptosis in
macrophages (Hibbs et al. 1988; Albina et al. 1993; Sarih et al. 1993; Messmer et al.
1995; Shimaoka et al. 1995; Messmer and Brune 1996b; Messmer and Brune 1996a;
Messmer et al. 1996), and recent studies have suggested a central role for S-
nitrosylation in macrophage apoptosis (Benhar and Stamler 2005; Hara et al. 2005).
However, without exception, these studies have been conducted in rodent cells,
either murine macrophage cell lines, such as RAW 264.7 cells, or isolated peritoneal
macrophages, and have used a variety of means, including stimulating the L-Arg
pathway, NO gas, and various NO donor compounds to deliver NO at relatively high
concentrations (usually >mM drug concentration). The concentration of NO, or NO-
related species, generated by the NO donor compounds in this study are an order of
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magnitude lower than this (in the pM range), indicating that the capacity of NO to
induce apoptosis is likely to be concentration-, as well as cell type-, specific, and
therefore may not occur in vivo as a result of endogenously generated NO.
Initial pilot experiments in THP-1 macrophages, implied that NO radical and
RS-N=0, as well as ONOO", are cytotoxic to human macrophages, but this was not
borne out in freshly isolated monocytes or macrophages, which underwent apoptosis
in response to ONOO" only. Interesting, cell death in THP-1 cells in response to
DEA/NO did not occur until 16 h, despite NO release from DEA/NO occurring in a
rapid and short burst (chapter three). The reasons for this lag time are not clear, but
may suggest NO-induced transcriptional up-regulation of proteins involved in the
execution of apoptosis, or down-regulation of proteins involved in the inhibition of
apoptosis. For example, in murine RAW 264.7 macrophages, NO (delivered by
diazeniumdiolate and RS-N=0 compounds) causes profound down-regulation of the
intracellular caspase inhibitors, inhibitor of apoptosis proteins (IAPs), with inhibition
correlating temporally with apoptosis (Manderscheid et al. 2001). The mechanisms
of NO-induced cytotoxicity in THP-1 cells has not been examined here, but the
observed differences between macrophages of the THP-1 cell line and freshly
isolated, terminally differentiated, monocyte-derived macrophages, may be due to
the immortalised nature of the THP-1 cells, which could potentially result in altered
cell death pathways.
Interestingly, serum starving had no effect on the level of cell death in THP-1
cells, despite being able to both initiate apoptosis, and augment transforming growth
factor p (TGF-P)- and hydrogen peroxide (H202)- induced apoptosis in endothelial
cells (Hogg et al. 1999). It is possible that the presence of serum protected
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monocytes and monocyte-derived macrophages from NO- or RS-N=0-induced
apoptosis. But given that serum withdrawal had no affect on apoptosis in THP-1
cells, macrophages may be less sensitive to serum deprivation than other cell types.
Additionally, extrapolation of the relevance of experimental serum starving in vitro
to the situation in vivo must be done with a degree of caution because serum proteins
will be present in vivo.
It is interesting to note that undifferentiated monocytes undergo apoptosis in
response to ONOO" in the same manner as differentiated monocyte-derived
macrophages. Atherosclerotic plaques are dynamic and cells are constantly being
recruited to the core. Therefore, ONOO" appears able to induce apoptosis in those
cells newly recruited to the site of inflammation before differentiation, and in those
cells that are already resident in the core and have undergone differentiation to
macrophages.
Apoptosis was characterised in human monocytes and monocyte-derived
macrophages by annexin V binding in the absence of propidium iodide (PI) staining.
This pattern indicates cell surface phosphatidylserine (PS) exposure with the outer
membrane remaining intact and, therefore, confirms that cell death is occurring by
apoptosis, rather than necrosis. Although higher concentrations of ONOO" appear to
cause a degree of PI staining, indicating some necrosis in addition apoptosis, PI
staining may not necessarily indicate primary necrosis in this case. This is because
the cells were incubated in the presence of ONOO" for 24 h, whilst the release profile
of GEA-3162 was demonstrated in earlier studies (chapter three) to be in the region
of approximately 4 h in IMDM. Therefore, it is possible that apoptosis is initiated
during the early stages of treatment, and in the absence of a population of
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phagocytes, the apoptotic cells enter late apoptosis or secondary necrosis, resulting in
membrane rupture and allowing PI staining. In order to clarify this, apoptosis should
be confirmed by alternative methods, such as DNA laddering or deoxynucleotidyl
transferase (TdT)-mediated dUTP-biotin nick end-labelling (TUNEL) staining;
constraints of time did not permit such experiments to be carried out as part of the
current study.
ONOO, at comparable concentrations to those used here, has previously been
shown to induce apoptosis in several cell types, including HL-60 (a human
leukaemia cell line), freshly isolated rat thymocytes, and murine macrophages (Lin et
al. 1995; Salgo et al. 1995; Sandoval et al. 1997a; Sandoval et al. 1997b), but this is
first report of ONOO" inducing apoptosis in human monocytes/macrophages.
Mechanisms for the disparate induction of apoptosis by ONOO" compared
NO and RS-N=0 in freshly isolated monocytes and monocyte-derived macrophages
have not been investigated here. One possibility is divergent effects on nuclear
transcription factor-xB (NF-kB). NF-kB transcriptional activity leads to the
expression of many anti-apoptotic proteins, including IAPs and the Bcl-2 family of
proteins, that limit caspase activity (Delhalle et al. 2004). The pro-apoptotic agent,
gliotoxin, used as a positive control in these studies, induces apoptosis by inhibiting
NF-kB activation (Pahl, 1996 #689;Ward, 1999 #91}, thereby preventing the
synthesis of survival proteins. Therefore, ONOO" may induce apoptosis in human
monocytes and monocyte-derived macrophages by inhibiting NF-kB activation,
whilst NO may sustain NF-kB activity in order to prevent apoptosis. ONOO" has
been shown to inhibit NF-kB activity in cardiomyocytes and endothelial cells
(Levrand et al. 2005), whilst NO sustains its activity in chondrocytes and RAW
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274.7 macrophages (von Knethen et al. 1999; Clancy et al. 2004). However, the role
of both ONOO" and NO in NF-kB inhibition/activation remains controversial, and in
fact, the opposite actions for these molecules have been also described, with NO
suppressing, and ONOO" sustaining, NF-kB activity in VSMCs and endothelial cells
(Cooke and Davidge 2002; Hattori et al. 2004). The actions of ONOO" and NO on
NF-kB activity are clearly complex and cell-type specific. In addition to actions on
NF-kB transcription, ONOO" is also known to be able to initiate DNA strand breaks
during ONOO -mediated cytotoxicity of murine macrophages (Szabo et al. 1996;
Zingarelli et al. 1996; Guidarelli et al. 2000). Therefore, whilst divergent actions on
NF-kB is one potential mechanism to rationalise variations in the NO-related species
induction of apoptosis, it is by no means the only possibility and thorough
investigation in this particular cell type is required before the precise mechanism of
ONOO -induced apoptosis can be identified.
The downstream effectors of ONOO" -induced apoptosis also remain to be
fully elucidated. ONOO" -induced apoptosis in rat thymocytes is inhibited by the
anti-oxidant, Trolox, indicating that apoptosis is triggered by oxidising species
(Salgo et al. 1995). If this were the case in human monocyte-derived macrophages,
SOD might be expected to inhibit apoptosis. In the current study, rather than
inhibiting ONOO" -induced apoptosis, SOD augmented the level of apoptosis. There
are two possible explanations for this; firstly, earlier EPR experiments (chapter three)
demonstrated that the concentration of SOD used in these studies (500 U.ml"1)
reduces the concentration of oxidising species generated by GEA-3162 by
approximately half. Therefore, as this concentration of SOD is insufficient to totally
abolish the production of oxidising species, there may be sufficient residual oxidising
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species remaining to trigger apoptosis. Alternatively, O2" may not be the mediator of
apoptosis. SOD catalyses the conversion of O2 to H2O2, prior to subsequent
catalytic conversion of H202 to H2O and O2 by the enzyme catalase (Beckman and
Koppenol 1996). H2O2 has been shown to induce apoptosis in murine cells by
inhibiting caspase enzymes (Borutaite and Brown 2001; Borutaite and Brown 2003).
Therefore, H202 may be the apoptotic trigger. This could be further investigating in
human monocyte-derived macrophages by examining whether a combination of SOD
and catalase successfully abolishes ONOO" - induced apoptosis.
It would be of interest to investigate if ONOO" - induced apoptosis in human
monocyte-derived macrophages occurs via the mitochondrial (or stress) pathway, or
by the death receptor pathway. Cytochrome-c release and mitochondrial
depolarisation have been reported to precede NO-induced apoptosis in a variety of
cells, including in murine macrophages (Brown and Borutaite 1999; Hortelano et al.
1999; Bal-Price and Brown 2000; Brown and Borutaite 2001; Brown and Borutaite
2002; Maneiro et al. 2005). Therefore, it is reasonable to speculate that ONOO" -
induced apoptosis in human macrophages might trigger mitochondrial-dependent
apoptosis. However, given the specificity and highly regulated nature of apoptosis
this would require through investigation in this cell type before the specific pathway
is identified.
In summary, the salient finding of these studies is that of a range of
compounds capable of generating NO or NO-related species, only the ONOO"
generator is capable of inducing apoptosis in human monocytes and monocyte-
derived macrophages. This NO-species variation could potentially be exploited as a
means to achieve cell-selective induction of apoptosis in the inflammatory cell
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population of atherosclerotic plaques, with the aim of stabilising the plaque by
limiting disease progression, or aiding plaque regression. However, this therapeutic
strategy can only be considered after through investigation into the effects of ONOO"
on other cell types critical to plaque stability.
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6. The Role of the NO:cGMP Pathway in
Protecting Human Monocyte-Derived
Macrophages and Vascular Smooth
Muscles Cells Against Cell Death
6.1 Introduction
NO can be both pro- and anti-apoptotic, depending on the nature and local
concentration of the NO-related species generated in the microenvironment, as well
as the characteristics of the target cell. Current evidence suggests that lower
concentrations of eNOS- and nNOS-derived NO are cytoprotective via primarily
cGMP-dependent mechanisms, whilst higher, supraphysiological concentrations
generated in some cell types by iNOS under pathological conditions, mediate
apoptosis via mechanisms independent of cGMP signalling (Nicotera et al. 1997).
Apoptosis, and subsequent phagocytic removal of apoptotic cells, is now thought to
be crucial to the successful resolution of the inflammatory response (Haslett 1997;
Madema and Godson 2003; Taylor et al. 2003; Rossi et al. 2004).
Disparities between the sensitivity of different cell types to NO-induced
cytoxocity suggests the presence of protective mechanism(s) in those cell types
resistant to NO-evoked cell death. This protective mechanism may depend on the
anti-apoptotic qualities of NO itself. Non-toxic doses of NO, and agents that elevate
cGMP, have been demonstrated to protect rodent macrophages and VSMCs against
subsequent NO-induced cell death (von Knethen et al. 1999; Yoshioka et al. 2003;
Pan et al. 2004).
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In healthy blood vessels, the endothelium secretes eNOS-derived NO to
control vasomotor tone and to maintain the integrity of the vessel wall. The ability
of low concentrations of NO to protect cells from a cytotoxic insult may well be an
additional cardio-protective property of NO. During atherogenesis the endothelium
becomes dysfunctional, resulting in decreased NO production, hence removing this
cytoprotection. However, rather than contributing directly to the atherogenic
process, this may, in fact, be the first line of defence in an attempt to resolve the
vascular inflammation now generally accepted to underlie atherosclerosis (Ross
1999a; Ross 1999b; Libby 2002; Libby et al. 2002). Allowing apoptosis, and
subsequent phagocytosis, to proceed by removing the protective actions of NO,
might prevent the accumulation of the necrotic inflammatory cells in the sub-
endothelial space that characterises atherosclerosis. However, if the population of
phagocytes is overwhelmed by the magnitude and duration of the inflammatory
response, then apoptotic cells remaining in situ would eventually become necrotic,
resulting in cell membrane rupture, release of the pro-inflammatory mediators
contained within the cell, ultimately causing an exacerbation of the inflammatory
response. Furthermore, the removal of NO-mediated cytoprotection from VSMCs
might contribute to weakening of the plaque cap, triggering plaque rupture, and
ultimately leading to the acute clinical consequences of atherosclerosis (Bauriedel et
al. 1999; Leskinen et al. 2003). Thus, the decrease in eNOS-derived NO may be part
of the initial defence mechanism that goes awry and develops from being an initial
protective response to vascular inflammation, to eventually contributing to the
disease process itself.
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The mechanism of such 'priming' by NO is currently unclear, and has been
reported to be cGMP-dependent (Yoshioka et al. 2003). Alternatively, NO might
cause nuclear transcription factor kB (NF-kB) activation, leading to subsequent
cyclooxygenase 2 (COX-2) up-regulation, although the mechanism by which COX-2
protects cells from apoptosis remains to be elucidated (von Knethen et al. 1999).
Development of inhibitors of the sGC:cGMP pathway including the specific
sGC inhibitor, ODQ (Garthwaite et al. 1995; Schrammel et al. 1996), and
phosphodiesterase (PDE) inhibitor, IBMX (van Staveren et al. 2001), together with
the recent advent of NO-independent stimulators of sGC such as YC-1 and BAY 41-
2772 (Ko et al. 1994; Stasch et al. 2001), allow the role of cGMP in the protective
effects of NO to be examined in detail. YC-1 and BAY 41-2772 both have
beneficial effects in the cardiovascular system including anti-platelet effects,
inhibition of VSMC proliferation and anti-hypertensive properties (Ko et al. 1994;
Stasch et al. 2001; Tubs et al. 2002). Furthermore, YC-1 has recently been
demonstrated to prevent NO-mediated apoptosis in VSMC, suggesting that cGMP
might confer the anti-apoptotic effects of NO (Pan et al. 2004).
Previous studies demonstrating the cyoprotective action of pre-treatment with
low concentrations of NO have used a variety of NO donor compounds (sodium
nitroprusside; SNP, and GSNO) at relatively high concentrations (>lmM drug
concentration; von Knethen et al. 1999; Yoshioka et al. 2003), which are likely to
generate NO at higher concentrations than the normal NO producing capacity of the
healthy endothelium. Concentrations of these compounds -100 fold lower than
those used in the studies quoted above are known to have considerable anti-platelet
and vasodilator actions (Sogo et al. 2000; Miller et al. 2004).
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Therefore, the aims of these studies were to rationalize the various paradoxes
relating to the disparate ability of NO and NO-related species to induce apoptosis. In
order to investigate this, the hypothesis that the anti-apoptotic actions of NO are due
to physiologically relevant concentrations of NO and ensuing increases in cGMP,
whilst the pro-apoptotic actions of NO are due to higher, supraphysiological doses of
NO and NO-related species was tested in human monocyte-derived macrophages and
BAoSMC. This was examined by stimulating the NO:cGMP pathway with a more
realistically physiological dose of NO in combination with augmentation of cGMP
levels, prior to subsequent treatment with a concentration of ONOO* known to
induce apoptosis. Additionally, the hypothesis that cellular protection is mediated by
cGMP, rather than NO radical per se was tested by treating the cells with NO in
combination with sGC inhibition.
6.2 Methods
6.2.1 Functional Studies In Isolated Rat Aortae
In order to test the efficacy of DETA/NO in combination with the NO-
independent sGC stimulator, BAY 41-2772, and the non-specific phosphodiesterase
(PDE) inhibitor, IBMX, relaxation in response to DETA/NO in the absence and
presence of supramaximal BAY 41-2772 (lpM) and IBMX (lpM) was measured as
isometric tension in isolated rat thoracic aortic rings as described chapter two
(section 2.7). Relaxations are expressed as a percentage of the maximum contraction
in response to ECgo phenylephrine (PE). Following pre-contraction with EC8o PE
(0.1 pM), cumulative concentration-responses to DETA/NO (0.001 - 100 pM) were
obtained in each aortic ring in order to establish the concentration of DETA/NO
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giving approximately 75% relaxation (EC75). The EC75 DETA/NO was selected for
subsequent experiments with cGMP modulators so that it would be possible to
observe additional responses evoked by BAY 41-2772 and IBMX.
Following pre-contraction with EC8o PE, the relaxation in response to EC75
DETA/NO (10 p,M) in the absence and presence of BAY 41-2772 (lp,M) or IBMX
(lp,M) was measured in each aortic ring. BAY 41-2772 was used in combination
with DETA/NO because recent evidence has suggested that rather than direct
stimulation sGC, the actions of this compound are a result of the synergistic effects
of inhibition of PDE V coupled with sensitisation of sGC toward endogenous NO
(Friebe et al. 1998; Mullershausen et al. 2004).
6.2.2 Cell Culture
6.2.2.1 Isolation and Culture ofHuman Monocyte-Derived Macrophages
Human monocytes were isolated from peripheral blood of healthy volunteers
as described in chapter two (section 2.2.2) and cultured (37 °C; 95% O2: 5% CO2) in
IMDM (containing supplements plus 10% autologous serum) for 5-7 days to allow
differentiation into monocyte-derived macrophages (section 2.2.2.1). At the end of
this period, the IMDM was aspirated from the wells and replaced with fresh IMDM
containing experimental treatments (see section 6.2.3 below).
6.2.2.2 BovineAortic Smooth Muscle Cell Culture
Bovine aortic smooth muscle cells (BAoSMC) were cultured in DMEM (plus
supplements) as described in chapter two (section 2.2.3). Cells were seeded in 48-
well, flat-bottomed tissue culture plates and cultured (37 °C; 95% O2: 5% C02) for
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24 h prior to experimental protocol in order to allow cells to adhere to the plate. At
the end of this period, the DMEM was aspirated from the wells and replaced with
fresh DMEM plus experimental treatments (see section 6.2.3 below)
6.2.3 Experimental Protocol For Cell Culture
Experiments
Following the initial culture period as appropriate for each cell type, cells
were treated (24 h; 37°C: 95% O2; 5% CO2) with the following pre-treatments: no
treatment (control); low concentration NO (DETA/NO; 10 pM); low concentration
NO (DETA/NO; 10 pM) + BAY 41-2272 (1 pM) to augment cGMP production; and
low concentration NO (DETA/NO; 10 pM) + IBMX (1 pM) to prevent cGMP
degradation. In order to establish that any protection conferred on the cells is due to
cGMP, rather than NO per se, a group was treated with DETA/NO (300 pM) in the
presence of the specific sGC inhibitor, ODQ (20 pM). Following incubation for 24 h
in the presence of these pre-treatments, the medium was aspirated from the wells and
the cells washed twice in Dulbeccos's phosphate buffered saline (PBS; containing
CaCl2*6H20; 0.133 M and MgCE^EhO; 0.1 M) prior to addition of fresh full media.
Cells were then incubated for a further 24 h (37°C: 95% 02; 5% CO2) in the absence
and presence of the ONOO" generator, GEA-3162 (100 pM), or the apoptotic agent,
gliotoxin (1 pg.mF1; figure 6.1). This concentration of GEA-3162 was selected as it
had previously been demonstrated to induce significant apoptosis in human
monocyte-derived macrophages without causing necrosis (chapter five), and to
induce necrosis in BAoSMC (chapter four). Following treatment with GEA-3162 or
202
Chapter Six - Role of theNOtcGMP Pathway in Protecting CellsAgainst Cell Death

























Figure 6.1 Schematic Representation of Experimental Protocol for Human Monocyte-
Derived Macrophages and BAoSMC
6.2.4 Measurement of cGMP
Cells were incubated (37°C: 95% O2; 5% CO2) for 24 h in the presence of the
pre-treatments described above plus IBMX (250 qM). Addition of IBMX (250 pM)
was necessary to inhibit PDEs, and therefore prevent cGMP breakdown. At the end
of this 24 h period, cells were lysed (Triton X 100; 2%) and cGMP measured in
human monocyte-derived macrophage and BAoSMC lysates as described in chapter
two (section 2.5).
6.2.5 Measurement of Protein
To avoid discrepancies in the exact number of cells seeded in each well, a
protein assay was carried out in order to express the concentration of cGMP per mg
of protein. Although the cells are counted and diluted to equal concentration prior to
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seeding (chapter two; sections 2.2.2.1 & 2.2.3), the method used is fairly crude and
may not be completely consistent, resulting in variations in the number of cells
seeded in each well. The greater the density of cells, the greater the cGMP
producing capacity of the cells in any given well will be. Expressing the
concentration of cGMP per mg of protein allows for such variation in cell density.
The total concentration of protein present in each well was measured by
bicinchoninic acid (BCA) colourimetric assay as described in chapter two (section
2.6).
6.3 Results
6.3.1 Functional Studies in Isolated Rat Aortae
DETA/NO (0.001 - 100 pM) evoked concentration-dependent relaxation in
isolated aortic rings (figure 6.2). For subsequent experiments, a concentration of 10
pM was selected as approximately EC75.
BAY 41-2772 (1 pM) and IBMX (1 pM) both induced relaxation in the
absence of DETA/NO (43.5 ± 18.5% for BAY 41-2772 and 39.5 ± 3.2% for IBMX).
Subsequent addition of DETA/NO (10 pM) induced a more profound relaxation than
DETA/NO alone (89.9% vs 72.3% for BAY 41-2772 the in presence of DETA/NO
compared to DETA/NO alone and 79.5% vs 58.5% for IBMX the in presence of
DETA/NO compared to DETA/NO alone).
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Figure 6.2 Cumulative Concentration-Response Curve for DETA/NO
Relaxation in response to DETA/NO (0.001 - 100 pM) was measured as isometric tension in
isolated rat aortic rings following pre-contraction with EC80 PE (0.1 pM). Data are expressed
as mean + SEM. (n=4).
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6.3.2 Effect of Low Concentration NO Pre-treatment
on ONOO' -Induced Cell Death
6.3.2.1 Human Monocyte-DerivedMacrophages
DETA/NO (10 pM; as selected from vasodilator experiments) in the absence
and presence of BAY 41-2772 (1 pM) or IBMX (1 pM), and DETA/NO (300 pM) in
presence of ODQ (20 pM), did not cause increased levels of either annexin V
binding, or PI staining compared to control, untreated cells (P>0.05 for all
treatments; matched, one-way ANOVA; n=8; figure 6.3).
In common with previous experiments (chapter five), GEA-3162 (100 pM)
induced a significant increase in the percentage of cells positive for annexin V
binding without significantly affecting PI staining compared to control cells (20.1 ±
5.3% vs 51.4 ± 5.9% for annexin V binding; P<0.001; matched, one-way ANOVA
followed by post hoc Tukey test; n=8, and 16.6 ± 7.2% vs 11.5 ± 3.4% for PI
staining; P>0.05; matched, one-way ANOVA; n=8; figure 6.3). The level of annexin
V binding induced by GEA-3162 was significantly attenuated in those cells that had
been subjected to previous treatment with DETA/NO (10 pM) in combination with
BAY 41-2772 (51.4 ± 5.9% vs 31.8 ± 3.6%; PcO.Ol) or IBMX (51.4 ± 5.9% vs 30.4
± 6.6%; PcO.Ol; matched, one-way ANOVA followed by post hoc Tukey test; n=8;
figure 6.3). Pre-treatment with DETA/NO (10 pM) alone, or DETA/NO (300 pM)
in combination with ODQ was unable to cause a significant reduction in GEA-3162-
induced annexin V binding (P>0.05; matched, one-way ANOVA; n=8; figure 6.3).
206
Chapter Six - Role of the NO. cGMP Pathway in Protecting Cells Against Cell Death
Annexin V +IVE
t=3 PI +IVE
Figure 6.3 The Effect of Pre-treatment with DETA/NO in Combination with Bay 41-2772
and IBMX on ONOO" -Induced Apoptosis In Human Monocyte-Derived Macrophages
Cell death in human monocyte-derived macrophages was assessed by flow cytometry
following pre-treatment (24 h) of cells with DETA/NO (10 pM) in combination with BAY 41-
2772 (1 pM) and IBMX (1 pM) or DETA/NO (300 pM) in presence of ODQ (20 pM), followed
by further treatment (24 h) with GEA-3162 (100 pM). Additionally, a set of cells was treated
for the final 24 h with gliotoxin (1 pg.ml"1). The percentage of cells positive for annexin V
binding is indicated by solid bars, and for PI staining by striped bars. Analysis by matched,
one-way ANOVA followed by post hoc Tukey test revealed GEA-3162 and gliotoxin induced
significant annexin V binding in the absence of PI staining compared to control, untreated cells
(*** = P<0.001). The GEA-3162-induced increase in annexin V binding was significantly
attenuated by pre-treatment of the cells with DETA/NO (10 pM) in the presence of BAY 41-
2772 or IBMX (## = P<0.01 compared to GEA-3162 treated cells; n=8).
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6.3.2.2 Bovine Aortic Smooth Muscle Cells
DETA/NO (10 pM) in the absence and presence of BAY 41-2772 (1 pM) or
IBMX (1 pM), and DETA/NO (300 pM) in presence of ODQ (20 pM), did not cause
increased levels of either annexin V binding, or PI staining compared to control,
untreated cells (P>0.05 for all treatments; unpaired, one-way ANOVA; n=6; figure
6.4).
GEA-3162 (100 pM) induced a significant increase in the percentage of cells
positive for annexin V binding compared to control, untreated cells (70.0 ± 5.7% vs
38.8 ± 9.9%; PcO.001; unpaired, one-way ANOVA followed by post hoc Tukey test;
n=6; figure 6.4). However, this occurred in combination with a significant increase
in the percentage of cells positive for PI staining (52.1 ± 10.9% vs 20.1 ± 3.9%;
P<0.001; unpaired, one-way ANOVA followed by post hoc Tukey test; n=6; figure
6.4). This pattern was repeated in cells treated with the apoptotic agent, gliotoxin (1
pg.ml"1) where annexin V binding and PI staining were both significantly increased
above control (67.5 ± 3.9% vs 38.8 ± 9.9%; PcO.001 for annexin V binding and 51.1
± 3.6% vs 20.1 ± 3.9%; P<0.001 for PI staining; unpaired, one-way ANOVA
followed by post hoc Tukey test; n=6; figure 6.4).
Pre-treatment (24 h) with DETA/NO (10 pM) in the absence and presence of
BAY 41-2772 or IBMX, or DETA/NO (300 pM) in the presence of ODQ, followed
by subsequent treatment (24 h) with GEA-3162 did not reduce the level of either
annexin V binding or PI staining compared to treatment with GEA-3162 in isolation
(figure 6.4). Cell death in cells pre-treated as described above remained significantly
above that in control, untreated cells.
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Figure 6.4 The Effect of Pre-treatment with DETA/NO in Combination with Bay 41-2772
and IBMX on ONOO" -Induced Apoptosis In Bovine Aortic Smooth Muscle Cells
Cell death in BAoSMC was assessed by flow cytometry following pre-treatment (24 h) of
cells with DETA/NO (10 pM) in combination with BAY 41-2772 (1 pM) and IBMX (1 pM) or
DETA/NO (300 pM) in presence of ODQ (20 pM), followed by further treatment (24 h) with
GEA-3162 (100 pM). Additionally, a set of cells was treated for the final 24 h with gliotoxin
(1 pg.mf1). The percentage of cells positive for annexin V binding is indicated by solid bars,
and for PI staining by striped bars. Analysis by unpaired, one-way ANOVA followed by post
hoc Tukey test revealed gliotoxin and all treatments involving GEA-3162 induced significant
annexin V binding in combination with PI staining compared to control, untreated cells (* =
P<0.05; ** = P<0.01; *** = P<0.001 for annexin V binding and ttt = P<0.001 for PI
staining). Pre-treatment of the cells with DETA/NO (10 pM) in the presence of BAY 41-2772
or IBMX and DETA/NO (300 pM) in the presence of ODQ had no effect on the level of
annexin V binding or PI staining induced by GEA-3162 (P>0.05; n=6)
209
Chapter Six - Role of the NO.cGMP Pathway in Protecting Cells Against Cell Death
6.3.3 cGMP and Protein Measurements
6.3.3.1 HumanMonocyte-DerivedMacrophages
Despite use of the acetylated procedure, specifically designed to detect low
concentrations of cGMP, the majority of the pre-treatments described above
generated levels of cGMP in human monocyte-derive macrophages below the limit
of detection for the assay (0.08 pM.mr1). The only exception to this was in those
cells treated with DETA/NO (10 pM) in the presence of BAY 41-2772 (1 pM) in
four out of a total of six experiments. When compared to the corresponding protein
concentration, this treatment resulted in an average of 2.8 pM cGMP per mg of
protein (n=4). The average concentration of protein per well was 0.35 mg.
6.3.3.2 Bovine Aortic Smooth Muscle Cells
None of the treatments resulted in detectable levels of cGMP in BAoSMC.
The average concentration of protein per well was 0.16 mg.
6.4 Discussion
The results from these studies demonstrate that pre-treatment with agents that
elevate cGMP levels protect monocyte-derived macrophages against apoptosis, but
not BAoSMCs against necrosis. ONOO" -induced apoptosis was attenuated in
human monocyte-derived macrophages following prior incubation with DETA/NO
in combination with BAY 41-2772 to augment cGMP production, or with IBMX to
inhibit cGMP breakdown. However, these treatments failed to abrogate ONOO" -
induced necrosis in BAoSMC.
These findings, together with the observation that a higher concentration of
DETA/NO in combination with the specific sGC inhibitor, ODQ, failed to protect
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monocyte-derived macrophages against apoptosis, suggest that such protection is
conferred by cGMP. cGMP has previously been demonstrated to be responsible for
the anti-apoptotic actions of NO in macrophages (Heinloth et al. 2002; Yoshioka et
al. 2003). Although it was not possible to measure cGMP concentrations in these
studies, previous studies (Stasch et al. 2001) and pilot experiments in rat aortae
demonstrated that the doses of DETA/NO, BAY 41-2772 and IBMX used in these
experiments are biologically active. The inability to detect cGMP is therefore likely
due to the density of cells seeded in each well being too low to provide a cell
population with sufficient overall cGMP-producing capacity in the range of detection
of the assay. Additionally, measuring cGMP at the end of the 24 h pre-incubation
period may not be the best time point. cGMP production would be predicted to
begin immediately upon exposure to NO, and therefore, may have peaked and
declined earlier in the 24 h period, despite the presence of the PDE inhibitor, IBMX.
However, because the cells are lysed in order to measure intracellular cGMP
concentration, it is not possible to examine cGMP levels sequentially at timed
intervals in the same set of cells over the 24 h incubation period.
It is interesting that although cGMP might be predicted to be elevated early
during the initial 24 h incubation, cellular protection persists for a further 24 h period
after this. There are two possibilities to explain this: firstly, BAY 41-2772 and
IBMX might persist in the cells despite the washing of wells with PBS and the
change of medium after the initial 24 h pre-treatment period. Secondly, cGMP
activates downstream transcriptional events in order to confer protection against
apoptosis. Apoptosis normally proceeds due to regulation of various pro- and anti-
apoptotic factors within the cell, such as the Bcl-2 family of proteins, cytochrome-c
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release from the mitochondria, and caspase signalling (Alnemri 1997; Kluck et al.
1997; Miller 1997; Nicholson and Thomberry 1997; Thornberry 1997; Yang et al.
1997; Green and Reed 1998; Zimmermann et al. 2001). In order to prevent
apoptosis, cGMP is likely to regulate one or more of these processes. Possibilities
include, for example, inhibiting apoptosis by phosphorylation of pro-apoptotic
proteins, or by regulating gene expression of anti-apoptotic proteins, such as anti-
apoptotic members of the Bcl-2 family, or the inhibitor of apoptosis proteins (AIPs),
which are inhibitors of the pro-apoptotic caspase enzymes (Liston et al. 1996; Roy et
al. 1997; Deveraux and Reed 1999; Deveraux et al. 1999).
The downstream effectors of cGMP protection have not been investigated in
this study, but previous studies have suggested that cGMP activates protein kinase G
(PKG) during NO-dependent cytoprotection (Yoshioka et al. 2003). PKG may alter
the balance of pro- and anti-apoptotic factors within the cell in favour of the later.
For example, PKG has been demonstrated to prevent hydrogen peroxide (H202)-
induced apoptosis in cultured astrocytes by inhibiting the opening of the
mitochondrial transition pore, and consequent pro-apoptotic cytochrome c release
from the mitochondria (Takuma et al. 2001). This inhibition had a rapid onset
(within 30 min) and although prevention of loss of mitochondrial membrane
potential persisted throughout a 24 h incubation period, cGMP-elevating agents were
present throughout this time. In the studies presented here, the cGMP-elevating
agents were removed at the end of the 24 h pre-treatment period, and cGMP levels
were below the limit of detection at this time. Therefore, whether PKG levels would
remain sufficiently elevated and active at the mitochondrial pore in the absence of
continued cGMP production is not clear.
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Alternatively, cGMP/PKG may trigger downstream signalling events to
provide longer-term protection against apoptosis. For example, non-toxic doses of
NO have been demonstrated to protect murine macrophages against subsequent
apoptotic concentraions of NO via activation of NF-kB and ensuing COX-2
expression (von Knethen and Brune 1997; von Knethen et al. 1999). Although the
studies quoted above did not investigate the absolute requirement for cGMP in this
protection, it is possible that cGMP activates PKG, which in turn triggers a signalling
cascade involving mitogen-activated protein (MAP) kinases as the link between
cGMP, and ultimately, NF-kB activation and COX-2 expression. Two such
signalling cascades have recently been demonstrated in human pulmonary epithelial
cells. The first involves cGMP/PKG triggering complicated sequential signalling
pathways involving activation of multiple enzymes and kinases, including GTPases,
phosphoinositide-3-OPI-kinase (PI3K), and Akt, which ultimately act to
phosphorylate and therefore, remove, the inhibitory subunit, IkBoi, from NF-kB.
Removal of this inhibitory subunit generates free NF-kB which is then able to
translocate to the nucleus to cause COX-2 transcription (figure 6.5; Chang et al.
2004). Alternatively, the second pathway involves cGMP/PKG leading to COX-2
expression via activation of protein kinase C (PKC), followed by p44/42 MAPK
activation (figure 6.5; Chang et al. 2002; Chang et al. 2004). However, since the
actions of NO in relation to apoptosis are cell-type specific, this would need
thorough investigation in human monocyte-derived macrophages before such a
pathway could be identified as the protective mechanism. Indeed, Yoshioka et al
reported that specific p38 MAPK inhibitors did not affect NO-mediated
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cytoprotection in murine macrophages (Yoshioka et al. 2003), although the effect of
specific p44/42 MAPK inhibitors were not investigated.
Clearly, the mechanism by which cGMP is able to prime cells against
subsequent apoptotic agents in the relatively long-term is likely to involve





















Figure 6.5 Possible Signalling Cascades in NO-Mediated Protection Against Apoptosis
Schematic representation of the possible signalling cascade triggered by cGMP/PKG. PKG
activates various kinases which ultimately remove the inhibitory sub-unit of NF-kB, allowing it
to translocate to nucleus and ultimately cause COX-2 expression. Adapted from (Chang et al.
2004)
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In rodent macrophages, the presence of NO-mediated protective
mechanism(s) may be a self-defence against the high NO concentrations produced by
these cells themselves. This is unlikely to be the case in human monocyte-derived
macrophages because the production of NO by human macrophages is either
exceedingly low, or absent (chapter five). In studies demonstrating this phenomenon
in murine macrophages (von Knethen et al. 1999; Yoshioka et al. 2003), both the
non-toxic (-100 pM) and toxic doses of NO (3-4 mM) are likely to be far higher than
normal NO producing capacity of the endothelium, although they may reflect
supraphysiological iNOS-generated concentrations in murine cells under
pathological conditions (von Knethen et al. 1999; Yoshioka et al. 2003). The results
presented here demonstrate that not only do human macrophages possess such
protective mechanisms, but also that they are active at far lower NO concentrations
(-2.5 pM; chapter three). This lower dose of NO is predicted to be a more
realistically physiological NO concentration that is closer to NO-producing capacity
of the healthy endothelium. Although the presence of NO-mediated protective
mechanisms is unlikely to be a self-defence mechanism in human macrophages, it
may initially be an indirect, protective anti-inflammatory mechanism. During
atherosclerosis, the net production of NO by the endothelium decreases
(Chowienczyk et al. 1992; Cooper and Heagerty 1998). Although in the later stages
of atherosclerosis this may contribute to the atherogenic process by promoting
vasoconstriction and platelet aggregation, in the earliest stages of atherogenesis
decreasing NO production may be beneficial. Allowing apoptosis to proceed by
removing NO-mediated inhibition of apoptosis may be an attempt to resolve the
vascular inflammation, now accepted to be a major component of atherosclerosis
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(Ross 1999a; Ross 1999b; Libby 2002; Libby et al. 2002). In keeping with this
hypothesis is the observation of apoptotic macrophages in the plaques of both human
excised carotid endarterectomy specimens and experimental models of
atherosclerosis (Han et al. 1995; Bjorkerud and Bjorkerud 1996; Haunstetter and
Izumo 1998), although whether this had been brought about by decreased NO
bioavailability is not known.
If decreasing NO output from the endothelium is an anti-inflammatory
defence, delivering NO later in atherosclerosis might be expected to exacerbate
vascular inflammation. However, increasing NO bioavailability by dietary
supplementation of L-Arg increased the number of apoptotic macrophages present in
vascular lesions and this was associated with plaque regression in a rabbit model of
atherosclerosis (Wang et al. 1999). Induction of apoptosis in this setting occurred
independently of cGMP-signalling, suggesting that a separate mechanism is
responsible for triggering apoptosis under these conditions. Given that the
environment of the atherosclerotic plaque is likely to be under considerable oxidative
stress, the additional NO generated by supplementary L-Arg would combine rapidly
with 02", generating ONOO" and, therefore, ONOO" may be the apoptotic trigger,
rather than NO per se. Thus, delivering NO in an appropriate chemical form to
induce cGMP-independent apoptosis later in atherosclerosis could be exploited to
induce apoptosis and reduce atheroma, without initiating NO-mediated inhibition of
apoptosis. Although it is not yet clear whether ONOO" -induced apoptosis involves
cGMP signalling, the absence of detectable cGMP in cells treated for 24 h with
GEA-3162 suggests that cGMP-independent pathways are responsible for ONOO" -
induced apoptosis.
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NO and elevated cGMP levels were unable to protect BAoSMC against
ONOO" -induced necrotic cell death. This is perhaps unsurprising because, unlike
apoptosis, necrosis is not a regulated process, so there are less potential regulatory
targets for the control of necrosis.
The NO-independent sGC activator, YC-1, has previously been shown to
inhibit NO-induced apoptosis in rat vascular smooth muscle cells (VSMC; Pan et al.
2004)). However, although the study quoted above did not measure NO, the
concentration of NO donor used to induce apoptosis (SNP; ImM) is likely to have
generated significantly higher NOx concentrations than those used in the current
study. The data presented here, and in previous chapters, demonstrates that lower
concentrations of NO do not induce apoptosis in BAoSMC, and that ONOO" induces
necrosis in this cell type. The results presented here do not necessarily demonstrate
that cGMP is incapable of protecting VSMCs against apoptosis, but do show that if
such protective mechanism exist in VSMCs they are not active at physiologically
relevant NO concentrations, and do not protect cells against necrotic cell death.
Preserving VSMCs is of fundamental importance to maintaining the integrity
of the atherosclerotic plaque cap, hence preventing plaque rupture and the acute
clinical consequences of atherosclerosis, such as myocardial infarction and stroke.
Although the determinants of plaque rupture have yet to be been fully identified,
such events are associated with a reduction in the thickness and VSMC content of the
plaque cap (Bauriedel et al. 1999; Leskinen et al. 2003). Therefore, it would seem
that the best therapeutic approach for the treatment of atherosclerosis would see
apoptosis and phagocytic clearance of lipid-laden inflammatory cells resident in the
plaque core, whilst maintaining the cap by protecting the VSMCs from cell death
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(either apoptosis or necrosis). The data presented here demonstrate that delivering
NO or NO-related species late in atherosclerosis may not be the best approach to this
theoretical strategy. Although the NO-related species, ONOO" may have beneficial
effects by inducing apoptosis in inflammatory cells, the cost of triggering necrosis in
the VSMC population of the cap is likely to be too great in terms of plaque stability,
and this cannot be off set by a two pronged approach aimed at elevating cGMP in
VSMC prior to delivery of ONOO" to induce inflammatory cell apoptosis.
These data also go some way to explain the disparate actions of NO and NO-
related species in inducing apoptosis. It appears from these studies that, under
normal physiological conditions, NO acts to inhibit apoptosis via an elevation in
cGMP levels, which subsequently triggers downstream signalling cascades and,
possibly, the transcription of anti-apoptotic genes. Alternatively, supraphysiological
concentrations of NO generated under pathological conditions induce apoptosis, but
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7. General Discussion and Future
Directions
7.1 Introduction
Despite decades of research, the clinical consequences of atherosclerosis
remain a major cause of morbidity and mortality in industrialised nations (Callow
2002; The American Heart Association Statistical Update 2005), and the mechanisms
underlying this widespread condition are still not fully understood. Atherosclerosis
is characterised by the formation of lipid rich plaques in the sub-endothelial space of
large conduit blood vessels (Ross 1993; Davies 1997), and it is now widely accepted
that there is a chronic inflammatory component to the condition (Ross 1999a; Ross
1999b; Libby 2002; Libby et al. 2002). Atherosclerosis develops over a period of
several decades and although atherosclerosis may be extensive by middle age, the
majority of such plaques are a latent presence in the vessel wall and remain
asymptomatic. However, a minority of plaques rupture, giving rise to the acute
cardiovascular syndromes such as unstable angina pectoris, myocardial infarction
and stroke (Davies 1995; Dalager-Pedersen et al. 1998; Gutstein and Fuster 1999;
Zhou et al. 1999; Corti and Badimon 2002; Mitra et al. 2004). What causes a given
plaque to rupture is still not fully understood, but current evidence points towards
inflammatory processes occurring within the plaque. Therefore, an urgent clinical
need exists to understand the processes underlying plaque rupture and to identify
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inflamed plaques so that drug intervention can be selectively targeted towards those
plaques with the greatest propensity to rupture.
Given that apoptosis of inflammatory cells is thought to be critical to the
successful resolution of the inflammatory response (Haslett 1997; Madema and
Godson 2003), and that inflammatory processes are implicated in both the
development of atherosclerotic plaques and their rupture, manipulation of
inflammatory cell apoptosis may hold the key to stabilising plaques, limiting their
development and preventing their rupture. However, because of the complicated
nature of atherosclerosis and the many different cell types present within plaques, it
is crucial to ensure that apoptosis is manipulated in a highly controlled manner. The
challenge, therefore, is to be able to distinguish, and selectively target, cells types
responsible for the demise of the plaque and whilst preserving those cell types
involved in maintaining plaque stability.
Use of NO as a means of inducing apoptosis in order to limit plaque
development and stabilise pre-existing lesions is a particularly attractive prospect
because in addition to aiding resolution of vascular inflammation via apoptosis, NO
possesses various additional anti-atherogenic properties such as inhibiting platelet
activation and aggregation, and promoting vasodilatation (Moncada et al. 1991;
Ignarro et al. 1999). However, NO radical readily forms other NO-related species
that have biological properties of their own, and these can be quite different to NO
per se. Formation of such NO-related species may account for the paradoxical
actions of NO reported in various settings. It is, therefore, crucial to understand the
precise nature of the NO-related species responsible for a particular process, and in
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order to use NO therapeutically, it is essential to ensure that NO is delivered in the
appropriate chemical form to induce the desired response.
This thesis has used a variety of synthetic putative NO donor compounds to
investigate differences between the actions of NO and NO-related species in cell
proliferation and viability in two of the major cell types of atherosclerotic plaques.
7.2 Summary
In order to investigate the disparate actions of NO and NO-related species,
exhaustive efforts were made to fully characterise the NO and NO-related species
generated by the putative NO donor compounds used in subsequent biological
investigations (chapter three). Using a combination of an isolated NO electrode and
EPR spectroscopy, diazeniumdiolate compounds were identified as fast and slow
release NO radical donors, DEA/NO and DETA/NO respectively. Contrary to initial
studies published on GEA-3162 (Kankaanranta et al. 1996; Holm et al. 1998), this
compound was found to co-generate NO and 02\ so should be regarded as a ONOO"
generator. Although the methods in chapter three did not identify the specific NO-
related species liberated by RS-N=0 compounds, they did rule out NO radical and
oxidising species as the main decomposition product of this class of compound. This
observation, considered in combination with previously published data on RS-N=0,
imply that transnitrosation reactions (transfer of NO+) are likely to account for the
biological actions of this group of compounds.
Somewhat surprisingly, the fundamental chemical composition of the
solution into which NO donor compounds were introduced significantly affected the
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concentration of NO generated, with a component of DMEM accelerating the
decomposition of all classes of compound. Although the specific component of
DMEM responsible for this acceleration was not identified, this observation
underlines the absolute requirement to conduct this type of preliminary
characterisation study in conditions closely modelling those used in subsequent
biological experiments. Furthermore, they suggest that the fate of NO in vivo might
be hard to predict, and therefore, it is crucial to be absolutely certain that any NO
donor compounds used therapeutically are able to deliver the precise NO-related
species necessary to achieve the desired response.
Studies examining the role of NO and NO-related species at concentrations
that might reasonably be expected in vivo, surprisingly demonstrated that only the
NO-related species, ONOO", had any impact on cell viability (chapters 4 & 5).
ONOO" was able to induce apoptosis in monocytes and monocyte-derived
macrophages, but also induced significant necrosis in VSMC. Although, ONOO"
appeared to inhibit VSMC proliferation, on further investigation this was found to be
due to a decrease in cell number as a result of necrotic cell death, and only a
prolonged release of NO radical was able to genuinely inhibit VSMC proliferation.
Contrary to previous reports (Assender et al. 1992; Newby et al. 1992; Garg and
Hassid 1993; Yu et al. 1997; Jeremy et al. 1999), RS-N=0 and short exposure to NO
radical and were unable to affect proliferation in VSMCs. Similarly, NO radical and
RS-N=0 did not induce apoptosis in VSMCs, monocytes or monocyte-derived
macrophages (figure 7.1 shows a summary of the findings of these experiments).
The main reasons for this contradiction between previously published data and that
presented in this thesis are likely to relate to both the concentrations of NO donor
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compounds involved and species origin of the cells examined. Most studies
reporting anti-mitogenic and pro-apoptotic actions of NO use significantly greater
concentrations of NO donor compound (usually >lmM) than those used in this thesis
(Albina et al. 1993; Sarih et al. 1993; Muhl et al. 1996; Bennett and Boyle 1998).
Such high concentrations of donor compound are likely to generate concentrations of
NO far in excess of the NO producing capacity of the healthy endothelium.
Previously published studies demonstrating that NO is capable of inducing
macrophage apoptosis have been conducted in rodent cells (both cell lines and
isolated peritoneal cells) rather than freshly isolated, terminally differentiated, human
macrophages used in thesis. Therefore, it might be argued that the results presented
in this thesis more realistically represent the in vivo actions of NO in humans, and
that many of the properties previously ascribed to NO do not occur under normal
physiological conditions.
Finally, experiments in chapter six demonstrated what might be considered a
physiologically relevant concentration of NO is able to trigger cGMP-dependent
protection against ONOO" -induced apoptosis in human monocyte- derived
macrophages, but is unable to protect VSMCs against ONOO" -induced necrosis
(figure 7.1). This phenomenon has been previously reported in rodent macrophages
where it has been proposed as a self-defence mechanism against the high iNOS-
derived NO generated by rodent cells (Albina et al. 1993; Sarih et al. 1993; Muhl et
al. 1996; Bennett and Boyle 1998; von Knethen et al. 1999; Yoshioka et al. 2003;
Pan et al. 2004). However, the cGMP-dependent protection against apoptosis
induced in human cells is unlikely to serve this purpose, because as experiments in
chapter five demonstrated, the monocyte-derived macrophages used in experiments
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in this thesis do not generate high levels of NO. In fact, one might predict that a self-
defence mechanism against high NO concentrations would be more likely, and more
necessary, in VSMCs, given that this cell type both produce NO themselves, and are
constantly exposed to NO generated by the endothelium. However, as discussed in
chapter four, VSMCs might be susceptible to apoptotic stimuli when the have
undergone phenotype alteration to the proliferative phenotype thought to dominate in
the VSMC population of atherosclerotic plaques. Therefore, it might be that in
healthy vessels VSMCs are exposed to only low concentrations of NO and are less



























Figure 7.1 Schematic Representation of the Actions of NO and NO-Related Species in
Human Monocyte-Derived Macrophages and BAoSMC
ONOO" induces apoptosis in monocyte-derived macrophages and necrosis in BAoSMC. A
prolonged delivery of NO radical inhibitions cell proliferation in BAoSMC. Low
concentrations of NO are able to active cGMP-dependent protection against ONOO -
induced apoptosis in monocyte-derived macrophages, but are unable to protect BAoSMC
against ONOO" -induced necrosis. NO radical does not induce apoptosis in either cell type,
and RS-N=0 compounds have no impact on cell proliferation or apoptosis in monocyte-
derived macrophages or BAoSMC.
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7.3 Clinical Implications for the
Treatment of Atherosclerosis
Although ONOO -mediated induction of apoptosis in inflammatory cells
within the plaque may be desirable as a means to reduce the inflammatory load in a
plaque and prevent rupture during the later stages of atherosclerosis, the cost of
decreasing the VSMC population of the plaque cap ONOO" -mediated necrosis is
likely to be too great in terms of de-stabilising the plaque and promoting rupture.
Unfortunately, these findings suggest that use of NO and NO-related species may not
be an appropriate therapy for atherosclerosis. However, the future development of
compounds with a greater degree of cell specificity may enable macrophage-specific
ONOO" generators to be used to this end. The macrophages resident in the plaque
core retain oxidised lipids and develop into lipid-laden foam cells. Therefore, one
possible means of achieving this higher degree of selectivity may be to exploit the
lipid nature of the foam cells by developing lipophilic compounds that would
accumulate in the core where selective induction of apoptosis might be beneficial.
Given that NO radical is non-toxic towards VSMCs it might be possible to use
lipophilic NO donor dmgs to deliver NO directly to the plaque core where the
environment of elevated oxidative stress would likely result in the formation of
ONOO". This might enable selective induction of apoptosis in the inflammatory cells
of the core whilst leaving the population of VSMC population unaffected. However,
two notes of caution must be bome in mind when considering this possibility.
Firstly, the accumulation of lipids within macrophages changes the nature of the cell
227
Chapter Seven - General Discussion & Future Directions
and it is unclear whether foam cells would respond in the same way as monocyte-
derived macrophages. Secondly, the success of inducing apoptosis to resolve
inflammation critically depends on efficient phagocytosis of apoptotic cells. The
identity of the cells responsible for the phagocytic clearance of apoptotic
macrophages remains to be established, but given that ONOO" induces apoptosis
both in undifferentiated monocytes and other types of inflammatory cells, such as
neutrophils, it is likely that ONOO" will also induce apoptosis in the population of
phagocytes. Removing phagocytosis will exacerbate the inflammatory response as a
result of secondary necrosis.
Unfortunately, the ability of NO to induce cGMP-dependent inhibition of
ONOO" -mediated apoptosis in monocyte-derived macrophages, but not VSMCs
means that a two-pronged strategy of delivering low concentrations of NO in
combination with ONOO" would be unsuccessful in terms of plaque stability.
7.4 Future Directions
This thesis has revealed some interesting insights into the disparate actions of
NO and NO-related species that might help explain some of the paradoxical actions
of NO previously reported. Whilst the effects of NO and NO-related species have
been explored in this thesis, the constraints of time did not permit investigations into
the mechanisms of these process.
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7.4.1 ONOO" -InducedApoptosis
Because apoptosis is such a tightly regulated, and cell specific process, it is
difficult to make comparisons about the mechanism of apoptosis between different
cell types. Therefore, the mechanism of ONOO" -induced apoptosis should be fully
investigated in human monocyte-macrophages. A crucial first step in this process
should be to identify the precise mediator of apoptosis. Results in chapter five
demonstrated that SOD increased ONOO" -induced apoptosis, suggesting that H2O2
is the final effector of apoptosis. This could be determined relatively simply by
treating cells with GEA-3162 in the presence of a combination of SOD and catalase
followed by flow cyotmetric analysis.
It would be of interest to identify the downstream mechanism of ONOO" -
induced apoptosis. A reasonable starting point would be to investigate if
*
mitochondrial depolarisation and cytochrome-c release precede apoptosis in human
monocyte-derived macrophages, as they have been reported to do in NO-induced
apoptosis in murine macrophages (Brown and Borutaite 1999; Hortelano et al. 1999;
Bal-Price and Brown 2000; Brown and Borutaite 2001; Brown and Borutaite 2002;
Maneiro et al. 2005). This can be done by use of fluorescent mitochondrial
permeable dyes such as JC-1, which can be detected by flow cytometry or visualised
under the fluorescent microscope. There are some technical considerations in
conducting this experiment in human monocyte-derived macrophages because these
cells adhere to tissue culture plates and are usually removed from the plates prior to
flow cytometric analysis by trypsin:EDTA solution. This is likely to disrupt
membrane potentials due to chelation of metal ions and so may give false results.
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One possible way to overcome this difficulty would be to culture the cells in
Teflon™ pots, which have been found by our group to resist cellular adhesion.
Examining the ratio of pro- to anti-apoptotic Bcl-2 proteins, and levels of
various caspase isoenzymes could further elucidate the mechanism of apoptosis.
This could be done by Western blotting techniques and, depending on the availability
of appropriate antibodies, the localisation of Bcl-2 proteins and caspases could be
visualised by immunofluorescence.
In the context of atherosclerosis, it would be interesting to investigate if the
pro-apoptotic actions of ONOO" apply to foam cells, as well as to macrophages.
Given that Toam cells are the major cellular component of the plaque core, inducing
apoptosis and subsequent phagocytosis in this cell type might be advantageous both
in terms of reducing the size, and the thrombogenicity, of the plaque. Lipid loading
is likely to change the characteristics of the cell considerably and therefore, they
might have altered responses to apoptotic stimuli.
7.4.2 NO Production Human Macrophages
The ability of human macrophages to generate NO has been debated for some
time (Albina 1995; Schneemann and Schoedon 2002). The results from thesis
(chapter five) demonstrate that NO production from LPS-stimulated monocyte -
derived macrophages isolated from peripheral blood is exceedingly low or absent.
However, as discussed in chapter five the stimulant used may have been insufficient.
It is worth pursuing this issue further for a definitive answer as whether or not these
cells produce NO, because this could have implications for various inflammatory
diseases, including atherosclerosis. Treating the cells with LPS in combination with
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a 'cocktail' of cytokines including TNF-a and interferon gamma (IFN-y) may
provide adequate stimulation. Additionally, the cells should be analysed for NOS
expression by Western Blot.
7.4.3 cGMP-DependentProtection AgainstApoptosis
The mechanism by which cGMP is able to confer protection on human
monocyte-derived macrophages should be further investigated in order to pin point
the precise signalling pathways involved. A number of potential pathways including
p38 MAP kinases, NF-kB signalling and protein kinase C activation leading to COX-
2 expression were discussed in chapter six. Commercially available kinase assays
could be used to assess the activity of various potential kinases in these pathways.
Western blotting could be used to detect kinase enzymes in their unphosphorylated
(inactive) and phosphorylated forms (active) forms. These pathways could also be
investigated pharmacologically using specific inhibitors of various potential
signalling enzymes. Finally, COX-2 as the ultimate inhibitor of apoptosis could be
confirmed by use of selective COX-2 inhibitors to abrogate cGMP-dependent
protection against apoptosis.
7.4.4 Phagocytic Clearance ofApoptoticMacrophages
Use of apoptosis to aid resolution of vascular inflammation in atherosclerosis
critically depends on the successful clearance of apoptotic cells from the site of
inflammation. The identity of the cells responsible for clearing apoptotic
macrophages has not been identified. It would be interesting to investigate if
macrophages themselves phagocytose populations of apoptotic macrophages, or
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whether this is done by a sub-set of specialised phagocytes. This could be
investigated by inducing apoptosis in a set of monocyte-derived macrophages
labelled with a fluorescent marker, and then introducing a second set of healthy
macrophages, labelled with a different fluorescent marker, to the culture. The cells
could then be analysed by flow cytometry and any healthy cells that had ingested
apoptotic cells would be double labelled.
Overall, these studies should provide further insights into the mechanisms of
action of NO and NO-related species. Identifying downstream signalling pathways
may enable specific pathways, or parts of pathways, to be targeted therapeutically.
Results presented in this thesis somewhat disappointingly suggest that NO or NO-
related species may not be able to selectively induce apoptosis in a particular cell
type during atherosclerosis without causing serious detrimental effects in other cell
types. However, identification of the downstream signalling pathways and ultimate
effectors of apoptosis may enable apoptotic pathways to be triggered whilst by¬
passing the detrimental effects in other cell types. Similarly, the development of
cell-specific NO donor compounds may allow selective targeting of pro-apoptotic
NO-related species directly to the macrophages within the plaque core, whilst
preserving the integrity of the VSMC cap.
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COMPONENTS Molecular Concentration Molarity
Weight (mg/L) (mM)
Amino Acids
Glycine 75 30 0.400
L-Arginine hydrochloride 211 84 0.398
L-Cystine 2HCI 313 63 0.201
L-Histidine hydrochloride-H20 210 42 0.200
L-lsoleucine 131 105 0.802
L-Leucine 131 105 0.802
L-Lysine hydrochloride 183 146 0.798
L-Methionine 149 30 0.201
L-Phenylalanine 165 66 0.400
L-Serine 105 42 0.400
L-Threonine 119 95 0.798
L-Tryptophan 204 16 0.0784
L-Tyrosine 181 72 0.398
L-Valine 117 94 0.803
Vitamins
Choline chloride 140 4 0.0286
D-Calcium pantothenate 477 4 0.00839
Folic Acid 441 4 0.00907
i-lnositol 180 7.2 0.0400
Niacinamide 122 4 0.0328
Pyridoxine hydrochloride 204 4 0.0196
Riboflavin 376 0.4 0.00106
Thiamine hydrochloride 337 4 0.0119
Inorganic Salts
Calcium Chloride (CaCI2-2H20) 147 264 1.80
Ferric Nitrate (Fe(N03)3"9H20) 404 0.1 0.000248
Magnesium Sulfate (MgS04-7H20) 246 200 0.813
Potassium Chloride (KCI) 75 400 5.33
Sodium Bicarbonate (NaHC03) 84 3700 44.05





D-Glucose (Dextrose) 180 4500 25.00












Glycine 75 30 0.400
L-Alanine 89 25 0.281
L-Arginine hydrochloride 211 84 0.398
L-Asparagine-H20 150 28.4 0.189
L-Aspartic acid 133 30 0.226
L-Cystine 240 70 0.292
L-Glutamic Acid 147 75 0.510
L-Glutamine 146 584 4.00
L-Histidine hydrochloride-H20 210 42 0.200
L-lsoleucine 131 105 0.802
L-Leucine 131 105 0.802
L-Lysine hydrochloride 183 146 0.798
L-Methionine 149 30 0.201
L-Phenylalanine 165 66 0.400
L-Proline 115 40 0.348
L-Serine 105 42 0.400
L-Threonine 119 95 0.798
L-Tryptophan 204 16 0.0784
L-Tyrosine disodium salt 225 104 0.462
L-Valine 117 94 0.803
Vitamins
Biotin 244 0.013 0.0000533
Choline chloride 140 4 0.0286
D-Calcium pantothenate 477 4 0.00839
Folic Acid 441 4 0.00907
i-lnositol 180 7.2 0.0400
Niacinamide 122 4 0.0328
Pyridoxal hydrochloride 204 4 0.0196
Riboflavin 376 0.4 0.00106
Thiamine hydrochloride 337 4 0.0119











Calcium Chloride (CaCI2-2H20) 147 219 1.49
Magnesium Sulfate (MgS04-2H20 176 200 1.14
Potassium Chloride (KCI) 75 330 4.40
Potassium Nitrate (KN03) 101 0.076 0.000752
Sodium Bicarbonate (NaHC03) 84 3024 36.00




Sodium Selenite (Na2SeO3-5H20) 263 0.0173 0.0000658
Other Components
D-Glucose (Dextrose) 180 4500 25.00
HEPES 238 5958 25.03
Phenol Red 376.4 15 0.0399
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Nitric oxide and the resolution of inflammation: implications for
atherosclerosis
Catherine A Shaw, Emma L Taylor*, Ian L Megson, Adriano G Rossi*/+
Centre for Cardiovascular Science, Hugh Robson Building, George Square *MRC Centre for Inflammation Research,
University ofEdinburgh, Teviot Place, Edinburgh, Scotland. UK
The ubiquitousfree radical, nitric oxide (NO), plays an important role in many biological processes including
the regulation of the inflammatory response. Alterations in NO synthesis by endogenous systems likely influence
inflammatory processes occurring in a wide range of diseases including many in the cardiovascular system (e.g.
atherosclerosis). Progression of inflammatory conditions depends not only upon the recruitment and activation of
inflammatory cells but also upon their subsequent removalfrom the inflammatory milieu. Apoptosis, orprogrammed
cell death, is afundamental process regulating inflammatory cell survival and is critically involved in ensuring the
successful resolution ofan inflammatory response. Apoptosis results in shutdown ofsecretory pathways and renders
effete, but potentially highly histotoxic, cells instantly recognisable for non-inflammatory clearance by phagocytes
(e.g., macrophages). However, dysregulalion of apoptosis and phagocytic clearance mechanisms can have drastic
consequencesfor development and resolution of inflammatory processes. In this review we highlight the complexi¬
ties ofNO-mediated regulation ofinflammatory cell apoptosis and clearance by phagocytes and discuss the molecu¬
lar mechanisms controlling these NO mediated effects. We believe that manipulation ofpathways involving NO may
have previously unrecognised therapeutic potential for limiting or resolving inflammatory and cardiovascular
disease.
Key words: nitric oxide - apoptosis - inflammation - resolution
The inorganic free radical, nitric oxide (NO), was first
identified as an endothelium-derived endogenous mes¬
senger responsible for the regulation of vascular tone
(Furchgott & Zawadzki 1980, Palmer etal. 1987). How¬
ever, since then it has become clear thatNO is the signal¬
ling molecule responsible for several diverse physiologi¬
cal and pathophysiological processes. Synthesised from
L-arginine by three isoforms of the enzyme nitric oxide
synthase (NOS), NO is now known to control vascular
smooth muscle tone, inhibit platelet and inflammatory cell
adhesion and activation, and to be a transmitter at non-
adrenergic non-cholinergic (NANC) synapses (Moncada
et al. 1991, Quinn et al. 1995). Recent studies have re¬
vealed that NO can also modulate apoptosis, or pro¬
grammed cell death, in a variety of cell types, including
human inflammatory cells (Tayloretal. 2003). Apoptosis
of inflammatory cells is a highly regulated process whereby
cellular death occurs without the disruption of the cell
membrane and subsequent release of the pro-inflamma¬
tory and histotoxic contents of the dying cell (Haslett
1997, Rossi et al. 2003). Apoptotic cells are instantly
recognised and ingested by phagocytes, such as mac¬
rophages, using mechanisms that down-regulate pro-in¬
flammatory mediator release and increase the release of
agents with anti-inflammatory potential from the ingest¬
ing cell (Meagher et al. 1992, Fadok et al. 1998, Liu et al.
1999). Hence, apoptosis represents a non-inflammatory
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mechanism to remove potentially damaging pro-inflam¬
matory cells from the site of inflammation and is therefore
critical to the successful resolution of the inflammatory
response. Pharmacological manipulation of the rate of
apoptosis in inflammatory cells, such as granulocytes and
macrophages, may represent a potential therapeutic strat¬
egy for the treatment of chronic inflammatory disorders
(Ward etal. 1999, Gilroy etal. 2004).
NO can be both pro- and anti-apoptotic, depending
on local concentrations and the specific cell type in ques¬
tion (Quinn et al. 1995, Kim etal. 1999, Taylor etal. 2003).
Current evidence suggests that lower concentrations of
NO produced by the constitutive endothelial and neu¬
ronal isoforms ofNOS (eNOS and nNOS) are cytoprotec-
tive, whilst supraphysiological concentrations produced
by the inducible NOS isoform (iNOS) trigger cell death
(Nicotera et al. 1997). This paradox may be explained, at
least in part, by the free radical nature ofNO and hence
the ease with which it will react with other radicals, par¬
ticularly reactive oxygen species, present in the milieu to
form various NO-related species in vivo. For example,NO
combines rapidlywith inflammatory cell derived superox¬
ide anions (02") to form highly cytotoxic peroxynitrite
(ONOO ) (Maxwell & Lip 1997).
NO as a mediator of inflammatory cell apoptosis
The pro- and anti-apoptotic actions ofNO have been
well documented in many cell systems. For example, high
concentrations ofeither exogenous or endogenous iNOS-
derived NO have been shown to induce apoptosis in mu¬
rine macrophage cell lines (Albina et al. 1993, Sarih et al.
1993). However, pre-treatment with low concentrations
of exogenous NO protects RAW 264 cells against cell
death upon subsequent exposure to higher concentra-
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tions ofNOwhich would normally be cytotoxic (Yoshioka
et al. 2003). However, despite the apparent reduced ca¬
pacity of human macrophages in comparison to murine
macrophages (Albina 1995, Schneemann & Schoedon
2002), to generate iNOS derived NO (Thomassen &
Kavuru 2001), human macrophages do undergo apoptosis
in response to exogenous NO. For example, the NO do¬
nors, S-nitrosoglutathione (GSNO), and spermine
diazenium diolate (SPER/NO) induce apoptosis in primary
human monocyte-derived macrophages (von Knethen et
al. 1999). Exogenously deliveredNO fromNO donors (e.g.,
sodium nitroprusside; SNP and GSNO) induce apoptosis
in human neutrophils (Fortenberry et al. 1999, Singhal et
al. 1999). However, it has also been established that NO
may have anti-apoptotic potential in neutrophils; low con¬
centrations of NO generated from the spontaneous NO
donors, SPER/NO and DEA/NO, reduce the rate of neu¬
trophil apoptosis (Taylor et al. 2001). In contrast, the
same study showed that the oxatriazole derivative, GEA-
3 162, at equivalent concentrations produced no such in¬
hibition. However, it was demonstrated that GEA-3 162
decomposes to co-generate both NO and 02", which then
react to form ONOO" (Taylor et al. 2004). This suggests
that the pro- or anti-apoptotic effects ofNO may be criti¬
cally governed by the specific NO-related species gener¬
ated.
Interestingly, the production ofONOO" may be ofpar¬
ticular importance at sites of inflammation where the con¬
centration of reactive oxygen species is likely to be el¬
evated (Crow & Beckman 1995). However, the precise
role ofONOO" in inflammatory cell apoptosis remains to
be fully elucidated. There is some evidence to suggest
that ONOO" at high concentrations increases apoptosis
in murine RAW 264.7 cells (Sandoval et al. 1997), whilst at
lower concentrations it may have a protective effect
against lipopolysaccharide (LPS) and interferon (IFN)-y-
induced apoptosis in these cells (Scivittaro et al. 1997). A
scavenger ofONOO", uric acid, had no effect on apoptosis
induced by the NO donors GSNO or SPER/NO in RAW
264.7 macrophages, but abolished apoptosis induced by
the ONOO" generator SIN-1, suggesting that ONOO" is a
mediator of apoptosis, at least not in this cell type
(Brockhaus & Brune 1999).
As is the case with macrophages, there are conflicting
reports about the ability ofONOO" to induce or suppress
apoptosis in neutrophils. Several investigators have dem¬
onstrated that SIN-1 and GEA-3162 increases the rate of
apoptosis in human neutrophils (Blaylock et al. 1998,Ward
et al. 2000, Taylor et al. 2004). Conversely, Blaylock et al.
(1998) reported SIN-1 produced no significant increase in
neutrophil apoptosis. However, this may be due to ex¬
perimental differences and the exact amounts of ONOO"
present rather than a true difference in the effect of ONOO"
(Taylor et al.2003).
NO and apoptosis in the resolution of inflammation
The ability ofNO to induce apoptosis is particularly
relevant during the resolution phase of inflammation. In a
mouse model ofkidney inflammation, activated macroph¬
ages have been shown to induce apoptosis in neigh¬
bouring mesangial cells priorto their ingestion by phago¬
cytes (Duffield et al. 2000). The ability of these activated
macrophages to induce apoptosis is greatly reduced in
the presence oftheNOS inhibitorN-E-monomethyl-L-argi-
nine (L-NMMA), suggesting that macrophage-directed
apoptosis of mesangial cell apoptosis occurs via a NO-
dependent mechanism (Duffield et al. 2001). Similarly,
several studies have demonstrated that activated mac¬
rophages infiltrating murine tumours induce apoptosis via
a NO-dependent pathway in both activated anti-tumour T
cells and in the tumour cells themselves (Saio et al. 2001,
Chattopadhyay et al. 2002). Thus, it appears that mac¬
rophages have the capacity to induce apoptosis of nearby
cells by the liberation ofNO to enhance the clearance of
apoptotic cells and thereby promote the resolution phase
of inflammation (Figure).
Mechanism ofaction ofNO
The classical pathway by which NO exerts many of its
actions is via activation of the enzyme soluble guanylate
cyclase (sGC) (Moncada et al. 1991) and resultant con¬
version of guanosine 5'-triphosphate (GTP) to the sec¬
ond messenger 3', 5'-cyclic guanosine monophosphate
(cGMP)(Ignarroetal. 1999). However, recent studies have
established that NO can also act via cGMP-independent
pathways in various systems, particularly during the inhi¬
bition ofplatelet aggregation and regulation of inflamma¬
tory cell apoptosis (Gordge et al. 1998, Sogo et al. 2000,
Ward et al. 2000, Crane et al. 2002).
It is generally thought that lower concentrations of
NO inhibit apoptosis via cGMP-dependent mechanisms,
whilst higher concentrations are cytotoxic on account of
cGMP-independent signalling. For example, Yoshoka et
al. (2003) demonstrated that pre-treatment of RAW 264
cells with a low concentration of the NO donor SNP, in¬
hibited cell death upon subsequent exposure to higher
concentrations of NO. This protection was negated in
the presence ofsGC inhibitors and could be mimicked by
cGMP analogues, suggesting that the cellular protection
was conferred by cGMP.
Conversely, at higher concentrations, NO has been
shown to induce apoptosis in rabbit macrophages - an
effect which was unaffected by antagonism ofcGMP-de-
pendent kinases and not mimicked by cGMP analogues,
suggesting that the pro-apoptotic action ofNO is cGMP-
independent (Wang et al. 1999). The peroxynitrite genera¬
tors, SIN-1 and GEA-3162, have also been shown to pro¬
duce a marked concentration-dependent induction of
apoptosis in isolated human neutrophils (Ward et al. 2000).
Again, this induction was unaffected by inhibitors ofsGC,
and cGMP analogues failed to elicit a pro-apoptotic re¬
sponse suggesting that a mechanism independent of
cGMP signalling also featured in neutrophils. Interest¬
ingly, superoxide dismutase (SOD), the enzyme respon¬
sible for converting 02" to hydrogen peroxide (H202),
antagonised the actions of SIN-1 and GEA-3162, whilst
"authentic" peroxynitrite mimicked their effects. This re¬
sult may, therefore, highlight the critical importance of
NO-related species in determining an anti- or pro-apoptotic
response, with the final outcome depending on the bal¬
ance between reactive oxygen and nitrogen species.
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Atherosclerosis
Atherosclerosis is a multi-factorial condition with a
complicated aetiology, and, in combination with the asso¬
ciated cardiovascular syndromes, such as myocardial in¬
farction and stroke, is a major cause of morbidity and
mortality. However, it is nowwidely recognised that there
is an inflammatory component to the disease pathogen¬
esis and progression (Ross 1999a, b, Ludewig et al. 2002).
Atherosclerosis is characterised by the development
of lipid-rich atherosclerotic plaques in the subendothelial
space of conduit vessels, such as the coronary artery and
aorta (Badimon et al. 1993). These plaques are usually
eccentric, with the lipid rich core encapsulated by a fi¬
brous, collagen-rich cap ofsmooth muscle cells and extra¬
cellular matrix (Davies 1997). The underlying causes of
atherogenesis remain largely unknown, although a criti¬
cal early stage is thought to be an insult to the endothe¬
lium, either physical or through oxidative stress. The con¬
sequences ofthis insult are multiple; firstly, in contrast to
the situation in healthy endothelium, the injured endot¬
helium becomes dysfunctional and production ofNO by
eNOS decreases, promoting vasoconstriction and plate¬
let and inflammatory cell adhesion. Secondly, a protective
inflammatory response is triggered. However, depending
on the nature and duration of the insult, this protective
response becomes excessive and over a period of years,
comes to constitute the disease process itself (Ross 1999a,
b). The inflammatory process begins with the expression
of chemotactic and adhesion molecules for monocytes
and lymphocytes, such as vascular cell adhesion mol¬
ecule 1 (VCAM-1), on dysfunctional endothelial cells.
Circulating monocytes adhere to the site of endothelial
damage and translocate to the sub-endothelial space
(Vogel 1997). Colony stimulating factors secreted from
areas of endothelial damage induce monocytes to differ¬
entiate into macrophages, which then express scavenger
receptors on their membranes, facilitating the in-
ternalisation ofoxidised low density lipoprotein (ox-LDL).
The accumulation of ox-LDL continues unchecked as,
unlike LDL receptors, scavenger receptors are not down-
regulated by cells in the cholesterol-replete state (Max¬
well & Lip 1997). In this lipid-laden state, macrophages
are known as foam cells and it is an aggregation of these
foam cells in the vessel intima which form the earliest
recognisable lesion of atherosclerosis — the fatty streak
(Ross 1993). The plaque continues to grow via the accu¬
mulation of further macrophage foam cells and eventually
becomes overlaid with a layerofsmooth muscle cells form¬
ing a fibrous, collagen-rich cap. The cap serves to keep
the highly thrombogenic contents of the plaque separate
from the circulation. However, if the plaque cap is com¬
promised and the contents exposed to the circulation,
platelets are rapidly recruited and activated resulting in
thrombus formation, leading to the more serious acute
cardiovascular syndromes (Badimon et al. 1993).
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High concentrations of nitric oxide (NO) synthesised by iNOS in phagocytes, such as macrophages, induce apoptosis in neighbouring cells.
In addition, apoptosis can also be induced by ONOO" generated as 02" produced by phagocytes reacts with NO. Apoptotic cells are
subsequently recognised and ingested by phagocytes, thus aiding the resolution of inflammation. Conversely, low concentrations of NO
produced constitutively by eNOS in endothelial cells can inhibit apoptosis.
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Inflammatory cell apoptosis in atherosclerosis
Recruitment of inflammatory cells, particularly mono¬
cytes and macrophages, is the major driving force behind
plaque growth and development. However, the plaque is
dynamic and inflammatory cells are constantly turning
over within the core. It is well established that apoptotic
cells, particularly macrophages, are present in atheroscle¬
rotic plaques in both human and animal models of the
disease. Apoptotic macrophages and smooth muscle cells
have been identified by TUNEL staining in sections from
human plaques by various authors (Bjorkerud & Bjorkerud
1996, Haunstetter & Izumo 1998). Because apoptotic cells
are ingested by phagocytes without initiating any further
proinflammatory response, it has been suggested that
apoptosis may represent a mechanism to regress the
plaque. NO is a particularly promising candidate fortius
strategy because, as well as the pro-apoptotic actions
discussed above, it has several other powerful antiathero¬
genic characteristics including a powerful inhibitory ef¬
fect on platelet and inflammatory cell activation (Moncada
etal. 1991, Armstrong 2001). Evidence is emerging in sup¬
port ofthis hypothesis. For example, administration ofL-
arginine (the substrate for NOS) to hypercholesterolemic
rabbits increases the number of apoptotic macrophages
in intimal lesions by three fold. This increase in apoptosis
was associated with a regression of the plaque, suggest¬
ing that manipulation of the NO synthase pathway may
well represent a therapeutic approach to resolving the
inflammatory response in the vessel wall (Wang et al. 1999).
However, care must by exercised when considering this
approach because NO is also known to induce apoptosis
in smooth muscle cells (Labelle et al. 2004). Loss ofcells
from the fibrous cap during the latter stages of athero¬
sclerosis maywell be detrimental, destabilising the plaque
and promoting rupture (Kockx & Knaapen 2000)
Conclusion
Apoptosis of inflammatory cells is a tightly regulated
processwhereby cells are removed from the site of inflam¬
mation without triggering a subsequent pro-inflammatory
response that would instigate further tissue injury. Phar¬
macological manipulation of apoptosis during chronic
inflammatory conditions, such as atherosclerosis, may aid
the resolution of inflammation and hence halt, or delay,
disease progression. The ubiquitous signalling molecule
and inducer of apoptosis, NO, is a likely candidate for
such manipulation and may represent a novel therapeutic
target for the treatment of such conditions.
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GEA 3162 decomposes to co-generate nitric oxide
and superoxide and induces apoptosis in human neutrophils
via a peroxynitrite-dependent mechanism
'Emma L. Taylor, *'Adriano G. Rossi, 2Catherine A. Shaw, 2Francesco P. Dal Rio,
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'Centre for Inflammation Research, Rayne Laboratory, Medical School, University of Edinburgh, Teviot Place, Edinburgh
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1 GEA 3162 (1,2,3,4,-oxatriazolium, 5-amino-3-(3,4-dichlorophenyl)-chloride), has powerful effects
on neutrophil function and apoptosis, but the underlying mechanisms are unclear, particularly with
respect to the possible roles of nitric oxide (NO) and/or peroxynitrite (ONOO-).
2 Our hypothesis was that GEA 3162 is a generator of ONOO- and that its biological effects on
neutrophil apoptosis differ from those of a conventional NO donor. The effects of GEA 3162 were
compared to those of the established ONOO- donor, 3-morpholinosydnonimine (SIN-1), and the NO
donor, diethylamine diazeniumdiolate (DEA/NO) in neutrophils from healthy volunteers. Electro¬
chemical detection and electron paramagnetic resonance were used to define the NO-related species
generated from these agents.
3 GEA 3162 and SIN-1 influence neutrophil apoptosis differently from DEA/NO. All three
compounds induced morphological neutrophil apoptosis. However, both GEA 3162 and SIN-1
paradoxically inhibited internucleosomal DNA fragmentation, whereas DEA/NO induced fragmenta¬
tion compared to control.
4 In contrast to DEA/NO, generation of free NO was not detectable in solutions of GEA 3162
or SIN-1 (lOOjtiM). However, Cu/Zn superoxide dismutase (SOD; 50-750 Uml-1) unmasked NO
generated from these compounds in a concentration-dependent manner. GEA 3162 and SIN-1
oxidised the 02- and ONOO-sensitive dye, dihydrorhodamine 123 (DHR 123; 1 /iM), suggesting that
ONOO released from these compounds is responsible for oxidation of DHR 123.
5 We conclude that GEA 3162 is an ONOO" donor with pro-apoptotic properties that more closely
resemble SIN-1 than the NO donor, DEA/NO. Moreover, unlike NO, ONOO induces apoptosis in
neutrophils via a mechanism that does not require DNA fragmentation.
British Journal of Pharmacology (2004) 143, 179-185. doi: 10.1038/sj.bjp.0705909
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Abbreviations: DEA/NO, diethylamine diazeniumdiolate; DHR 123, dihydrorhodamine 123; EPR, electron paramagnetic
resonance; GEA 3162, 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-dichlorophenyl)-chloride; H202, hydrogen peroxide;
HOC1, hypochlorous acid; IMDM, Iscove's modified Dulbecco's medium; NO, nitric oxide; NOS, nitric oxide
synthase; 02, superoxide anion; ONOO-, peroxynitrite; PBS, phosphate-buffered saline; PI, propidium iodide;
PMA, phorbol 12-myristate 13-acetate; SIN-1, 3-morpholinosydnonimine; SOD, superoxide dismutase
Introduction
Nitric oxide (NO) is a free radical that was originally identified
as an endogenous endothelium-derived vasodilator (Furchgott
& Zawadzki, 1980; Palmer et al., 1987), but is now recognised
to have a role in a large number of other physiological and
pathophysiological processes, including haemostasis, neuro¬
transmission and inflammation (Quinn et al., 1995). The role
of NO in inflammation is particularly complex, with macro¬
phages in particular capable of generating high levels of NO
through promotion of transcription factor activity and
consequent expression of the unregulated, inducible isoform
of NO synthase (iNOS) in response to inflammatory stimuli
'Author for correspondence; E-mail: a.g.rossi@cd.ac.uk
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(Hecker et al., 1996). The primary role of iNOS-derived NO is
accepted to be that of a powerful antipathogenic agent, but it
is also clear that NO has a complex impact on apoptosis
(Dimmeler & Zeiher, 1997; Kim et al., 1999; Taylor et al.,
2003), a physiological form of cell death which eliminates
effete or unhealthy cells. The issue is further complicated by
the rapid reaction of NO with superoxide anion (Of) to form
the powerful oxidising agent, peroxynitrite (ONOO-; Kelm
et al., 1997).
Despite NO and ONOO- sharing several biological proper¬
ties (Ronson et al., 1999; Low et al., 2002), including an ability
to induce apoptosis (Taylor et al., 2003), key differences have
been noted in their biological effects and mechanisms of
action. For example, although both NO and ONOO- are
180 E.L. Taylor et at GEA 3162, peroxynitrite and neutrophil apoptosis
capable of blocking mitochondrial respiration, they do so
through inhibition of different complexes in the respiratory
chain and their effects are differentially susceptible to reversal
by thiols and carbohydrates (Lizasoain et al., 1996). These
differences highlight the importance of the accurate identifica¬
tion of the nature of the species generated by the so-called
'NO donors'; ONOCL generated as a result of concomitant
release of NO and 02 may exert effects that are similar but
mechanistically distinct from pure NO in biological
systems. To date, however, little is known about potential
differential effects of NO and ONOCL on inflammatory cell
apoptosis.
GEA 3162 is an oxatriazole-5-imine derivative with
vasodilator (Nurminen & Vapaatalo, 1996) and pro-apoptotic
(Ward et al., 2000; Taylor et al., 2001) properties. However,
its identity as a 'pure' NO donor is controversial (Kankaan-
ranta et al., 1996; Holm et al., 1998; Schmidt et al., 2001).
In this study, we set out to establish the identity of the
NO-related species generated from GEA 3162, and to
compare its biological properties to an established NO donor
(diethylamine diazeniumdiolate; DEA/NO) and an ONOO~
donor (SIN-1) with respect to neutrophil apoptosis. All
the three compounds have previously been shown to
accelerate the rate of programmed cell death in neutrophils
in vitro (Blaylock et al., 1998; Ward et al., 2000; Taylor el al.,




Neutrophils were isolated from the blood of healthy volunteers
as described previously (Ward et al., 1999a). Briefly, whole,
citrated blood was centrifuged (200 x g, 20min) and platelet-
rich plasma aspirated. Leukocytes were separated from
erythrocytes by dextran sedimentation, then further divided
into mononuclear cell and granulocyte populations by
centrifugation through a discontinuous Percoll gradient
(720 x g, 20min). Granulocytes were harvested from the
79:68% interface of the gradient, and only neutrophil
preparations of ^95% purity were used. Neutrophil prepara¬
tions were tested for cellular homogeneity by preparation of a
cytospin slide (100p\ of cell suspension, 300r.p.m., 3min),
which was then stained and examined by oil-immersion light
microscopy, with at least 500 cells counted. The percentage
of contaminating leukocytes (eosinophils, monocytes and
lymphocytes) was then calculated and the cell preparation
was discarded if levels of contamination reached or exceeded
5% of the total cell population.
Apoptosis studies
Neutrophils (4.5 x 106 cellsmL1) were suspended in Iscove's
modified Dulbecco's medium (IMDM; Life Technologies,
Paisley, U.K.) containing penicillin (100 Uml1) and strepto¬
mycin (lOO^gmL1), and supplemented with 10% (vv~')
autologous serum. They were cultured in flat-bottomed 96-
well Falcon polypropylene plates (37°C, 5% C02) for 1-20 h in
the presence of either phosphate-buffered saline (PBS) at pH
7.4 (controls) or NO donors (100/xM-3 mM). The concentra¬
tions of NO donors used in these studies were selected
on the basis of previously published data (Taylor et al.,
2001), which have been shown to modulate neutrophil
apoptosis.
Following incubation, 100/tl of recovered cells were
cytocentrifuged in duplicate, fixed in methanol and stained
using Diff-Quik™ physiological stain, then observed by light
microscopy ( x 100 objective) to determine the proportion of
darkly stained cells with condensed nuclei. At least 500 cells
per slide were counted, with the observer blinded to the
experimental conditions.
A further 100 /zl of recovered cells were centrifuged (200 x g,
3min), then fixed and permeabilised in 70% ethanol (4°C,
lOmin). The cells were washed ( x 3) in PBS without Ca2 + /
Mg2+ before addition of 60p\ RNase A (0.5mgml_1) and 60 pi
propidium iodide (PI; O.lmgml"1), then assessed by flow
cytometry using an EPICS XL2 (Coulter Electronics, Luton,
U.K.), to measure DNA fragmentation.
Dihydrorhodamine 123 studies
Dihydrorhodamine 123 (DHR 123) is a fluorescent dye which
is activated by various reactive oxygen species, including
ONOO-, Oj, hydrogen peroxide (H202) and HOC1, but not
by NO (Crow, 1997). This compound can therefore be used to
discriminate between agents that release NO only and those
that generate NO and 02 simultaneously.
PBS (100/il), the neutrophil-activating agent, phorbol 12-
myristate 13-acetate (PMA; final concentration 10 nM), SIN-1
(1 mM), GEA 3162 (100//M) or DEA/NO (1 mM) was added to
900/d PBS in 2ml Eppendorf tubes. DHR 123 was added to
each tube to a final concentration of 1 pM. Tubes were
incubated for 60min (37°C, 5% C02). A volume of 450/d was
then transferred to a 0.5 ml cuvette, excited at 480 nm and the
fluorescence emitted at 500 nm was read using a spectro-
fluorimeter (Perkin Elmer, U.K.).
Electrochemical detection ofNO
Free NO from GEA 3162 or SIN-1 (both 100 ^M) and IDEA/
NO (5 ^M) was measured in Iscove's MDM cell culture
medium using an NO electrode (Iso-NO II, World Precision
Instruments) calibrated daily with DEA/NO (0.1-1.6pM) in
pH 4 buffer. Superoxide dismutase (SOD; 50-750 U mL1) was
added cumulatively in an effort to unmask NO generated from
these agents (Lizasoain et al., 1996), and the concentration of
NO was measured at plateau approx. 5min following SOD
addition.
Electron paramagnetic detection ofOl and ONOO
Spin-trapping experiments were performed in Iscove's MDM
cell culture medium containing 100^M SIN-1, GEA 3162 or
DEA/NO in the presence or absence of SOD (500 U ml"1), and
the spin trap Tempone-H (ImM) (Dikalov et al., 1997)
prepared in water containing EDTA (10mM). Reaction
mixtures were incubated at 37°C throughout the experiments
and the intensity of the electron paramagnetic resonance
(EPR) signal corresponding to the formation of 4-oxo-Tempo
(triplet centred at 3364G) was measured (arbitrary units) at
timed intervals for each of the donor drugs (Magnettech®
miniscope MS100 with the following parameter settings: field
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sweep 51.2G, microwave frequency 9.5GHz, microwave
power 20 mW, modulation amplitude 1500mG). In control
experiments without any NO-generating compounds present,
there was a slow increase in EPR signal corresponding to the
auto-oxidation of Tempone-H to 4-Oxo-Tempo; these signals
have been subtracted from the data shown.
Statistical analysis
Data were assessed for statistical significance using two-way
analysis of variance (ANOVA) with a Student-Neuman-Keuls
post-test. Probability values of PC0.05 were considered
statistically significant.
Results
Electrochemical detection of DEA/NO-derived NO revealed
that this compound liberated free NO in a spontaneous and
predictable manner. A bolus addition of DEA/NO (5/tm)
to culture medium caused a rapid transient rise in NO
concentration, reaching a maximum of ~5/tm, before subsid¬
ing over the subsequent 30min (Figure la). The signal was not
altered by incubation with SOD (150 Umf1), but the rate of
decay of the NO signal was markedly enhanced in the presence
of neutrophils (5 x 106mF'; Figure la). SOD (150Uml ')
failed to increase the signal seen with neutrophils; instead,
it caused a significant and surprising inhibition of NO
generation.
In contrast to DEA/NO, NO was not detectable from GEA
3162 (100/rM) in medium. However, NO generation from this
agent was detected in the presence of SOD (15011ml-1), with
maximal NO concentrations reaching ~ 3 ytM after 30min
incubations (Figure lb). In the presence of neutrophils
(5xl0''ml ') and SOD (150Uml '), NO generation was
markedly attenuated for incubation periods of >10 min. NO
generation bore a nonlinear relationship to SOD concentration
for both GEA 3162 and SIN-1 (Figure lc), and there was no
significant difference between the two agents under these
conditions (P>0.05).
Results from EPR spectroscopy identified a signal
corresponding to 4-oxo-Tempo formation from the reduced
form of the spin-trap, Tempone-H, after incubation with
GEA 3162 or SIN-1 (Figure 2a). The intensity of the
signal obtained with both GEA-3162 and SIN-1 was
dependent on the incubation time and was severely attenuated
in the presence of SOD (500Umf'). DEA/NO failed to
generate a significant signal under the same conditions
(Figure 2b).
Assessment of the oxidation of DHR 123 to fluorescent
rhodamine 123 using a spectrofluorimeter showed that both
SIN-1 (1 mM) and GEA 3162 (100/rM) produced high levels of
fluorescence (803 + 74 and 757+ 100U, respectively; P<0.05;
n = 3) compared to control (PBS alone, 23 + 5U; Figure 3). In
contrast, DEA/NO failed to significantly oxidise DHR 123
(53 + 9 U; n = 3). None of the compounds alone (in the absence
of DHR 123) produced a fluorescent signal that exceeded 1.0
arbitrary units (data not shown), thus excluding autofluores-
cence as a possible explanation for the differential fluorescence
observed.
High concentrations of DEA/NO (1 mM) and GEA 3162
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Figure 1 Measurement of NO release from DEA/NO, SIN-1 and
GEA 3162 in the absence and presence of neutrophils and/or SOD.
Mean NO electrode recordings for (a) DEA/NO (5/iM) and (b)
GEA-3162 (100 ;rM) in Iscovc's medium, in the presence and absence
of human neutrophils (4.5 x 106cells m+). NO release from GEA
3162 was not detectable in the absence of SOD (150UmF').
Concentrations of NO were calculated using a calibration curve
generated using DEA/NO (100nMl.6yrM) in pH 4 buffer. Results
are mean + s.e.m. (n = 6). (c) Generation of NO by SIN-1 and GEA
3162 (both 100ixm) in the presence of SOD (50-750Uml '). Data
represent NO concentrations at plateau approx. 5min following
addition of SOD. Results are mean+ s.e.m. (n = 6).
neutrophil apoptosis over a 20-h time course compared to
untreated controls (Figure 4a). Approximately 50-60% of
control cells underwent spontaneous apoptosis during the
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Figure 2 Generation of Oy/ONOO- by donor drugs, (a) Repre¬
sentative EPR spectra showing the signal generated through
oxidation of Tempone-H (imm) by Oy/ONOO- after incubation
(30 min, 37°C) with SIN-1, GEA 3162 and DEA/NO (all 100//M) in
the presence or absence of SOD (500 U ml-1). Control spectra of
Iscove's medium and 1 niM Tempone-H have been subtracted from
each trace, (b) Relative intensities (arbitrary units) for EPR signals
generated over time in the presence of SIN-1, GEA-3162 or DEA/
NO (100/rm) in the presence or absence of SOD (500 Uml-1).
Results are mean+ s.e.m. (n = 6).
culture period, whereas those treated with either compound
were virtually all apoptotic. However, when internucleosomal
DNA fragmentation was assessed by flow cytometric measure¬
ment of PI intercalation, key differences were observed
between the two compounds. Whereas DEA/NO increased
DNA fragmentation compared to control, GEA 3162 pro¬
duced an unexpected inhibition of this process (Figure 4b).
The effects of 1-3 mM SIN-1 on morphology and DNA
fragmentation at 20 h were then studied in order to determine
how ONOO- influences these apoptotic events in neutrophils.
This compound had effects similar to GEA 3162 but opposing
effects to DEA/NO, in that a concentration-dependent
inhibition of DNA fragmentation occurred alongside an
induction of apoptotic morphology (Figure 4c).
1000 -i
PBS SIN-1 DEANO GEA 3162
Figure 3 Spectrofluorimetric assessment of DFIR 123 oxidation.
DHR 123 (1 fiM) was added to solutions of PBS (control), SIN-1
(1 mm), DEA/NO (1 mm) or GEA 3162 (100 /im) and incubated for
60 min at 37°C. The extent of DHR 123 oxidation to rhodamine 123
was assessed using a spectrofluorimeter at an emission wavelength
of 500 nm. Results are mean + s.e.m. (n = 3). Asterisks represent
significant difference (P< 0.05) from control fluorescence.
Discussion
Our results show that the oxatriazole-5-imine-derived com¬
pound, GEA 3162, generated an oxidising species that induced
apoptosis in human neutrophils via a mechanism that was
independent of DNA fragmentation. Similar results were
obtained with the known ONOO- generator, SIN-1, but the
NO donor, DEA/NO, failed to generate an oxidising species,
and apoptosis induction in response to this agent was
associated with increased DNA fragmentation. Further
experiments to determine the NO-related species generated
from these agents established that GEA 3162 and SIN-1
concomitantly generate NO with 02, resulting in rapid
formation of ONOO-. The NO component was unmasked
by removal of 02 by high concentrations of the enzyme, SOD.
These results were in common with those of the recognised
ONOO- generator, SIN-1 (Hogg et al., 1992), but were at odds
with the NO donor drug, DEA/NO (Maragos et al., 1991),
which was found to generate NO in the absence of 02
scavenger systems, and did not oxidise Tempone-H to generate
an EPR signal.
Previous studies have suggested that GEA 3162 does not
liberate 02 alongside NO; therefore it was suggested to be
a 'pure' NO donor (Holm et al., 1998). However, in contrast,
recent preliminary data have indicated that GEA 3162
resembles SIN-1, in that both compounds simultaneously
generate NO and Oj and are therefore both ONOO- donors
(Schmidt et al., 2001). Given that SIN-1 is accepted to be an
ONOO donor (Hogg et al., 1992), while DEA/NO generates
pure NO (Maragos et al., 1991), our results suggest that
ONOO- is a requirement for the inhibition of DNA frag¬
mentation and implies that GEA 3162 is also an ONOO-
generating agent. We therefore carried out a number of
experiments to determine the nature of the NO-related species
liberated from GEA 3162.
An NO-specific electrode detected NO release from DEA/
NO in culture medium, as has been shown previously (Crane
et al., 2002). Release of NO from this compound (5 fiM)
occurred spontaneously at physiological temperature and pH.
The signal was not significantly affected by SOD alone,
suggesting that there was no concurrent release of 02 under
these conditions. In the presence of neutrophils, there was a
mild acceleration of the decay of NO signal from DEA/NO,
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Figure 4 Differential effects of compounds on independent para¬
meters of neutrophil apoptosis. Human neutrophils were incubated
at 37°C for l —20 h with PBS (control), DEA/NO (1 mM) or GEA
3162 (100/rM). Apoptosis was then assessed by (a) morphological
changes using oil-immersion light microscopy and (b) PI intercala¬
tion to show hypodiploid DNA content characteristic of apoptotic
cells. Results are mean + s.e.m. (ti = 3-6). (c) Neutrophils were
incubated for 20 h with SIN-1 (1 -3 mM) and apoptosis was assessed
by morphology and PI intercalation. Results are mean + s.e.m.
(n = 5).
suggesting a scavenging effect of the cells. However, NO
detection in the presence of neutrophils and SOD was not
enhanced; indeed, it was surprisingly blunted, perhaps
indicating a scavenging effect of the enzyme under these
conditions. On the other hand, SIN-1 and GEA 3162 failed
to produce measurable free NO under the same conditions,
despite the relatively high concentrations of these drugs used
(IOO^m). The limit for NO detection of the electrode used
in these studies is ~50nM. Rapid scavenging of NO through
reaction with O7 generated simultaneously might account for
the lack of detectable NO under these conditions. It is well
established that this is the case for SIN-1, which is recognised
to be an ONOO donor rather than a pure NO donor (Hogg
et al., 1992), but it was a matter of debate whether NO release
from GEA 3162 also involves the concomitant liberation of
Of. In order to test this, the buffer into which the electrode
was immersed was preincubated with varying concentrations
of Cu/Zn SOD, which rapidly converts OT to H202, in an
effort to 'unmask' NO by removal of 07. If SIN-1 and GEA
3162 both liberate a combination of NO and Oj, then free NO
might be detectable in the presence of SOD, which would
prevent at least some of the NO being oxidised to ONOO-
(Lizasoain et al., 1996). With reference to the rate constants,
the relative rates of reaction can be estimated as follows (for a
concentration of 1 ytM NO and assuming the amount of NO
generated is matched by Oj):
20f + H+ H202 + 02 k = 2x 109M-1s-1 Rate = 2^Ms-1
02 + NO —> ONOO- k = 6x lO'lVD's-1 Rate = 6,uMs-'
From these reaction rates, it is reasonable to predict that some
NO might be unmasked in the presence of SOD, but that the
amount observed would be a relatively small percentage of the
total amount generated, on account of the fact that the rate
of reaction of NO with Oy is three times faster than that
catalysed by SOD. In the event, NO was detected from both
SIN-1 and GEA 3162; indeed, the profile of NO release from
the two compounds in the presence of SOD was virtually
identical, and correlated well with previously published data
for SIN-1 (Lizasoain et al., 1996). The role of oxygen-derived
free radicals in quenching of NO was confirmed by EPR
experiments using the O7 and ONOO--specific spin-trap,
Tempone-H. A signal corresponding to 4-oxo-Tempo in¬
creased in intensity during incubations with both SIN-1 and
GEA-3162, but was not seen with DEA/NO. The 4-oxo-
Tempo signal was quenched by SOD, indicating that the
species responsible for oxidation of Tempone-H was O7, or
a downstream product of Oy (e.g. ONOO ). Taken together,
these results indicate that GEA-3162 is indeed an ONOO"
generator, with characteristics that are very similar to SIN-1
and quite distinct from the NO donor, DEA/NO.
DHR 123 is oxidised to the fluorochrome, rhodamine 123,
by a number of oxidative and nitrosative species, including
ONOO y 02, H202 and HOC1, and is widely used in flow
cytometric assessment of respiratory burst in neutrophils
(Smith & Weidemann, 1993; Ruchaud-Sparagano et al.,
1997). However, it has been demonstrated that NO does not
have the capacity to oxidise this molecule (Crow, 1997). This
makes DHR 123 an ideal tool for discriminating between
agents that release NO and those that liberate ONOO .
Addition of DHR 123 to solutions of SIN-1 (1 mm) and GEA
3162 (100/tm) led to the generation of fluorescent rhodamine
123, whereas with PBS and DEA/NO (1 mM), no fluorescence
could be detected. This suggests that both SIN-1 and GEA
3162 generate species distinct from NO, such as ONOO-,
which does react with DHR 123.
Functionally, SIN-1 and GEA 3162 share properties that
differ from DEA/NO. Apoptosis studies showed that all the
three compounds accelerated morphological neutrophil apop¬
tosis at high concentrations, as has previously been demon¬
strated by this group (Ward et al., 2000; Taylor et al., 2001).
Only extremely high concentrations of DEA/NO were able to
induce neutrophil apoptosis (Taylor et al., 2001), which are
likely to be suprapathophysiological, thereby suggesting that
even high concentrations of NO generated from iNOS during
excessive inflammation are unable to promote neutrophil
apoptosis by themselves. Therefore, endogenously formed NO,
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whatever its source, is unlikely to induce apoptosis in this cell
type if it is not converted to ONOO .
Only DEA/NO produced the expected rise in the level
of internucleosomal DNA fragmentation that mirrored the
morphological changes observed. In the presence of both SIN-
1 and GEA 3162, this process was inhibited compared
to control, indicating an uncoupling of DNA fragmentation
from other apoptotic events with these two compounds, and
provides further evidence that the species generated by GEA
3162 more closely resembles that from SIN-1 than from DEA/
NO. Although this study did not investigate the potential
underlying mechanism, this phenomenon could potentially be
due to the inhibitory modification of tyrosine (nitration) or
reduced cysteine (S-nitrosation) residues (Kuo & Kocis, 2002)
in critical proteins of the DNA fragmentation pathway such as
caspase 3 (Kim et al., 1997) or DFF40 (Widlak, 2000), thus
affecting the activity of these proteins and therefore the DNA
fragmentation process.
Overall, we have demonstrated that GEA 3162 is an
ONOO donor that induces neutrophil apoptosis via a
mechanism that is not dependent on DNA fragmentation.
Chemically and biologically, therefore, GEA 3162 resembles
SIN-1 and is clearly distinct from DEA/NO. The induction
of neutrophil apoptosis may be of therapeutic benefit in a
number of inflammatory conditions in which resolution of
inflammation is impaired (such as arthritis, pancreatitis,
pneumonia and asthma), which causes neutrophils to persist
in the tissue and then potentially subsequently die by necrosis
(Ward et al., 1999b; Taylor et al., 2003). ONOO- is an
important molecule in inflammation as iNOS-derived NO and
Of are both produced by inflammatory cells and the resulting
ONOO- may contribute to the pathophysiology of a number
of chronic inflammatory conditions (Szabo, 1996).
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Abstract: Atherosclerosis, and its associated complications, are a major cause ofmorbidity and mortality, and it is now
recognised as a chronic inflammatory disorder. Progression of inflammation depends on the balance between recruitment
of inflammatory cells and their subsequent removal from a site of inflammation. Apoptosis, or programmed cell death, is a
fundamental process governing cell survival and is a major determinant of the resolution of the inflammatory response.
Apoptotic cells are instantly recognised for non-inflammatory clearance by phagocytes (e.g. macrophages) and removed
from the vicinity of inflammation without the release of their pro-inflammatory cell contents. Nitric oxide (NO) plays an
important role in many biological processes and has several anti-atherogenic properties including vasodilatation, inhibi¬
tion of platelet activation and aggregation, and the regulation of apoptosis in a variety of cell types involved in athero-
genesis. A critical early event during atherogenesis is injury to the endothelium. The ensuing damage results in endothelial
dysfunction, including a reduction in the capacity of the endothelium to generate NO. Decreased NO bioavailability is
likely to influence many cellular processes occurring within atherosclerotic lesions, including apoptosis. Modulation of
apoptosis is a novel target for therapeutic intervention in the treatment of chronic inflammatory disorders, such as athero¬
sclerosis. This modulation may help limit or resolve inflammation without the concomitant recruitment of subsequent in¬
flammatory cells, thereby reducing the potential for further tissue damage. NO is a possible candidate for manipulation of
atherosclerotic processes due to both its powerful anti-atherogenic characteristics and ability to affect apoptosis. This re¬
view highlights the role of apoptosis in atherosclerosis and discusses the therapeutic potential of NO to limit and/or re¬
solve vascular inflammation.
J
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INTRODUCTION
Atherosclerosis and its associated secondary complica¬
tions, such as myocardial infarction and stroke, remain a
major cause of morbidity and mortality in industrialised na¬
tions. Atherosclerosis is a multifactorial disease process with
a complicated aetiology. However, it is now widely recog¬
nised that there is a chronic inflammatory component to the
disease process, which is characterised by the formation of
lipid-rich plaques in the wall of major conduit vessels such
as the coronary arteries and aorta [1-4]. These lesions are
usually eccentric and made up of a necrotic core of lipid-
laden inflammatory cells encapsulated by a fibrous, colla¬
gen-rich cap consisting of vascular smooth muscle cells
(VSMC) and extracellular matrix [5]. In this state, the plaque
is considered 'stable'; its physical presence results in partial
occlusion of the vessel, but because the vessel is dynamic
rather than static, it can often compensate for this occlusion
and accommodate for the presence of the plaque without a
decrease in lumen diameter [6]. However, if the cap is sub¬
ject to mechanical breakdown or erosion, the plaque can be¬
comes 'unstable' and ruptures. When the plaque cap is com¬
promised, the highly thrombogenic contents of the core are
released into the circulation. Platelets are rapidly recruited
and activated resulting in thrombus formation. Plaque rup¬
ture can occur several times and remain sub-clinical with the
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VSMC cap reforming, or healing, over the top of the throm¬
bus which becomes incorporated into the lesion, resulting in
a layering effect within the plaque [7]. This process can fur¬
ther occlude the vessel in situ, or the thrombus can detach
from the plaque surface, and the resulting embolus occlude
smaller vessels downstream, leading to the more serious
acute cardiovascular syndromes, such as myocardial infarc¬
tion and stroke [8]. The determinants of plaque vulnerability
to destabilisation and rupture have yet to be fully identified,
but a growing body of evidence is emerging that points to¬
ward a critical role for both the thickness of the VSMC layer
overlaying the core [9] and to inflammatory processes occur¬
ring within the plaque [ 10-121.
APOPTOSIS
Inflammatory cell apoptosis, or programmed cell death,
is a highly regulated process whereby cellular death and sub¬
sequent phagocytosis occur without disruption of the cell
membrane and ensuing release of the histotoxic and pro¬
inflammatory mediators from the cytoplasm [13-15]. Apop¬
tosis therefore represents a non-inflammatory mechanism for
the removal of cells from a site of tissue damage, and hence,
is critical to the successful resolution of the inflammatory
response. Pharmacological manipulation of apoptosis in a
variety of cell types, particularly inflammatory cells, may
represent a novel therapeutic strategy for the treatment of
chronic inflammatory disorders, including atherosclerosis
[16, 17],
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Apoptosis can be modulated by the endogenous messen¬
ger nitric oxide (NO), which can be both pro- and anti-
apoptotic depending on local concentration, the specific cell
type in question and the NO-related species generated in vivo
[18, 19]. The aim of this review is to examine the role of
apoptosis in atherosclerosis and to discuss the potential of
this process as a target for therapeutic intervention by NO
donor drugs, whereby disease progression may be stabilised
in an effort to prevent the acute cardiovascular syndromes.
ATHEROSCLEROSIS
Despite arduous research in both humans and animal
models of the process, the underlying causes of atherogene-
sis remain largely unknown. It is widely accepted that a criti¬
cal early event of atheroma development is endothelial cell
injury and damage. This can occur by several mechanisms:
chemical injury can occur through oxidative stress, including
oxidation of circulating low density lipids (LDL) resulting in
the formation of damaging oxidised LDL (ox-LDL); and
physical damage to the endothelium can result from shear
stress within the vessel, with plaques tending to form at sites
usually subjected to elevated shear stress, such as bifurcation
points in the arterial tree or where low shear stress results in
reduced stimulation ofNO synthase and NO generation [20].
The consequences of an insult to the endothelium are num-
rous fold: firstly, the damaged endothelium becomes dys¬
functional and the net production ofNO by eNOS decreases,
promoting vasoconstriction. This is reflected in patients with
risk factors for atherosclerosis, such as hypercholesterolae-
mia. In hypercholesterolaemic individuals, vasodilatation in
response to the endothelium-dependent vasodilator, acetyl¬
choline (which acts by triggering NO release from the endo¬
thelium), is impaired in forearm resistance vessels compared
to normocholesterolaemic controls. However, vasodilatation
in response to the endothelium-independent NO donor, so¬
dium nitroprusside (SNP), is unaffected. This suggests that
endothelial injury resulting from the hypercholesterolaemic
state decreases the normal NO-producing capacity of the
endothelium [21]. Although resistance vessels are not usu¬
ally susceptible to plaque formation, they are widely ac¬
cepted to reflect changes occurring globally throughout the
arterial tree.
In addition, in response to the insult to the endothelium,
an inflammatory response is triggered. Depending on the
nature and duration of the insult, this response can become
excessive and, over a period of years, constitutes the disease
process itself [2, 3]. The inflammatory process begins with
the expression of chemotactic and adhesion molecules for
monocytes and lymphocytes, including vascular cell adhe¬
sion molecule 1 (VCAM-1), on the surface of dysfunctional
endothelial cells. Circulating monocytes adhere to the site of
endothelial damage and translocate to the sub-endothelial
space where they accumulate [22]. Colony stimulating fac¬
tors secreted from areas of endothelial damage induce mono¬
cytes to differentiate into macrophages, which then begin to
express scavenger receptors, facilitating the internalisation of
oxidised low density lipoprotein (ox-LDL) [23], Cultured
macrophages do not accumulate native LDL on account of
downregulation of LDL receptors in the cholesterol-replete
state. However, once LDL has been modified by oxidation,
accumulation of the resultant ox-LDL by macrophages con¬
tinues unchecked because scavenger receptors are not down-
regulated by cholesterol accumulation. The mechanism of
lipid peroxidation is still not fully understood, but free radi¬
cals such as superoxide (02~) and hydroxyl radicals ("OH),
undoubtedly have a role to play [24, 25]. Peroxynitrite
(ONOO ), formed by the rapid reaction of NO with 02~, can
also initiate lipid peroxidation, both in vitro, and in mem¬
brane lipids and lipoproteins [26, 27], In the lipid-laden con¬
dition, macrophages are known as foam cells and it is an
accumulation of these cells in the vessel intima which forms
the earliest recognisable lesion of atherosclerosis - the fatty
streak (Fig. 1A) [20, 28]. Fatty streaks have been observed in
the vessels of young adults and children (including neo¬
nates), suggesting that atherosclerosis may be initiated early
in life but remains sub-clinical unless vessel occlusion and/or
plaque rupture lead to diagnosis [29].
Once the fatty streak is established, the plaque grows in
size as the ox-LDL accumulated in macrophage-derived
foam cells causes both further endothelial damage and is
chemoattractant for circulating monocytes, which freely mi¬
grate through the endothelium, accumulate in the sub-
endothelial space, and differentiate into macrophages which
then go on to become foam cells [30]. This establishes a per¬
petual cycle of endothelial damage, leading to monocyte
recruitment and accumulation of ox-LDL, which encourages
further endothelial damage (Fig. 1). Activated macrophages
in fatty streaks secrete numerous cytokines and growth fac¬
tors including platelet derived growth factor (PDGF), basic
fibroblast growth factor (bFGF), interleukin-1 (IL-1), tumour
necrosis factor-a (TNF-a), and transforming growth factor-13
(TGF-|3) [20]. All of these factors and cytokines induce vas¬
cular smooth muscle cell (VSMC) hypertrophy and/or hy¬
perplasia. This represents a change in phenotype for VSMCs,
from the usual adult vascular contractile phenotype to the
synthetic phenotype usually seen only in developing vessels.
However, characterisation of VSMCs into only two distinct
phenotypes is a vast over-simplification. A wide spectrum of
diverse intermediary phenotypes exist under different
physiological and pathophysiological conditions, without a
clear distinction between phenotypes. This is especially true
when VSMCs are undergoing phenotypic transition and there
may, in fact, be several sub-populations of VSMCs present
within the plaque at any given time [31 ]. In a synthetic phe¬
notype, VSMCs have the ability to proliferate and synthesise
large amounts of collagen. Proliferation begins in the media
of the vessel, but after a time the cells begin to migrate, in¬
vade the intima and form a layer over the top of the fatty
streak. This layer of VSMCs secretes large amounts of ex¬
tracellular matrix and connective tissue consisting of gly-
cosaminoglycans, dermatan sulfate, and collagen. These
molecules form a mesh over the fatty streak, which becomes
calcified and forms the fibrous cap of the plaque, encapsu¬
lating the highly thrombogenic lipid core and maintaining a




Recruitment of inflammatory cells, particularly mono¬
cytes and macrophages, is the major driving force behind
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plaque growth and development. Apoptosis of inflammatory
cells within an atherosclerotic lesion may result in their sub¬
sequent phagocytosis and removal from the plaque core
without the concomitant recruitment of additional inflam¬
matory cells (Fig. IB). The identity of the cells responsible
for clearing the apoptotic macrophages from the plaque re¬
mains to be confirmed. It is currently unclear whether acti¬
vated macrophages can themselves phagocytose populations
of apoptotic inflammatory cells, or if this is done by a sepa¬
rate subset of specialised phagocytes.
Apoptotic macrophages have been located by TUNEL
staining in plaques from animal models of atherosclerosis
and in plaques excised from human vessels [32-34]. The
apoptotic macrophages tend to be clustered in areas of the
plaque most vulnerable to rupture, most notably the base, or
shoulder, regions where the VSMC prevalence is also de¬
creased [35]. It is currently unclear why these areas of the
plaque are particularly susceptible to rupture, however, re¬
duced VSMC localisation in these areas of vulnerable
plaques may indicate that apoptosis of a variety of cell types,
including VSMCs, may play a role in plaque susceptibility to
rupture (Fig. 1C) [36]. Recently, it has been suggested that
the macrophage-enzyme, myeloperoxidase (MPO), could
also have an important role in determining plaque vulner¬
ability. MPO, a member of the heme peroxidase superfamily,
generates reactive oxidants including hypochlorous acid
(HOCI) as part of its normal function in innate host defences
[37, 38]. Sugiyama et al. have described a strong co-
localisation between macrophage MPO expression and
FlOCI-modified proteins at sites of lesion rupture in patients
who suffer acute cardiac events [39]. MPO-generated HOCI
at relatively high physiological concentrations, but still
within the range expected to be produced at areas of vascular
inflammation (30 - 50 pM), has been shown to promote en¬
dothelial cell death by stimulating apoptotic pathways in¬
cluding rapid caspase-3 activation and DNA fragmentation
[40]. This observation suggests that, prior to undergoing
apoptosis themselves, activated macrophages may induce
apoptosis of neighbouring endothelial cells through MPO
expression, resulting ultimately in plaque rupture.
Vascular Smooth Muscle Cells
As previously mentioned, loss of VSMCs from the pro¬
tective plaque cap is a major determinant of plaque rupture.
Because healthy endothelial cells secrete factors that pro¬
mote VSMC survival, a consequence of activated macro-
Stable plaque Unstable plaque
Fig. (1). During atherogenesis circulating monocyes translocate to the subendothelial space where they accumulate modified lipids and form
an atherosclerotic plaque, overlain with a fibrous cap of VSMCs (A). Apoptosis can be induced in a variety of cell types by NO. Apoptotic
inflammatory cells are cleared by phagocytes, aiding resolution of the inflammatory response, and ultimately facilitating plaque regression
(B). However, apoptosis of VSMC may be detrimental, resulting in degradation of the plaque cap and leading to plaque rupture, particularly
in the shoulder regions, and ultimately to thrombus formation (C).
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phage-induced endothelial cell death is an increase in VSMC
death [41]. Direct induction of VSMC apoptosis in the apol-
ipoprotein E null murine model of atherosclerosis induces
both rupture and thrombosis of the plaque [42]. In addition to
removing the protective presence of the endothelium,
macrophages can also influence VSMC apoptosis directly.
Activated human monocytes/macrophages have been found
to be responsible for the death of human VSMCs in vitro
[43, 44], Seshiah et al. have hypothesised that macrophage
colony-stimulating factor (M-CSF), a haematopoietic growth
factor supporting survival and differentiation of monocytes,
is secreted from VSMCs resulting in macrophage activation,
ultimately triggering subsequent VSMC apoptosis [44]. The
exact mechanism of this process remains to be fully under¬
stood but is thought that macrophages prime VSMCs to re¬
spond to apoptotic stimuli, for example by triggering the
expression of death receptor ligands such as TNFa on the
cell surface [45].
NITRIC OXIDE
NO was first identified as the biological messenger re¬
sponsible for endothelium dependent vasodilatation [46, 47].
Since then, it has become increasingly clear that NO has
many diverse actions beyond that of control of vascular tone.
Synthesised by three isoforms of the enzyme NO synthase
(NOS), NO is now known to inhibit platelet and inflamma¬
tory cell adhesion and activation, to act as a transmitter at
non-adrenergic non-cholinergic (NANC) neurones, and to
exhibit both pro- and anti-apoptotic effects depending on the
NO-related species, concentration and cell type in question
[48],
The classical pathway by which NO exerts its effects is
via activation of the enzyme soluble guanylate cyclase (sGC)
and resultant conversion of guanosine 5'-triphosphate (GTP)
to 3', 5'-cyclic guanosine monophosphate (cGMP) [48, 49].
However, recent studies have established that NO can act
via, as yet unidentified, cGMP-independent pathways in
various systems, particularly during the inhibition of platelet
aggregation [50-53] and regulation of inflammatory cell
apoptosis [51-54],
There is currently much debate as to whether all of the
effects of NO are mediated by the NO radical per se, or by
other NO-related species formed in situ. Due to its free radi¬
cal status, NO is highly reactive, and combines readily with
reactive oxygen species (ROS) to form a variety of NO-
related species. For example, superoxide anions (02), often
generated at sites of inflammation by the inflammatory cell
enzyme NADPH oxidase [55], react rapidly with NO to pro¬
duce toxic peroxynitrite (ONOO"). This reaction is usually
prevented in vivo by the battery of antioxidants that inacti¬
vate ROS. For instance, the enzyme superoxide dismutase
(SOD) removes 02" by catalysing its conversion to hydrogen
peroxide (H202), which is subsequently further inactivated
by catalase [56]. However, if the production of ROS is such
that the antioxidant capacity is overcome, then any free NO
present will react rapidly with the 0"2 to form ONOO". NO
can also form S-nitrosothiols via the transfer of NO+ from
higher oxides of nitrogen (e.g. N203) to reduced thiol groups
on proteins such as albumin, resulting in the formation of S-
nitrosoalbumin [57, 58]. It has recently been hypothesised
that the formation of S-nitrosothiols may act as a slow-
release NO store in vivo [50]. S-nitrosation of a range of
cellular proteins is now considered to be one of a number of
post-translational modifications that can alter protein func¬
tion, and these modifactions are likely to be responsible for
many of the cGMP-independent effects of NO, including
inhibition of caspase-3 activation [59, 60].
NO AS A MEDIATOR OF APOPTOSIS
The pro- and anti-apoptotic actions ofNO have been well
documented in many cell systems. Current evidence suggests
that lower concentrations of NO produced constitutively by
endothelial and neuronal NOS (eNOS and nNOS) are cyto-
protective via primarily cGMP-dependent mechanisms,
whilst higher, supraphysiological concentrations generated in
some pathologies by inducible NOS (iNOS) mediate apopto¬
sis via mechanisms independent of cGMP signalling [61].
For example, high concentrations of either exogenous or
endogenous iNOS-derived NO have been shown to induce
apoptosis in murine and rabbit macrophage cell lines [62,
63]. Apoptosis in rabbit macrophages was unaffected by
inhibition of cGMP-dependent kinases and not mimicked by
cGMP analogs, suggesting that the pro-apoptotic actions of
NO are cGMP-independent [64]. Conversely, pre-treatment
with relatively low concentrations of exogenous NO, deliv¬
ered by the synthetic NO donor sodium nitroprusside (SNP)
protects RAW 264 cells (a mouse macrophage cell line)
against cell death upon subsequent exposure to higher con¬
centrations of NO which would normally be cytotoxic [65],
Furthermore, this protection was mimicked by cGMP
analogs but negated in the presence of sGC inhibitors, sug¬
gesting that the cellular protection was conferred by cGMP.
Similarly, high levels of NO produced by activated macro¬
phages as a consequence of iNOS upregulation may also
induce VSMC apoptosis through DNA damage and subse¬
quent p53 activation [66].
This dual role, and apparent paradox of NO, may be ex¬
plained, at least in part, by the free radical nature of NO and
the ease with which it will form various NO-related species
in vivo. As already mentioned, NO will react rapidly with 02"
to form ONOO'. The production of ONOO" may be of par¬
ticular importance at sites of vascular inflammation such as
atherosclerotic lesions, where the concentration of reactive
oxygen is likely to be elevated [67]. The precise role of
ONOO" in inflammatory cell apoptosis remains to be eluci¬
dated. There is some evidence to suggest that at high con¬
centrations (100 pM - 300 pM), ONOO" induces apoptosis
in RAW 264.7 cells [68], whilst at lower concentrations (30
pM - 50 pM), it may have a protective effect against lipo-
polysaccharide (LPS) and interferon (IFN)-y-induced apop¬
tosis in these cells [69]. Brockhaus et al. [70] have demon¬
strated that overexpression of copper/zinc SOD (CuZnSOD)
can protect RAW 264.7 cells against apoptosis initiated by
NO, either exogenous or iNOS-derived. This implies a role
for ONOO" as the mediator ofNO-initiated apoptosis. How¬
ever, whilst a specific scavenger of ONOO", uric acid, effec¬
tively abolishes apoptosis induced by the ONOO" generator
SIN-1, it left apoptosis induced by the NO donors S-nitroso-
glutathione (GSNO) and spermine diazeniumdiolate SPER7
NO unaltered, suggesting that NO and NO-related species
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may be able to activate several pathways when initiating
apoptosis [70],
Whilst endogenous macrophage iNOS-derived NO has
been shown to induce apoptosis in animal models, this is not
necessarily the case in human macrophages, which might not
produce any NO at all. [71-73]. However, despite this re¬
duced capability to produce endogenous NO, human macro¬
phages still undergo apoptosis in response to exogenous NO
and NO-related species. For example, the NO donors GSNO
and SPER/NO induce apoptosis in primary human mono-
cyte-derived macrophages [74],
NO AND APOPTOSIS IN THE RESOLUTION OF
INFLAMMATION
Apoptosis is now thought to be key to the resolution of
the inflammatory response. Pharmacological manipulation of
the rate of apoptosis during chronic inflammatory disorders
such as atherosclerosis, may aid the resolution of inflamma¬
tion and delay disease progression. NO is a promising candi¬
date for such manipulation, because its ability to induce
apoptosis and aid inflammatory resolution has already been
demonstrated in several animal models. In a mouse model of
kidney inflammation, activated macrophages have been
shown to induce apoptosis in neighbouring mesangial cells
prior to ingestion by phagocytes [75]. The ability of the acti¬
vated macrophages to induce apoptosis is greatly reduced in
the presence of the NOS inhibitor, NG-monomethyl-L-
arginine (L-NMMA), indicating that macrophage-directed
apoptosis of mesangial cell apoptosis occurs via NO-
dependent mechanism [76], Similarly, several studies have
demonstrated that activated macrophages infiltrating murine
tumours induce apoptosis via a NO-dependent pathway in
both activated anti-tumour T cells and in the tumour cells
themselves [77, 78]. Thus, it appears that macrophages have
the capacity to induce apoptosis of nearby cells by the lib¬
eration of NO, or a related species, to enhance the clearance
of apoptotic cells.
Inducing apoptosis in inflammatory cells within an athe¬
rosclerotic lesion is an attractive prospect as it may represent
a mechanism to stabilise the plaque or to resolve the vascular
inflammation and lead to regression of the plaque, thereby
halting disease progression. Reducing the number of acti¬
vated macrophages present in the plaque would have multi¬
ple consequences. Firstly, the physical presence of the
plaque in the vessel wall would be decreased, reducing
stenosis. Secondly, because activated macrophages induce
apoptosis in neighbouring endothelial cells and VSMCs,
reducing the number of activated macrophages may help to
preserve endothelial function and maintain the integrity of
the plaque cap.
NO as a mechanism to regress atherosclerosis is an ap¬
pealing possibility because in addition to the pro-apoptotic
properties described above, NO also has a number of other
powerful anti-atherogenic characteristics including inhibition
of platelet and inflammatory cell activation [48, 79]. Animal
studies are emerging to support the hypothesis that manipu¬
lation of apoptosis could be used to reverse atherosclerosis.
For example, L-arginine (the substrate for NOS) or the NO
donor SNP, administered to hypercholesterolaemic rabbits
increases the number of apoptotic macrophages in intimal
lesions by three fold [64]. This increase in apoptosis was
accompanied by a significant reduction in lesion surface
area, suggesting that manipulation of the NO synthase path¬
way, or delivery of exogenous NO, may be a way to boost
NO availabilty in order to stabilise, or even regress, the
plaque via an apoptotic mechanism. However, the treatments
used in this study are by no means selective for macro¬
phages, and as already discussed, NO will also induce apop¬
tosis in endothelial cells and VSMCs. This could have sev¬
eral serious detrimental consequences for the plaque; firstly,
additional loss of endothelial function would occur, leading
to further exacerbation of the disease process. Secondly, be¬
cause VSMCs are essential for maintaining the integrity of
the plaque cap, loss of this population of cells in vulnerable
areas of the lesion could de-stabilise the plaque resulting in
plaque rupture which could result in myocardial infarction or
stroke. The potential benefit of regressing the plaque in this
way must also be offset against the cost of reducing the size
of the macrophage population available for scavenging ex¬
isting apoptotic macrophages, endothelial cells and VSMC.
If left in situ, these apoptotic cells will undergo secondary
necrosis, thereby increasing the thrombogenicity of the
plaque as a whole. In the study by Wang et al. [64] discussed
above, apoptosis is quantified by the number of apoptotic
nuclei per area of plaque, rather than as a percentage of the
total macrophage population. Therefore, it is not possible to
draw any conclusions as to whether the phagocytosis capac¬
ity of the plaque has been effected in this case.
Although human macrophages appear unable to generate
the supraphysiological concentrations that murine cells pro¬
duce, human macrophages will respond to exogenous NO
delivered by synthetic NO donor compounds, suggesting that
NO could potentially be used to manipulate rates of apopto¬
sis in human atherosclerosis. However, it is essential to tar¬
get any therapeutic intervention to specific cell types within
the plaque, and in particular, to appropriate cell types within
plaques vulnerable to rupture. Indiscriminate pro-apoptotic
events may have serious adverse consequences for the
plaque dynamic.
At present, existing NO donor drugs are not selective for
particular cell types. Common clinically used organic ni¬
trates, such as nitroglycerin (NTG), tend to have an unfa¬
vourable selectivity profile when considered in the context of
atherosclerosis, they are more selective for veins (which are
not subject to plaque formation) than arteries, and more se¬
lective for arteries than platelets (which play a major role in
thrombus formation following plaque ruture). In order to use
NO donor drugs as effectors of apoptosis in atherosclerosis,
compounds which are able to selectively act on, for example,
macrophages but not endothelial cells or VSMC, will have to
be developed in the future. This however, may be difficult
given that macrophages are relatively resistant to oxidative
stress induced apoptosis.
In addition to selectivity, a major consideration when
contemplating the use of NO donor drugs for the treatment
of atherosclerosis is that of delivery. Global, non-selective
release of NO throughout the circulation may have various
anti-atherosclerotic actions, but dosing will be limited by
concurrent vasodilatation resulting in systemic hypotension.
The challenge therefore, is to generate high local concentra-
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tions in the vicinity of a plaque. One possible means of
achieving this is to employ NO donor drugs which are selec¬
tive for areas of endothelial damage. S-nitrosothiols are gen¬
erally accepted to be platelet-selective NO donor drugs [80]
and have been shown in vitro to have vasodilator actions
which are selective for areas of experimentally denuded en¬
dothelium [81]. Furthermore, in a rabbit balloon angioplasty
model of vascular injury, the S-nitrosothiol, S-nitroso-/V-
valerylpenicillamine (SNVP), in contrast to the traditional
organic nitrate NTG, reduced the adhesion of radio-labelled
platelets in areas of endothelial damage without significantly
affecting systemic blood pressure [82]. In this study, the NO
donors were delivered directly into the carotid artery via a
cannula; obviously this is not practical in humans as a long -
term therapy, but a possible alternative is to deliver NO via
drug-eluting stents. There has been some success in humans
with the use of sirolimus (rapamycin)-eluting stents in pre¬
venting neointimal proliferation (which can lead to re¬
stenosis) following angioplasty, although long-term effec¬
tiveness (>1 year) remains to be established [83]. A further
potential method of delivering high local concentrations of
NO directly to the interior of the plaque may be to exploit
the lipid nature of the plaque core by developing novel lipo¬
philic NO donor drugs designed to induce apoptosis in the
lipid-laden macrophages within the core.
CONCLUSION
Atherosclerosis is now considered a chronic vascular
inflammatory disorder involving complicated interactions
between many cell types. Apoptosis plays a key role in de¬
termining both turnover of cells within the plaque, and
plaque vulnerability to rupture. Because apoptotic cells are
removed from the site of inflammation without triggering a
subsequent pro-inflammatory response, inflammatory cell
apoptosis is a promising target for therapeutic intervention in
the treatment of this disease. The ability of NO to induce
apoptosis, combined with the additional anti-atherogenic
properties of NO, points to this molecule being a powerful
tool in the treatment of atherosclerosis. The challenge will be
to deliver NO in the appropriate chemical form and to bal¬
ance any benefit in reducing inflammatory cell number
within the plaque against the potential deleterious effects of
destabilising the plaque cap and promoting plaque rupture.
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